Query Query
Results
Date
1 substances in Reaxys
2018-02-22 00h:00m:27s (EST)
O O
1. Query
O O
Search as: As drawn AND (IDE.XRN=984320)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
1/162
2018-02-22 00:03:45
Reaxys ID 984320 View in Reaxys
1/1 CAS Registry Number: 94-36-0 Chemical Name: dibenzoyl peroxide; Dibenzoyl peroxide; dibenzoylperoxide; BENZOYL PEROXIDE Linear Structure Formula: [C6H5C(O)O]2 Molecular Formula: C14H10O4 Molecular Weight: 242.231 Type of Substance: isocyclic InChI Key: OMPJBNCRMGITSC-UHFFFAOYSA-N Note:
O O
O
O
Substance Label (36) Label References BPO
Sueishi, Yoshimi; Miyake, Yuzo; Bulletin of the Chemical Society of Japan; vol. 70; nb. 2; (1997); p. 397 403, View in Reaxys; Phanstiel IV; Wang; Powell; Ospina; Leeson; Journal of Organic Chemistry; vol. 64; nb. 3; (1999); p. 803 - 806, View in Reaxys; Ho, Zwei-Chang; Livant, Peter; Lott, William B.; Webb, Thomas R.; Journal of Organic Chemistry; vol. 64; nb. 22; (1999); p. 8226 - 8235, View in Reaxys; Yang, Zhixiang; Kitano, Yoshikazu; Chiba, Kazuhiro; Shibata, Naohiro; Kurokawa, Hiroshi; Doi, Yohei; Arakawa, Yoshichika; Tada, Masahiro; Bioorganic and Medicinal Chemistry; vol. 9; nb. 2; (2001); p. 347 - 356, View in Reaxys; Guo, Hongyan; Naser, Saleh A.; Ghobrial, George; Phanstiel IV, Otto; Journal of Medicinal Chemistry; vol. 45; nb. 10; (2002); p. 2056 - 2063, View in Reaxys; Andruzzi, Luisa; Chiellini, Emo; Galli, Giancarlo; Li, Xuefa; Kang, Seok H.; Ober, Christopher K.; Journal of Materials Chemistry; vol. 12; nb. 6; (2002); p. 1684 - 1692, View in Reaxys; Sueishi; Yoshioka; Takemoto; Kotake; Zeitschrift fur Physikalische Chemie; vol. 216; nb. 11; (2002); p. 1353 - 1360, View in Reaxys; Nemchik, Anne; Badescu, Valentina; Phanstiel IV, Otto; Tetrahedron; vol. 59; nb. 24; (2003); p. 4315 - 4325, View in Reaxys; Higaki, Yuji; Otsuka, Hideyuki; Endo, Takeshi; Takahara, Atsushi; Macromolecules; vol. 36; nb. 5; (2003); p. 1494 1499, View in Reaxys; Moorhoff, Cornelis M.; Braybrook, Carl; Journal of Chemical Research, Miniprint; nb. 3; (2003); p. 339 - 361, View in Reaxys; Luo, Ning; Metters, Andrew T.; Hutchison, J. Brian; Bowman, Christopher N.; Anseth, Kristi S.; Macromolecules; vol. 36; nb. 18; (2003); p. 6739 - 6745, View in Reaxys; McNulty, James; Capretta, Alfredo; Laritchev, Vladimir; Dyck, Jeff; Robertson, Al J.; Angewandte Chemie - International Edition; vol. 42; nb. 34; (2003); p. 4051 - 4054, View in Reaxys; Gardner, Richard A.; Ghobrial, George; Naser, Saleh A.; Phanstiel IV, Otto; Journal of Medicinal Chemistry; vol. 47; nb. 20; (2004); p. 4933 - 4940, View in Reaxys; Li, Dejin; Sheng, Xia; Zhao, Bin; Journal of the American Chemical Society; vol. 127; nb. 17; (2005); p. 6248 - 6256, View in Reaxys; Galli; Martinelli; Chiellini; Ober; Glisenti; Molecular Crystals and Liquid Crystals; vol. 441; (2005); p. 211 - 226, View in Reaxys; Ghani, Mohmad Asri Abd; Abdallah, Dalia; Kazmaier, Peter M.; Keoshkerian, Barkev; Buncel, Erwin; Canadian Journal of Chemistry; vol. 82; nb. 9; (2004); p. 1403 - 1412, View in Reaxys; He, Tao; Li, Dejin; Sheng, Xia; Zhao, Bin; Macromolecules; vol. 37; nb. 9; (2004); p. 3128 - 3135, View in Reaxys; Achilias, Dimitris S.; Sideridou, Irini D.; Macromolecules; vol. 37; nb. 11; (2004); p. 4254 - 4265, View in Reaxys; Sessions, Laura B.; Miinea, Liliana A.; Ericson, Kjell D.; Glueck, David S.; Grubbs, Robert B.; Macromolecules; vol. 38; nb. 6; (2005); p. 2116 - 2121, View in Reaxys; Bhasin, Gayatri; Kauser, Hina; Athar, Mohammad; Archives of Toxicology; vol. 78; nb. 3; (2004); p. 139 - 146, View in Reaxys; Hsueh, Mao-Lin; Huang, Bor-Hunn; Wu, Jincai; Lin, Chu-Chieh; Macromolecules; vol. 38; nb. 23; (2005); p. 9482 - 9487, View in Reaxys; Fennell, Kelley A.; Miller, Marvin J.; Organic Letters; vol. 9; nb. 9; (2007); p. 1683 - 1685, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys; Arora, Jasbir Singh; Kaur, Navneet; Phanstiel IV, Otto; Journal of Organic Chemistry; vol. 73; nb. 16; (2008); p. 6182 6186, View in Reaxys; Ansong, Omari E.; Jansen, Susan; Wei, Yen; Pomrink, Gregory; Lu, Hui; Li, Shuxi; Guo, Yi; Journal of Materials Chemistry; vol. 17; nb. 42; (2007); p. 4499 - 4507, View in Reaxys; Furmick, Julie K.; Kaneko, Ichiro; Walsh, Angela N.; Yang, Joanna; Bhogal, Jaskaran S.; Gray, Geoffrey M.; Baso, Juan C.; Browder, Drew O.; Prentice, Jessica L.S.; Montano, Luis A.; Huynh, Chanh C.; Marcus, Lisa M.; Tsosie, Dorian G.; Kwon, Jungeun S.; Quezada, Alexis; Reyes, Nicole M.; Lemming, Brittney; Saini, Puneet; vanderVaart, Arjan; Groy, Thomas L.; Marshall, Pamela A.; Jurutka, Peter W.; Wagner, Carl E.; ChemMedChem; vol. 7; nb. 9; (2012); p. 1551 - 1566, View in Reaxys; Sakaguchi, Toshikazu; Sato, Miki; Hashimoto, Tamotsu; Polymer (United Kingdom); vol. 54; nb. 9; (2013); p. 2272 - 2277, View in Reaxys; Mashiach, Roi; Meijler, Michael M.; Organic Letters; vol. 15; nb. 7; (2013); p. 1702 - 1705, View in Reaxys; Kuo, Cheng-Yu; Huang, Yu-Chen; Hsiow, Chuen-Yo; Yang, Yu-Wen; Huang, Ching-I; Rwei, Syang-Peng; Wang, Hsing-Lin; Wang, Leeyih; Macromolecules; vol. 46; nb. 15; (2013); p. 5985 5997, View in Reaxys; Patent; DIGNITY SCIENCES LIMITED; COUGHLAN, Dave; DOWNES, Bill; CLIMAX, John; MANKU, Mehar; WO2013/124479; (2013); (A1) English, View in Reaxys; Tsuchiya, Daisuke; Kawagoe, Yuhsuke; Moriyama, Katsuhiko; Togo, Hideo; Organic Letters; vol. 15; nb. 16; (2013); p. 4194 4197, View in Reaxys; Kaiser, Manuel; Leitner, Sebastian P.; Hirtenlehner, Christa; List, Manuela; Gerisch, Alexander; Monkowius, Uwe; Dalton Transactions; vol. 42; nb. 41; (2013); p. 14749 - 14756, View in Reaxys; Shahrisa, Aziz; Safa, Kazem Dindar; Esmati, Somayeh; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 117; (2014); p. 614 - 621, View in Reaxys; Desbois, Andrew P.; Lawlor, Keelan C.; Marine Drugs; vol. 11; nb. 11; (2013); p. 4544 - 4557, View in Reaxys; Peng, HuiQing; Xu, Jiang-Fei; Chen, Yu-Zhe; Wu, Li-Zhu; Tung, Chen-Ho; Yang, Qing-Zheng; Chemical Communications; vol. 50; nb. 11; (2014); p. 1334 - 1337, View in Reaxys; Patent; NOVARTIS AG; BEHNKE, Dirk; CARCACHE, David; ERTL, Peter; KOLLER, Manuel; ORAIN, David; WO2014/30128; (2014); (A1) English, View in Reaxys; Singleton, Michael L.; Castellucci, Nicola; Massip, Stephane; Kauffmann, Brice; Fer-
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
2/162
2018-02-22 00:03:45
rand, Yann; Huc, Ivan; Journal of Organic Chemistry; vol. 79; nb. 5; (2014); p. 2115 - 2122, View in Reaxys; Qiu, Di; Meng, He; Jin, Liang; Tang, Shengbo; Wang, Shuai; Mo, Fangyang; Zhang, Yan; Wang, Jianbo; Organic Syntheses; vol. 91; (2014); p. 106 - 115, View in Reaxys; Qu, Wei; Zhu, Xingqi; Chen, Jiahui; Niu, Lin; Liang, Dehai; Fan, Xinghe; Shen, Zhihao; Zhou, Qifeng; Macromolecules; vol. 47; nb. 8; (2014); p. 2727 - 2735, View in Reaxys; Wang, Jianhong; Gan, Ying; Li, Shaobin; Luo, Tianwei; Zhang, Yahong; Zhao, Jin; Medicinal Chemistry Research; vol. 23; nb. 4; (2014); p. 2106 - 2112, View in Reaxys; Yuan, Chan'E; Zhang, Ming Qiu; Rong, Min Zhi; Journal of Materials Chemistry A; vol. 2; nb. 18; (2014); p. 6558 - 6566, View in Reaxys; He, Minghui; Jiang, Shun; Xu, Ruixin; Yang, Jianwen; Zeng, Zhaohua; Chen, Guangxue; Journal of Polymer Science, Part A: Polymer Chemistry; vol. 52; nb. 11; (2014); p. 1560 - 1569, View in Reaxys; Gao, Min; Wang, Zhijian; Jia, Xinru; Supramolecular Chemistry; vol. 26; nb. 5-6; (2014); p. 435 - 441, View in Reaxys; Tang, Shi; Zhou, Dong; Wang, Ying-Chun; European Journal of Organic Chemistry; vol. 2014; nb. 17; (2014); p. 3656 - 3661, View in Reaxys; Zhang, Zhi-Jing; Quan, Xue-Jing; Ren, Zhi-Hui; Wang, Yao-Yu; Guan, Zheng-Hui; Organic Letters; vol. 16; nb. 12; (2014); p. 3292 - 3295, View in Reaxys; Gao, Yuting; Qu, Yi; Jiang, Tao; Zhang, Hao; He, Nannan; Li, Bo; Wu, Junchen; Hua, Jianli; Journal of Materials Chemistry C; vol. 2; nb. 31; (2014); p. 6353 - 6361, View in Reaxys; Peng, HuiQing; Sun, Cai-Li; Xu, Jiang-Fei; Niu, Li-Ya; Chen, Yu-Zhe; Wu, Li-Zhu; Tung, Chen-Ho; Yang, QingZheng; Chemistry--A European Journal; vol. 20; nb. 37; (2014); p. 11699 - 11702,4, View in Reaxys; Storch, Jan; Zadny, Jaroslav; Strasak, Tomas; Kubala, Martin; Sykora, Jan; Dusek, Michal; Cirkva, Vladimir; Matejka, Pavel; Krbal, Milos; Vacek, Jan; Chemistry - A European Journal; vol. 21; nb. 6; (2015); p. 2343 2347, View in Reaxys; Chen, Zhaolai; Liu, Fangyuan; Zeng, Qingsen; Cheng, Zhongkai; Du, Xiaohang; Jin, Gan; Zhang, Hao; Yang, Bai; Journal of Materials Chemistry A; vol. 3; nb. 20; (2015); p. 10969 - 10975, View in Reaxys; Yin, Yan-Bing; Wang, Hui-Song; Yang, Yu-Lin; Fan, Rui-Qing; Dong, Guo-Hua; Wei, LiGuo; Chinese Chemical Letters; vol. 27; nb. 4; (2016); p. 613 - 618, View in Reaxys; Xu, Yuan-Yuan; Qian, An-Ran; Cao, Xu-Feng; Ling, Chen-Yu; Cao, Yong-Bing; Wang, Rui-Lian; Li, Yi-Su; Yang, Yu-She; Chinese Chemical Letters; vol. 27; nb. 5; (2016); p. 703 - 706, View in Reaxys; Li, Shen; Song, Run-Jiang; Wang, Dong-Hui; Tian, Xue; Shao, Xu-Sheng; Li, Zhong; Chinese Chemical Letters; vol. 27; nb. 5; (2016); p. 635 - 639, View in Reaxys; Li, Qian; Zhai, Yangyang; Luo, Wen; Zhu, Zixin; Zhang, Xin; Xie, Songqiang; Hong, Chen; Wang, Yuxia; Su, Yabin; Zhao, Jin; Wang, Chaojie; European Journal of Medicinal Chemistry; vol. 121; (2016); p. 110 - 119, View in Reaxys; Guan; Jia; Zhang; Ma; Lu; Lai; Lei; Dyes and Pigments; vol. 136; (2017); p. 873 - 880, View in Reaxys; Patent; Samsung Display Co., Ltd.; Jin, Haizhen; Han, Xiangxuan; Jin, Rongguo; Jin, Zhongyou; Huang, Xihuan; Jin, Henggen; (168 pag.); CN105481829; (2016); (A) Chinese, View in Reaxys; Manikandan, Chitrarasu; Ganesan, Kilivelu; Journal of Heterocyclic Chemistry; vol. 54; nb. 1; (2017); p. 503 - 508, View in Reaxys; Wang, Xiaobin; Huang, Wenqian; Wang, Qingyan; Liu, Chen; Wang, Chaopeng; Yang, Guiyan; Zhao, Chunjiang; Journal of Molecular Structure; vol. 1138; (2017); p. 6 - 11, View in Reaxys; Pan, Chongqing; Zhu, Zixi; Zhang, Mingkai; Gu, Zhenhua; Angewandte Chemie - International Edition; vol. 56; nb. 17; (2017); p. 4777 - 4781; Angew. Chem.; vol. 129; nb. 59; (2017); p. 4855 - 4859,5, View in Reaxys; Fujino, Shota; Yamaji, Minoru; Okamoto, Hideki; Mutai, Toshiki; Yoshikawa, Isao; Houjou, Hirohiko; Tani, Fumito; Photochemical and Photobiological Sciences; vol. 16; nb. 6; (2017); p. 925 - 934, View in Reaxys; Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys; Patent; IMMUNE SENSOR, LLC; THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM; ZHONG, Boyu; SUN, Lijun; SHI, Heping; LI, Jing; CHEN, Chuo; CHEN, Zhijian; (270 pag.); WO2017/176812; (2017); (A1) English, View in Reaxys; Zhao, Baodong; Zhao, Weidong; Yu, Liujian; Li, Jie; Zhao, Yuming; Wang, Tao; New Journal of Chemistry; vol. 41; nb. 21; (2017); p. 13156 - 13165, View in Reaxys; Yadav, Arvind Kumar; Singh, Krishna Nand; New Journal of Chemistry; vol. 41; nb. 24; (2017); p. 14914 - 14917, View in Reaxys; Yu, Fei; Wang, Ting; Zhou, Huan; Li, Yajun; Zhang, Xinhao; Bao, Hongli; Organic Letters; vol. 19; nb. 24; (2017); p. 6538 - 6541, View in Reaxys 2a
Qian, Cheng; Lin, Dongen; Deng, Yuanfu; Zhang, Xiao-Qi; Jiang, Huanfeng; Miao, Guang; Tang, Xihao; Zeng, Wei; Organic and Biomolecular Chemistry; vol. 12; nb. 31; (2014); p. 5866 - 5875, View in Reaxys; Li, Dengke; Xu, Ning; Zhang, Yicheng; Wang, Lei; Chemical Communications; vol. 50; nb. 94; (2014); p. 14862 - 14865, View in Reaxys; Pan, Changduo; Zhang, Honglin; Han, Jie; Cheng, Yixiang; Zhu, Chengjian; Chemical Communications; vol. 51; nb. 18; (2015); p. 3786 - 3788, View in Reaxys; Terent'ev, Alexander O.; Vil', Vera A.; Gorlov, Evgenii S.; Nikishin, Gennady I.; Pivnitsky, Kasimir K.; Adam, Waldemar; Journal of Organic Chemistry; vol. 81; nb. 3; (2016); p. 810 - 823, View in Reaxys; Zhu, Hui; Teng, Fan; Pan, Changduo; Cheng, Jiang; Yu, Jin-Tao; Tetrahedron Letters; vol. 57; nb. 22; (2016); p. 2372 - 2374, View in Reaxys; Qian, Bo; Xiong, Haigen; Zhu, Nengbo; Ye, Changqing; Jian, Wujun; Bao, Hongli; Tetrahedron Letters; vol. 57; nb. 30; (2016); p. 3400 - 3403, View in Reaxys; Sun, Meng; Wang, Zhe; Wang, Jiaxin; Guo, Peiyu; Chen, Xiangxiang; Li, Ya-Min; Organic and Biomolecular Chemistry; vol. 14; nb. 45; (2016); p. 10585 - 10588, View in Reaxys; Zhu, Nengbo; Qian, Bo; Xiong, Haigen; Bao, Hongli; Tetrahedron Letters; vol. 58; nb. 43; (2017); p. 4125 - 4128, View in Reaxys
2
Patel, Darshan C.; Breitbach, Zachary S.; Woods, Ross M.; Lim, Yeeun; Wang, Andy; Foss, Frank W.; Armstrong, Daniel W.; Journal of Organic Chemistry; vol. 81; nb. 3; (2016); p. 1295 - 1299, View in Reaxys; Sharma; Utreja; Bedi; Asian Journal of Chemistry; vol. 28; nb. 10; (2016); p. 2153 - 2158, View in Reaxys; Kanemitsu, Takuya; Sato, Miho; Yoshida, Miyuki; Ozasa, Eisuke; Miyazaki, Michiko; Odanaka, Yuki; Nagata, Kazuhiro; Itoh, Takashi; Organic Letters; vol. 18; nb. 21; (2016); p. 5484 - 5487, View in Reaxys; Piras, Enrico; Secci, Francesco; Caboni, Pierluigi; Casula, Maria Francesca; Frongia, Angelo; RSC Advances; vol. 7; nb. 78; (2017); p. 49215 - 49219, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
3/162
2018-02-22 00:03:45
1a
Chen, Meng; Li, Yang; Tang, Hong; Ding, Hao; Wang, Kai; Yang, Lingen; Li, Cuiting; Gao, Meng; Lei, Aiwen; Organic Letters; vol. 19; nb. 12; (2017); p. 3147 - 3150, View in Reaxys
dbp
Ravat, Prince; Hinkelmann, Rahel; Steinebrunner, David; Prescimone, Alessandro; Bodoky, Ina; Juríček, Michal; Organic Letters; vol. 19; nb. 14; (2017); p. 3707 - 3710, View in Reaxys
1o
Pan, Changduo; Zhu, Jiawei; Chen, Rongzhen; Yu, Jin-Tao; Organic and Biomolecular Chemistry; vol. 15; nb. 31; (2017); p. 6467 - 6469, View in Reaxys
14
He, Benzhao; Wu, Yongwei; Qin, Anjun; Tang, Ben Zhong; Macromolecules; vol. 50; nb. 15; (2017); p. 5719 - 5728, View in Reaxys
1c
Zhu, Nengbo; Wang, Ting; Ge, Liang; Li, Yajun; Zhang, Xinhao; Bao, Hongli; Organic Letters; vol. 19; nb. 18; (2017); p. 4718 - 4721, View in Reaxys
2i
Li, Yougui; Han, Yulong; Xiong, Haigen; Zhu, Nengbo; Qian, Bo; Ye, Changqing; Kantchev, Eric Assen B.; Bao, Hongli; Organic Letters; vol. 18; nb. 3; (2016); p. 392 - 395, View in Reaxys
(PhCOO)2
Terentjeva, Svetlana; Muceniece, Dzintra; Petushkova, Jekaterina; Lusis, Viesturs; Journal of Chemical Research; vol. 40; nb. 4; (2016); p. 224 - 227, View in Reaxys
In.
Bahia, Samara Ben B. B.; Reis, Wallace J.; Jardim, Guilherme A. M.; Souto, Francielly T.; De Simone, Carlos A.; Gatto, Claudia C.; Menna-Barreto, Rubem F. S.; De Castro, Solange L.; Cavalcanti, Bruno C.; Pessoa, Claudia; Araujo, Maria H.; Da Silva Júnior, Eufrânio N.; MedChemComm; vol. 7; nb. 8; (2016); p. 1555 - 1563, View in Reaxys
9a
Yedage, Subhash L.; Bhanage, Bhalchandra M.; Green Chemistry; vol. 18; nb. 20; (2016); p. 5635 - 5642, View in Reaxys
BP
Opeida; Turovskii; Maksyuta; Russian Journal of Organic Chemistry; vol. 36; nb. 11; (2000); p. 1646 1649, View in Reaxys; Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester; Toxicology; vol. 165; nb. 2-3; (2001); p. 225 - 234, View in Reaxys; Mosnacek, Jaroslav; Weiss, Richard G.; Lukac, Ivan; Macromolecules; vol. 35; nb. 10; (2002); p. 3870 - 3875, View in Reaxys; MacManus-Spencer, Laura A.; Edhlund, Betsy L.; McNeill, Kristopher; Journal of Organic Chemistry; vol. 71; nb. 2; (2006); p. 796 - 799, View in Reaxys; Waller; Dreher; Behnam; Ford; Lee; Tiet; Weinstein; Maibach; Skin Pharmacology and Physiology; vol. 19; nb. 5; (2006); p. 283 - 289, View in Reaxys; Shoinbekova; Nikitina; Moldagazyeva; Mukhitdinova; Ergozhin; Russian Journal of Applied Chemistry; vol. 78; nb. 12; (2005); p. 2010 - 2013, View in Reaxys; Islamova; Puzin; Kraikin; Fatykhov; Dzhemilev; Monakov; Russian Journal of Applied Chemistry; vol. 79; nb. 9; (2006); p. 1509 - 1513, View in Reaxys; Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys; Serebryakova, Maria K.; Solomonov, Alexey V.; Rumyantsev, Evgeniy V.; Ivanov, Sergei P.; International Journal of Chemical Kinetics; vol. 47; nb. 1; (2015); p. 27 - 35, View in Reaxys; Murinov, Yu. I.; Grabovskiy, S. A.; Kuramshina, A. R.; Antipin, A. V.; Kabal'Nova, N. N.; Russian Journal of General Chemistry; vol. 85; nb. 1; (2015); p. 123 - 125; Zhurnal Obshchei Khimii; vol. 85; nb. 1; (2015); p. 132 134,3, View in Reaxys; Nasibullin; Safiullin; Sigaeva; Yakupova; Kolesov; Kinetics and Catalysis; vol. 56; nb. 1; (2015); p. 71 - 75; Kinet. Katal.; vol. 56; nb. 1; (2015); p. 77 - 81,5, View in Reaxys; Patent; Swenholt, Karen C.; US2015/320794; (2015); (A1) English, View in Reaxys
(PhCO&2%)&2%
Kojima, Hiroyuki; Takahata, Chisato; Lemin, David; Takahashi, Masato; Kumamoto, Takuya; Nakanishi, Waka; Suzuki, Noriyuki; Ishikawa, Tsutomu; Helvetica Chimica Acta; vol. 96; nb. 3; (2013); p. 379 388, View in Reaxys; Kisin-Finfer, Einat; Shabat, Doron; Bioorganic and Medicinal Chemistry; vol. 21; nb. 12; (2013); p. 3602 - 3608, View in Reaxys; Stopka, Tobias; Marzo, Leyre; Zurro, Mercedes; Janich, Simon; Würthwein, Ernst-Ulrich; Daniliuc, Constantin G.; Alemán, José; Mancheño, Olga García; Angewandte Chemie - International Edition; vol. 54; nb. 17; (2015); p. 5049 - 5053; Angew. Chem.; vol. 127; nb. 17; (2015); p. 5137 - 5141,5, View in Reaxys
(PhCOO)&2%
Braga, Saulo F.P.; Alves, Erika V.P.; Ferreira, Rafaela S.; Fradico, Jordana R.B.; Lage, Paula S.; Duarte, Mariana C.; Ribeiro, Tatiana G.; Junior, Policarpo A.S.; Romanha, Alvaro J.; Tonini, Maiko L.; Steindel, Mario; Coelho, Eduardo F.; De Oliveira, Renata B.; European Journal of Medicinal Chemistry; vol. 71; (2014); p. 282 - 289, View in Reaxys; Zhang, Xi-Sha; Zhang, Yun-Fei; Li, Zhao-Wei; Luo, Fei-Xian; Shi, Zhang-Jie; Angewandte Chemie - International Edition; vol. 54; nb. 18; (2015); p. 5478 - 5482; Angew. Chem.; vol. 127; nb. 18; (2015); p. 5568 - 5572,5, View in Reaxys
BzOOBz
Reeves, Jonathan T.; Lorenc, Chris; Camara, Kaddy; Li, Zhibin; Lee, Heewon; Busacca, Carl A.; Senanayake, Chris H.; Journal of Organic Chemistry; vol. 79; nb. 12; (2014); p. 5895 - 5902, View in Reaxys; Moore, Jane N.; Laskay, Nicholas M.; Duque, Kevin S.; Kelley, Steven P.; Rogers, Robin D.; Shaughnessy, Kevin H.; Journal of Organometallic Chemistry; vol. 777; (2015); p. 16 - 24, View in Reaxys
BPO; 3
Wang, Dehong; Xu, Changming; Zhang, Long; Luo, Sanzhon; Organic Letters; vol. 17; nb. 3; (2015); p. 576 - 579, View in Reaxys
DBP
Rickhaus, Michel; Bannwart, Linda Maria; Neuburger, Markus; Gsellinger, Heiko; Zimmermann, Kaspar; Häussinger, Daniel; Mayor, Marcel; Angewandte Chemie - International Edition; vol. 53; nb. 52; (2014); p. 14587 - 14591; Angew. Chem.; vol. 126; nb. 52; (2014); p. 14816 - 14820,5, View in Reaxys; See-
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
4/162
2018-02-22 00:03:45
tharamsingh; Ramesh, Remya; Dange, Santoshkumar S.; Khairnar, Pankaj V.; Singhal, Smita; Upadhyay, Dilip; Veeraraghavan, Sridhar; Viswanadha, Srikant; Vakkalanka, Swaroop; Reddy, D. Srinivasa; ACS Medicinal Chemistry Letters; vol. 6; nb. 11; (2015); p. 1105 - 1110, View in Reaxys 12
Zhu, Rong; Buchwald, Stephen L.; Journal of the American Chemical Society; vol. 137; nb. 25; (2015); p. 8069 - 8077, View in Reaxys
(PhCO2)2
Sefkow, Michael; Hoefle, Gerhard; Heterocycles; vol. 48; nb. 12; (1998); p. 2485 - 2488, View in Reaxys; Bottle, Steven E.; Micallef, Aaron S.; Organic and Biomolecular Chemistry; vol. 1; nb. 14; (2003); p. 2581 2584, View in Reaxys; Quek, Ser Kiang; Lyapkalo, Ilya M.; Huynh, Han Vinh; Synthesis; nb. 9; (2006); p. 1423 - 1426, View in Reaxys; Patent; NOGRA PHARMA LIMITED; HOMMES, Daan; VERHAAR, Auke; VAN DEN BRINK, Gijs; VITI, Francesa; WO2013/178816; (2013); (A1) English, View in Reaxys; Garcia-Rubin, Silvia; Gonzalez-Rodriguez, Carlos; Garcia-Yebra, Cristina; Varela, Jesus A.; Esteruelas, Miguel A.; Saa, Carlos; Angewandte Chemie - International Edition; vol. 53; nb. 7; (2014); p. 1841 - 1844; Angew. Chem.; vol. 53-126; nb. 7; (2014); p. 1872 - 1875, View in Reaxys
(BzO)&2%
Li, Xun; Jain, Nareshkumar; Russell, Ronald K.; Ma, Robert; Branum, Shawn; Xu, Jiayi; Sui, Zhihua; Organic Process Research and Development; vol. 10; nb. 2; (2006); p. 354 - 360, View in Reaxys; Bugera, Maksym Ya.; Tarasenko, Karen V.; Kukhar, Valery P.; Röschenthaler, Gerd-Volker; Gerus, Igor I.; Synthesis (Germany); vol. 45; nb. 22; (2013); p. 3157 - 3163; Art.No: SS-2013-T0354-OP, View in Reaxys; Zheng, Jun; You, Shu-Li; Angewandte Chemie - International Edition; vol. 53; nb. 48; (2014); p. 13244 13247; Angew. Chem.; vol. 126; nb. 48; (2014); p. 13460 - 13463,4, View in Reaxys
(PhCO)2O2
Wang, Fang; Sun, Jun-Rong; Huang, Mei-Yan; Wang, Hui-Ying; Sun, Ping-Hua; Lin, Jing; Chen, WeiMin; European Journal of Medicinal Chemistry; vol. 72; (2014); p. 35 - 45, View in Reaxys
2b
Chen, Zhi-Yuan; Ye, Chang-Qing; Zhu, Hui; Zeng, Xing-Ping; Yuan, Jian-Jun; Chemistry - A European Journal; vol. 20; nb. 15; (2014); p. 4237 - 4241, View in Reaxys
Bz&2%O&2%
Hong, Jun Bae; Davidson, James P.; Jin, Qingwu; Lee, Gary R.; Matchett, Michael; O'Brien, Erin; Welch, Michael; Bingenheimer, Bill; Sarma, Keshab; Organic Process Research and Development; vol. 18; nb. 1; (2014); p. 228 - 238, View in Reaxys; Kotha, Sambasivarao; Meshram, Milind; Synthesis (Germany); vol. 46; nb. 11; (2014); p. 1525 - 1531; Art.No: SS-2014-Z0002-OP, View in Reaxys
E-BPO
Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys
DBPO
Reichardt, Christian; Schroeder, Joerg; Voehringer, Peter; Schwarzer, Dirk; Physical Chemistry Chemical Physics; vol. 10; nb. 12; (2008); p. 1662 - 1668, View in Reaxys; Lennartz, Petra; Raabe, Gerhard; Bolm, Carsten; Advanced Synthesis and Catalysis; vol. 354; nb. 17; (2012); p. 3237 - 3249, View in Reaxys; Schmidt, Bernd M.; Topolinski, Berit; Yamada, Mihoko; Higashibayashi, Shuhei; Shionoya, Mitsuhiko; Sakurai, Hidehiro; Lentz, Dieter; Chemistry - A European Journal; vol. 19; nb. 41; (2013); p. 13872 13880, View in Reaxys
(PhCO)&2%O&2 %
Zhang, Xin; Li, Ridong; Qiao, Kang; Ge, Zemei; Zhang, Liangren; Cheng, Tieming; Li, Runtao; Archiv der Pharmazie; vol. 346; nb. 1; (2013); p. 44 - 52, View in Reaxys
Bz&2%O&3%
Reber, Keith P.; Tilley, S. David; Carson, Cheryl A.; Sorensen, Erik J.; Journal of Organic Chemistry; vol. 78; nb. 19; (2013); p. 9584 - 9607, View in Reaxys
(BzO)2
Yang, Dexi; Micalizio, Glenn C.; Journal of the American Chemical Society; vol. 134; nb. 37; (2012); p. 15237 - 15240, View in Reaxys
PS-36
Patent; RHODIA CHIMIE; US2008/287562; (2008); (A1) English, View in Reaxys
Bz2O2
Clark, Andrew J.; Deeth, Robert J.; Samuel, Christopher J.; Wongtap, Hathaichanuk; Synlett; nb. 4; (1999); p. 444 - 446, View in Reaxys; Nowak, Ireneusz; Rogers, Lillian M.; Rogers, Robin D.; Thrasher, Joseph S.; Journal of Fluorine Chemistry; vol. 99; nb. 1; (1999); p. 73 - 81, View in Reaxys; Clark, Andrew J.; Al-Faiyz, Yassair S.S.; Broadhurst, Michael J.; Patel, Divya; Peacock, Joanne L.; Journal of the Chemical Society, Perkin Transactions 1; nb. 7; (2000); p. 1117 - 1127, View in Reaxys; Jang, Yeong-Jiunn; Wu, Jhenyi; Lin, Yung-Feng; Yao, Ching-Fa; Tetrahedron; vol. 60; nb. 31; (2004); p. 6565 - 6574, View in Reaxys
I
Turovskii; Opeida; Kushch; Russian Journal of Organic Chemistry; vol. 39; nb. 5; (2003); p. 642 - 645, View in Reaxys
18
Ahn, Chuljin; Correia, Reuben; DeShong, Philip; Journal of Organic Chemistry; vol. 67; nb. 6; (2002); p. 1751 - 1753, View in Reaxys
4
Adam, Waldemar; Grimm, Guenther N.; Saha-Moeller, Chantu R.; Dall'Acqua, Francesco; Miolo, Gorgia; Vedaldi, Daniela; Chemical Research in Toxicology; vol. 11; nb. 9; (1998); p. 1089 - 1097, View in Reaxys; Martinez, Alicia; Urios, Amparo; Blanco, Manuel; Mutation Research - Genetic Toxicology and Environmental Mutagenesis; vol. 467; nb. 1; (2000); p. 41 - 53, View in Reaxys
BZP
Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 - 196, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
5/162
2018-02-22 00:03:45
BzPO
Matsui; Mintz; DeLeo; Skin Pharmacology; vol. 8; nb. 3; (1995); p. 130 - 138, View in Reaxys
Patent-Specific Data (7) Prophetic ComLocation in Patent References pound Page/Page column
Patent; DOW AGROSCIENCES LLC; Lowe, Christian T.; Trullinger, Tony K.; Hunter, Ricky; US2012/220453; (2012); (A1) English, View in Reaxys; Patent; Odorisio, Paul; Andrews, Stephen M.; Thompson, Thomas F.; Wu, Si; Thanki, Paragkumar; Rane, Deepak M.; Joseph, Delina; Wang, Jianzhao; US2013/35451; (2013); (A1) English, View in Reaxys; Patent; BioMarin Pharmaceutical, Inc.; Wang, Bing; Chu, Daniel; US2013/53365; (2013); (A1) English, View in Reaxys; Patent; HANMI SCIENCE CO., LTD.; CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION; KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY; Son, Jung Beom; Jung, Seung Hyun; Choi, Wha ll; Jung, Young Hee; Choi, Jae Yul; Song, Ji Yeon; Lee, Kyu Hang; Lee, Jae Chul; Kim, Eun Young; Ahn, Young Gil; Kim, Maeng Sup; Choi, Hwan Geun; Sim, Tae Bo; Ham, Young Jin; Park, Dong-sik; Kim, Hwan; Kim, Dong-Wook; US2013/53370; (2013); (A1) English, View in Reaxys; Patent; EISAI RandD MANAGEMENT CO., LTD.; YOSHIDA, Ichiro; OKABE, Tadashi; MATSUMOTO, Yasunobu; WATANABE, Nobuhisa; ONIZAWA, Yuji; OHASHI, Yoshiaki; HARADA, Hitoshi; US2013/65925; (2013); (A1) English, View in Reaxys; Patent; Gruenenthal GmbH; FRANK, Robert; Bahrenberg, Gregor; Christoph, Thomas; Lesch, Bernhard; Lee, Jeewoo; US2013/79320; (2013); (A1) English, View in Reaxys; Patent; GALDERMA RESEARCH and DEVELOPMENT; Rodeville, Nicolas; Pascal, Jean-Claude; Bouix-Peter, Claire; US2013/79544; (2013); (A1) English, View in Reaxys; Patent; Incyte Corporation; Huang, Taisheng; Feng, Hao; Kong, Lingquan; Wang, Anlai; Ye, Hai Fen; US2013/96144; (2013); (A1) English, View in Reaxys; Patent; Curis, Inc.; Bao, Rudi; Lai, Chengjung; Qian, Changgeng; US2013/102595; (2013); (A1) English, View in Reaxys; Patent; PFIZER INC.; DOROSKI, Matthew David; MADERNA, Andreas; O'DONNELL, Christopher John; SUBRAMANYAM, Chakrapani; VETELINO, Beth; DUSHIN, Russell George; STROP, Pavel; GRAZIANI, Edmund Idris; US2013/129753; (2013); (A1) English, View in Reaxys; Patent; The Regents of the University of Colorado, a body corporated; Wang, Xiang; Xu, Wenqing; US2013/137720; (2013); (A1) English, View in Reaxys; Patent; EISAI RandD MANAGEMENT CO., LTD.; Norimine, Yoshihiko; Takeda, Kunitoshi; Hagiwara, Koji; Suzuki, Yuichi; Ishihara, Yuki; Sato, Nobuaki; US2013/143907; (2013); (A1) English, View in Reaxys; Patent; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.; Bartolomé-Nebreda, José Manuel; MacDonald, Gregor James; Conde-Ceide, Susana; Jones, Carrie K.; Luz Martín-Martín, María; Tong, Han Min; US2013/245043; (2013); (A1) English, View in Reaxys; Patent; RVX Therapeutics Inc.; McLure, Kevin G.; Young, Peter R.; US2013/281399; (2013); (A1) English, View in Reaxys; Patent; Babaoglu, Kerim; Brizgys, Gediminas; Cha, Jake; Chen, Xiaowu; Guo, Hongyan; Halcomb, Randall L.; Han, Xiaochun; Huang, Richard; Liu, Hongtao; McFadden, Ryan; Mitchell, Michael L.; Qi, Yingmei; Roethle, Paul A.; Xu, Lianhong; Yang, Hong; US2013/281433; (2013); (A1) English, View in Reaxys; Patent; NOVARTIS AG; Cotesta, Simona; Furet, Pascal; Guagnano, Vito; Holzer, Philipp; Kallen, Joerg; Mah, Robert; Masuya, Keiichi; Schlapbach, Achim; Stutz, Stefan; Vaupel, Andrea; US2013/317024; (2013); (A1) English, View in Reaxys; Patent; NOVARTIS AG; Bock, Mark Gary; Gaul, Christoph; Gummadi, Venkateshwar Rao; Moebitz, Henrik; Sengupta, Saumitra; US2014/45872; (2014); (A1) English, View in Reaxys; Patent; Gavai, Ashvinikumar V.; DeLucca, George V.; O'Malley, Daniel; Gill, Patrice; Quesnelle, Claude A.; Fink, Brian E.; Zhao, Yufen; Lee, Francis Y.; US2014/87992; (2014); (A1) English, View in Reaxys; Patent; Arrington, Kenneth L.; Burgey, Christopher; Gilfillan, Robert; Han, Yongxin; Patel, Mehul; Li, Chun Sing; Li, Yaozong; Luo, Yunfu; Lei, Zhiyu; US2014/100231; (2014); (A1) English, View in Reaxys; Patent; LEWIS, Richard T.; ALLEN, Jennifer R.; CHENG, Yuan; CHOQUETTE, Deborah; EPSTEIN, Oleg; GUZMAN-PEREZ, Angel; HARRINGTON, Paul E.; HUA, Zihao; HUNGATE, Randall W.; HUMAN, Jason Brooks; JUDD, Ted; LIU, Qingyian; LOPEZ, Patricia; MINATTI, Ana Elena; OLIVIERI, Philip; ROMERO, Karina; RUMFELT, Shannon; RZASA, Robert M.; SCHENKEL, Laurie; STELLWAGEN, John; WHITE, Ryan; XUE, Qiufen; ZHENG, Xiao; ZHONG, Wenge; US2014/107109; (2014); (A1) English, View in Reaxys; Patent; CHIESI FARMACEUTICI S.p.A.; Armani, Elisabetta; Amari, Gabriele; Riccaboni, Mauro; Rizzi, Andrea; Baker-Glenn, Charles; Blackaby, Wesley; Van de Poel, Herve'; Whittaker, Ben; US2014/155427; (2014); (A1) English, View in Reaxys; Patent; Chiesi Farmaceutici S.p.A.; RANCATI, Fabio; Linney, Ian; Knight, Chris; Schmidt, Wolfgang; US2014/163066; (2014); (A1) English, View in Reaxys; Patent; Borealis AG; Resconi, Luigi; Castro, Pascal; Virkkunen, Ville; Izmer, Vyatcheslav V; Kononovich, Dimitry S.; Kulyabin, Pavel Sergeevich; Voskoboynikov, Alexander Z.; EP2746301; (2014); (A1) English, View in Reaxys; Patent; Meiji Seika Pharma Co., Ltd.; NAKANISHI Nozomu; FUKUDA Yoshimasa; KITSUDA Shigeki; OHNO Ikuya; EP2749555; (2014); (A1) English, View in Reaxys; Pat-
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
6/162
2018-02-22 00:03:45
ent; THE REGENTS OF THE UNIVERSITY OF MICHIGAN; Wang, Shaomeng; Chen, Jianfang; McEachern, Donna; Bai, Longchuan; Liu, Liu; Sun, Duxin; Li, Xiaoqin; Aguilar, Angelo; US2014/199234; (2014); (A1) English, View in Reaxys; Patent; Eisai RandD Management Co., Ltd.; YOSHIDA Ichiro; OKABE Tadashi; MATSUMOTO Yasunobu; WATANABE Nobuhisa; OHASHI Yoshiaki; ONIZAWA Yuji; HARADA Hitoshi; EP2757103; (2014); (A1) English, View in Reaxys; Patent; Maisch, Tim; Späth, Andreas; US2014/212459; (2014); (A1) English, View in Reaxys; Patent; Dow AgroSciences LLC; Eckelbarger, Joseph D.; Epp, Jeffrey B.; Fischer, Lindsey G.; Lowe, Christian T.; Petkus, Jeff; Roth, Joshua; Satchivi, Norbert M.; Schmitzer, Paul R.; Siddall, Thomas L.; US2014/274701; (2014); (A1) English, View in Reaxys; Patent; DIC CORPORATION; Tojo, Kenta; Takeuchi, Kiyofumi; Osawa, Masashi; Kaneoya, Masakazu; Kusumoto, Tetsuo; US2014/275577; (2014); (A1) English, View in Reaxys; Patent; Beijing Medisan Technology Co. Ltd.; WANG, Mingxin; LIU, Jinai; YANG, Fan; WANG, Ailing; SUN, Jiguo; WANG, Yan; CUI, Jin; JI, Lei; EP2784077; (2014); (A1) English, View in Reaxys; Patent; Council of Scientific and Industrial Research; Reddy, Dumbala Srinivasa; Balamkundu, Seetharam Singh; Ramesh, Remya; US2014/296133; (2014); (A1) English, View in Reaxys; Patent; CandC RESEARCH LABORATORIES; Ho, Pil Su; Yoon, Dong Oh; Han, Sun Young; Lee, Won Il; Kim, Jung Sook; Park, Woul Seong; Ahn, Sung Oh; Kim, Hye Jung; US2014/315888; (2014); (A1) English, View in Reaxys; Patent; KBP Biosciences Co., Ltd.; ZHANG, Yan; ZHANG, Min; LO, HoYin; (52 pag.); EP2781508; (2014); (A1) English, View in Reaxys; Patent; UNIVERSITA DEGLI STUDI DI FERRARA; Balzarini, Jan; Dehaen, Wim; Thomas, Joice; Liekens, Sandra; Romagnoli, Romeo; Baraldi, Pier Giovanni; US2015/126559; (2015); (A1) English, View in Reaxys; Patent; BAYER PHARMA AKTIENGESELLSCHAFT; Fürstner, Chantal; Ackerstaff, Jens; Straub, Alexander; Meier, Heinrich; Tinel, Hanna; Zimmermann, Katja; Tersteegen, Adrian; Zubov, Dmitry; Kast, Raimund; Schamberger, Jens; Schäfer, Martina; Börngen, Kirsten; US2015/148340; (2015); (A1) English, View in Reaxys; Patent; CHIESI FARMACEUTICI S.p.A.; Biagetti, Matteo; Capelli, Anna Maria; Accetta, Alessandro; Carzaniga, Laura; US2015/166549; (2015); (A1) English, View in Reaxys; Patent; Lantheus Medical Imaging, Inc.; Cesati, Richard R.; Radeke, Heike S.; Pandey, Suresh K.; Purohit, Ajay; Robinson, Simon P.; US2015/196672; (2015); (A1) English, View in Reaxys Claim
Patent; Norac Pharma; US2012/64135; (2012); (A1) English, View in Reaxys; Patent; PEKING UNIVERSITY; US2012/184768; (2012); (A1) English, View in Reaxys; Patent; Peking University; EP2481742; (2012); (A1) English, View in Reaxys; Patent; Glenmark Generics Limited; US2012/252897; (2012); (A1) English, View in Reaxys Patent; SYNTOPIX LIMITED; WO2006/100495; (2006); (A1) English, View in Reaxys Patent; Dainippon Sumitomo Pharma Co., Ltd.; AstraZeneca AB; EP1728792; (2006); (A1) English, View in Reaxys Patent; BP CORPORATION NORTH AMERICA INC.; WO2003/91195; (2003); (A1) English, View in Reaxys
prophetic product
Patent; The Procter and Gamble Company; US6338855; (2002); (B1) English, View in Reaxys; Patent; Yu, Ruey J.; Van Scott, Eugene J.; US6335023; (2002); (B1) English, View in Reaxys
prophetic catalyst
Patent; Eastman Chemical Company; US6348623; (2002); (B2) English, View in Reaxys
Druglikeness (1) 1 of 1
LogP
3.32
H Bond Donors
0
H Bond Acceptors
4
Rotatable Bonds
5
TPSA
52.6
Lipinski Number
4
Veber Number
2
Highest Clinical Phase (1) Highest Clinical Phase Marketed Related Structure (2) Related Structure References
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
7/162
2018-02-22 00:03:45
Lee; Minoura; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 74; (1978); p. 1726,1729,1731-1733, View in Reaxys Constitution.
Willstaetter; Hauenstein; Chemische Berichte; vol. 42; (1909); p. 1850, View in Reaxys
Catalyst Investigation (3) 1 of 3
Investigated characteris- Catalytic activity tic(s) Kotha, Sambasivarao; Meshram, Milind; Synthesis (Germany); vol. 46; nb. 11; (2014); p. 1525 - 1531; Art.No: SS-2014-Z0002-OP, View in Reaxys; Wang, Yaxin; Li, Guo-Xing; Yang, Guohui; He, Gang; Chen, Gong; Chemical Science; vol. 7; nb. 4; (2016); p. 2679 - 2683, View in Reaxys; Gobbi, Silvia; Hu, Qingzhong; Zimmer, Christina; Engel, Matthias; Belluti, Federica; Rampa, Angela; Hartmann, Rolf W.; Bisi, Alessandra; Journal of Medicinal Chemistry; vol. 59; nb. 6; (2016); p. 2468 - 2477, View in Reaxys
2 of 3
Investigated characteris- Catalytic activity tic(s) Type of reaction (Catalyst Investigation)
Annulation
Pan, Changduo; Huang, Bifan; Hu, Weiming; Feng, Xiaomei; Yu, Jin-Tao; Journal of Organic Chemistry; vol. 81; nb. 5; (2016); p. 2087 - 2093, View in Reaxys 3 of 3
Investigated characteris- Catalytic activity tic(s) Location
Paragraph 0071
Patent; Gao Tingmei; Gao, Tingmei; (9 pag.); CN105481767; (2016); (A) Chinese, View in Reaxys Derivative (3) Comment (Derivative) Mol.Komplex 1:1 mit Piperidin in DMF; K (9-24grad, potentiometrisch)
References Vartapetyan et al.; Russian Journal of Physical Chemistry; vol. 47; (1973); p. 774; ; p. 1351, View in Reaxys
Komplex (1:1) mit Vartapetyan; Khachatryan; Uchenye Zapiski, Erevanskii Gosudarstvennyi Universitet; vol. 2; (1973); p. 1,4-Dipiperid-yl-2- 50,51-54; Chem.Abstr.; vol. 81; nb. 151933e; Chem. Zentralbl.; 1974, Nr.8, B119B, View in Reaxys Me-buten-2 K(Stab.): Spektrophotometr., nur i.Orig. bei 9-20grad -> ΔH(Standard), ΔS(Standard), vorausgesetzt Bindung von -OO- zu freien El.Paaren des Piperidins Komplex (1:1) mit Vartapetyan; Khachatryan; Uchenye Zapiski, Erevanskii Gosudarstvennyi Universitet; vol. 2; (1973); p. 1-Piperid-yl-250,51-54; Chem.Abstr.; vol. 81; nb. 151933e; Chem. Zentralbl.; 1974, Nr.8, B119B, View in Reaxys Cl-3-Me-5-MeObuten-2 K(Stab.): Spektrophotometr., nur i.Orig. bei 9-20grad -> ΔH(Standard), ΔS(Standard), vorausgesetzt Bindung von -OO- zu freien El.Paaren des Piperidins Melting Point (38) 1 of 38
Melting Point [°C]
107.84
Solvent (Melting Point)
methanol
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
8/162
2018-02-22 00:03:45
Nasibullin; Safiullin; Sigaeva; Yakupova; Kolesov; Kinetics and Catalysis; vol. 56; nb. 1; (2015); p. 71 - 75; Kinet. Katal.; vol. 56; nb. 1; (2015); p. 77 - 81,5, View in Reaxys 2 of 38
Melting Point [°C]
108
Solvent (Melting Point)
methanol
Comment (Melting Point)
Decomposition
Islamova; Puzin; Kraikin; Fatykhov; Dzhemilev; Monakov; Russian Journal of Applied Chemistry; vol. 79; nb. 9; (2006); p. 1509 - 1513, View in Reaxys 3 of 38
Melting Point [°C]
106 - 108
Solvent (Melting Point)
methanol
Shoinbekova; Nikitina; Moldagazyeva; Mukhitdinova; Ergozhin; Russian Journal of Applied Chemistry; vol. 78; nb. 12; (2005); p. 2010 - 2013, View in Reaxys 4 of 38
Melting Point [°C]
108
Solvent (Melting Point)
methanol
Yumagulova; Kolesov; Monakov; Russian Journal of Applied Chemistry; vol. 78; nb. 2; (2005); p. 291 - 294, View in Reaxys 5 of 38
Melting Point [°C]
104
Solvent (Melting Point)
ethanol
Achilias, Dimitris S.; Sideridou, Irini D.; Macromolecules; vol. 37; nb. 11; (2004); p. 4254 - 4265, View in Reaxys 6 of 38
Melting Point [°C]
107
Solvent (Melting Point)
methanol
Puzin, Yu.I.; Leplyanin, G.V.; Kozheparova, E.A.; Tolstikov, G.A.; Doklady Chemistry; vol. 320; nb. 1-3; (1991); p. 251 - 253; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 320; nb. 2; (1991); p. 349 - 352, View in Reaxys; Puzin, Yu. I.; Leplyanin, G.V.; Muslikhov, R.R.; Tolstikov, G.A.; Doklady Chemistry; vol. 320; nb. 1-3; (1991); p. 277 - 281; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 320; nb. 3; (1991); p. 638 - 642, View in Reaxys; Puzin, Yu. I.; Leplyanin, G. V.; Spirikhin, L. V.; Parmenova, I. P.; Muslukhov, R. M.; Tolstikov, G. A.; Doklady Chemistry; vol. 279; (1984); p. 422 - 426; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 279; nb. 3; (1984); p. 646 - 650, View in Reaxys 7 of 38
Melting Point [°C]
106 - 107
Solvent (Melting Point)
CHCl3; methanol
Comment (Melting Point)
Decomposition
Auricchio, Sergio; Citterio, Attilio; Sebastiano, Roberto; Journal of Organic Chemistry; vol. 55; nb. 26; (1990); p. 6312 - 6316, View in Reaxys 8 of 38
Melting Point [°C]
107.5
Solvent (Melting Point)
methanol
Puzin, Yu. I.; Leplyanin, G. V.; Rafikov, S. R.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 33; (1984); p. 1892 - 1895; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 9; (1984); p. 2073 - 2076, View in Reaxys 9 of 38
Melting Point [°C]
105 - 106
Tanner et al.; Canadian Journal of Chemistry; vol. 48; (1970); p. 1492,1496, View in Reaxys; Bolton et al.; Journal of Fluorine Chemistry; vol. 4; (1974); p. 363,364-368, View in Reaxys; Bolton et al.; Journal of Fluorine Chemistry; vol. 11; (1978); p. 591,593, 599, View in Reaxys; El'nitskii, A. P.; Serrano, K. F.; Poluyan, O. S.; Journal of Organic Chemistry USSR (English Translation); vol. 19; nb. 8; (1983); p. 1565 - 1566; Zhurnal Organicheskoi Khimii; vol. 19; nb. 8; (1983); p. 1764, View in Reaxys 10 of 38
Melting Point [°C]
106 - 108
Baeyer; Villiger; Chemische Berichte; vol. 33; (1900); p. 1581, View in Reaxys; Rakhimov, A. I.; Androsyuk, E. R.; Shelyazhenko, S. V.; Yagupol'skii, L. M.; Journal of Organic Chemistry USSR (English Translation); (1981); p. 1470 - 1475; Zhurnal Organicheskoi Khimii; vol. 17; nb. 8; (1981); p. 1652 - 1657, View in Reaxys 11 of 38
Melting Point [°C]
104 - 106
Ogata, Yoshiro; Tomizawa, Kohtaro; Furuta, Kyoji; Kato, Hiroshi; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); (1981); p. 110 - 112, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
9/162
2018-02-22 00:03:45
12 of 38
Melting Point [°C]
106
Razuvaev et al.; J. Gen. Chem. USSR (Engl. Transl.); vol. 40; (1970); p. 1804,1789,1791,1792,1793, View in Reaxys; Voronkov et al.; Soobshcheniya Akademii Nauk Gruzinskoi SSR; vol. 93; nb. 1; (1979); p. 61,62,63,64, View in Reaxys 13 of 38
Melting Point [°C]
104
Kiparisova,E.G.; Rabinovich,I.B.; Doklady Chemistry; vol. 199; (1971); p. 675 - 677; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 199; nb. 5; (1971); p. 1075 - 1077, View in Reaxys; Prileshajew; Zhurnal Russkago Fiziko-Khimicheskago Obshchestva; vol. 42; (1910); p. 1409; Chem. Zentralbl.; vol. 82; nb. I; (1911); p. 1280, View in Reaxys; Rychly; Andrasik; Staudner; Beniska; Journal of Luminescence; vol. 11; nb. 3-4; (1976); p. 173 - 183, View in Reaxys 14 of 38
Melting Point [°C]
105 - 107
Swern et al.; Analytical Chemistry; vol. 41; (1969); p. 412, View in Reaxys; Johnson; Tetrahedron Letters; (1976); p. 331, View in Reaxys 15 of 38
Melting Point [°C]
103
Fichter; Schnider; Helvetica Chimica Acta; vol. 13; (1930); p. 1428,1430, 1433, View in Reaxys; Karawya; Ghourab; Egyptian Journal of Pharmaceutical Sciences; vol. 16; (1975); p. 35,36, View in Reaxys; Yousufzai et al.; Pakistan Journal of Scientific and Industrial Research; vol. 15; (1972); p. 148, View in Reaxys 16 of 38
Melting Point [°C]
108
Borsig et al.; Collection of Czechoslovak Chemical Communications; vol. 40; (1975); p. 3845, View in Reaxys 17 of 38
Melting Point [°C]
105.5
Burn et al.; Journal of the Chemical Society; (1963); p. 1527,1531, View in Reaxys; Gill; Williams; Journal of the Chemical Society; (1965); p. 7127,7130, View in Reaxys; Bolton et al.; Journal of Fluorine Chemistry; vol. 4; (1974); p. 363,364-368, View in Reaxys; Gill; Williams; Journal of the Chemical Society; (1965); p. 995,999, View in Reaxys; Gill; Williams; Journal of the Chemical Society [Section] B: Physical Organic; (1966); p. 880,881,882, View in Reaxys; Lewis; Williams; Journal of the Chemical Society [Section] B: Physical Organic; (1969); p. 120, View in Reaxys 18 of 38
Melting Point [°C]
107 - 108
Berre; Bergue; Bulletin de la Societe Chimique de France; (1966); p. 2368,2373, View in Reaxys; Otsuka et al.; Journal of the American Chemical Society; vol. 94; (1972); p. 3761,3767, View in Reaxys 19 of 38
Melting Point [°C]
106 - 107
Kuhnert-Brandstaetter et al.; Scientia Pharmaceutica; vol. 38; (1970); p. 154,156,162, View in Reaxys 20 of 38
Melting Point [°C]
101.5 - 102
Solvent (Melting Point)
ethanol
Mikhailov; Nenkov; Izvestiya na Otdelenieto za Khimicheski Nauki (Bulgarska Akademiya na Naukite); vol. 2; (1969); p. 103,109, View in Reaxys 21 of 38
Melting Point [°C]
108
Solvent (Melting Point)
CHCl3; methanol
Hashimoto et al.; Kogyo Kagaku Zasshi; vol. 72; (1969); p. 2277,2278-2280; Chem.Abstr.; vol. 72; nb. 42508; (1970), View in Reaxys 22 of 38
Melting Point [°C]
96.85 - 99.85
Lazar; Ambrovic; Chemicke Zvesti; vol. 23; (1969); p. 881,883,885,886,889, View in Reaxys 23 of 38
Melting Point [°C]
105
Marvel; Nichols; Journal of Organic Chemistry; vol. 6; (1941); p. 296,299, View in Reaxys; Cadogan et al.; Journal of the Chemical Society; (1965); p. 3939,3941, View in Reaxys; Sprecher; Nativ; Tetrahedron Letters; (1968); p. 4405, View in Reaxys 24 of 38
Melting Point [°C]
103.5
Sax; McMullan; Acta Crystallographica; vol. 22; (1967); p. 281,284, 286, View in Reaxys 25 of 38
Melting Point [°C]
105
Solvent (Melting Point)
CHCl3; methanol
Huyser; Kim; Journal of Organic Chemistry; vol. 32; (1967); p. 618,619, 620, View in Reaxys; Ol'dekop; El'nizkii; J. Gen. Chem. USSR (Engl. Transl.); vol. 34; (1964); p. 3478,3520, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
10/162
2018-02-22 00:03:45
26 of 38
Melting Point [°C]
104 - 105
Staab,H.A. et al.; Chemische Berichte; vol. 98; (1965); p. 1122 - 1127, View in Reaxys; Vanino; Herzer; Archiv der Pharmazie (Weinheim, Germany); vol. 253; (1915); p. 434, View in Reaxys 27 of 38
Melting Point [°C]
106
Solvent (Melting Point)
methanol; CHCl3
Hasegawa et al.; Bulletin of the Chemical Society of Japan; vol. 36; (1963); p. 522, View in Reaxys 28 of 38
Melting Point [°C]
105 - 105.5
Solvent (Melting Point)
CHCl3; methanol
Greene,F.D.; Kazan,J.; Journal of Organic Chemistry; vol. 28; (1963); p. 2168 - 2171, View in Reaxys 29 of 38
Melting Point [°C]
105 - 106
Solvent (Melting Point)
CCl4; methanol
Greene,F.D.; Kazan,J.; Journal of Organic Chemistry; vol. 28; (1963); p. 2168 - 2171, View in Reaxys 30 of 38
Melting Point [°C]
101 - 101.5
Milowskaja et al.; J. Gen. Chem. USSR (Engl. Transl.); vol. 32; (1962); p. 621,612; Chem.Abstr.; vol. 58; nb. 445; (1963), View in Reaxys 31 of 38
Melting Point [°C]
103 - 104
Solvent (Melting Point)
CHCl3; methanol
Lawesson et al.; Arkiv foer Kemi; vol. 17; (1961); p. 429,433, View in Reaxys 32 of 38
Melting Point [°C]
110
Kirmse; Horner; Chemische Berichte; vol. 89; (1956); p. 836,840, View in Reaxys 33 of 38
Comment (Melting Point)
Decomposition.at:110 degreeC.Explosionspunkt.
Dickey et al.; Industrial and Engineering Chemistry; vol. 41; (1949); p. 1674, View in Reaxys 34 of 38
Solvent (Melting Point)
CHCl3
Fichter; Schnider; Helvetica Chimica Acta; vol. 13; (1930); p. 1428,1430, 1433, View in Reaxys 35 of 38
Comment (Melting Point)
Decomposition.at:107 degreeC.Explosionspunkt.
Fichter; Helvetica Chimica Acta; vol. 13; (1930); p. 92,96, View in Reaxys 36 of 38
Comment (Melting Point)
Decomposition.at:104 degreeC. - :105 degreeC.Explosionspunkt.
Fichter; Schnider; Helvetica Chimica Acta; vol. 13; (1930); p. 1428,1430, 1433, View in Reaxys 37 of 38
Melting Point [°C]
110
Comment (Melting Point)
bei raschem Erhitzen.
Baeyer; Villiger; Chemische Berichte; vol. 33; (1900); p. 1581, View in Reaxys 38 of 38
Melting Point [°C]
103.5
Solvent (Melting Point)
diethyl ether
Comment (Melting Point)
Decomposition.
Brodie; Jahresbericht ueber die Fortschritte der Chemie und Verwandter Theile Anderer Wissenschaften; (1863); p. 317, View in Reaxys; Brodie; Journal of the Chemical Society; vol. 17; (1864); p. 269; Ann. d. Physik; vol. 121; (1864); p. 377, View in Reaxys Density (2) 1 of 2
Type (Density)
crystallographic
Vary; McBride; Molecular Crystals and Liquid Crystals (1969-1991); vol. 52; (1979); p. 133,134,136,140, View in Reaxys; Sax; McMullan; Acta Crystallographica; vol. 22; (1967); p. 281,284, 286, View in Reaxys 2 of 2
Density [g·cm-3]
1.334
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
11/162
2018-02-22 00:03:45
Type (Density)
crystallographic
Kasatotschkin; Perlina; Ablesowa; Doklady Akademii Nauk SSSR; S.S.S.R.; vol. 47; (1945); p. 36,37, View in Reaxys Adsorption (MCS) (3) 1 of 3
Description (Adsorption (MCS))
Adsorption
Solvent (Adsorption (MCS))
acetonitrile
Partner (Adsorption (MCS))
poly(dimethylsiloxane) modified with Si(OC2H5)4 and VO(acetylacetonate)2(pyrazole)*tris(1-pyrazolyl)methane
Silva, Telma F.S.; Leod, Tatiana C.O. Mac; Martins, Luisa M.D.R.S.; Guedes Da Silva, M. Fatima C.; Schiavon, Marco A.; Pombeiro, Armando J.L.; Journal of Molecular Catalysis A: Chemical; vol. 367; (2013); p. 52 - 60, View in Reaxys 2 of 3
Description (Adsorption (MCS))
Adsorption
Solvent (Adsorption (MCS))
acetonitrile
Partner (Adsorption (MCS))
poly(dimethylsiloxane) modified with Si(OC2H5)4 and VOCl2(2,2,2-tris(1-pyrazolyl)ethanol)
Silva, Telma F.S.; Leod, Tatiana C.O. Mac; Martins, Luisa M.D.R.S.; Guedes Da Silva, M. Fatima C.; Schiavon, Marco A.; Pombeiro, Armando J.L.; Journal of Molecular Catalysis A: Chemical; vol. 367; (2013); p. 52 - 60, View in Reaxys 3 of 3
Description (Adsorption (MCS))
Adsorption
Mar'in; Shlyapnikov; Doklady Physical Chemistry; vol. 219; (1974); p. 1205,1206, 1207; ; p. 1409, View in Reaxys; Sokolova; Boichinova; J. Appl. Chem. USSR (Engl. Transl.); vol. 43; (1970); p. 798,802, View in Reaxys Association (MCS) (13) 1 of 13
Description (Association Stability constant of the complex with ... (MCS)) Solvent (Association (MCS))
various solvents
Partner (Association (MCS))
β‐cyclodextrin
Xie, Hui; Wang, Huai You; Ma, Li Ying; Xiao, Yan; Han, Juan; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 62; nb. 1-3; (2005); p. 197 - 202, View in Reaxys 2 of 13
Description (Association UV/VIS spectrum of the complex (MCS)) Solvent (Association (MCS))
various solvents
Comment (Association (MCS))
concentration dependence
Partner (Association (MCS))
β‐cyclodextrin
Xie, Hui; Wang, Huai You; Ma, Li Ying; Xiao, Yan; Han, Juan; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 62; nb. 1-3; (2005); p. 197 - 202, View in Reaxys 3 of 13
Description (Association IR spectrum of the complex (MCS)) Solvent (Association (MCS))
toluene
Comment (Association (MCS))
solvent dependence. Object(s) of Study: time dependence. Object(s) of Study: concentration dependence
Partner (Association (MCS))
hydrogenated diamond powder
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
12/162
2018-02-22 00:03:45
Tsubota, Toshiki; Hirabayashi, Osamu; Ida, Shintaro; Nagaoka, Shoji; Nagata, Masanori; Matsumoto, Yasumichi; Physical Chemistry Chemical Physics; vol. 4; nb. 5; (2002); p. 806 - 811, View in Reaxys 4 of 13
Description (Association NMR spectrum of the complex (MCS)) Solvent (Association (MCS))
various solvent(s)
Temperature (Association (MCS)) [°C]
21.85
Partner (Association (MCS))
C96H108N12O16
Koerner, Steffi K.; Tucci, Fabio C.; Rudkevich, Dmitry M.; Heinz, Thomas; Rebek Jr., Julius; Chemistry - A European Journal; vol. 6; nb. 1; (2000); p. 187 - 195, View in Reaxys 5 of 13
Description (Association UV/VIS spectrum of the complex (MCS)) Solvent (Association (MCS))
H2O
Temperature (Association (MCS)) [°C]
20
Partner (Association (MCS))
cetylpyridinium chloride; KI3
Lunar; Rubio; Perez-Bendito; Journal of Pharmaceutical Sciences; vol. 83; nb. 3; (1994); p. 407 - 409, View in Reaxys 6 of 13
Description (Association IR spectrum of the complex (MCS)) Solvent (Association (MCS))
CCl4
Partner (Association (MCS))
bis(amylthio)bis(phenyl)methane
Puzin, Yu. I.; Leplyanin, G. V.; Tolstikov, G. A.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 37; (1988); p. 1586 - 1588; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 8; (1988); p. 1780 - 1782, View in Reaxys 7 of 13
Description (Association IR spectrum of the complex (MCS)) Solvent (Association (MCS))
CCl4
Partner (Association (MCS))
2,2-bis(amylthio)propane
Puzin, Yu. I.; Leplyanin, G. V.; Tolstikov, G. A.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 37; (1988); p. 1586 - 1588; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 8; (1988); p. 1780 - 1782, View in Reaxys 8 of 13
Description (Association NMR spectrum of the complex (MCS)) Solvent (Association (MCS))
CDCl3
Temperature (Association (MCS)) [°C]
24.9 - 59.9
Partner (Association (MCS))
bis(amylthio)bis(phenyl)methane
Puzin, Yu. I.; Leplyanin, G. V.; Tolstikov, G. A.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 37; (1988); p. 1586 - 1588; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 8; (1988); p. 1780 - 1782, View in Reaxys 9 of 13
Description (Association NMR spectrum of the complex (MCS))
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
13/162
2018-02-22 00:03:45
Solvent (Association (MCS))
CD2Cl2
Partner (Association (MCS))
pyridine; InI
Peppe, Clovis; Tuck, Dennis G.; Canadian Journal of Chemistry; vol. 62; (1984); p. 2798 - 2802, View in Reaxys 10 of 13
Description (Association IR spectrum of the complex (MCS)) Solvent (Association (MCS))
CCl4
Temperature (Association (MCS)) [°C]
25
Partner (Association (MCS))
formaldehyde S,S'-diamylomercaptal
Puzin, Yu. I.; Leplyanin, G. V.; Rafikov, S. R.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 33; (1984); p. 1892 - 1895; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 9; (1984); p. 2073 - 2076, View in Reaxys 11 of 13
Description (Association NMR spectrum of the complex (MCS)) Solvent (Association (MCS))
CDCl3
Temperature (Association (MCS)) [°C]
24.9
Partner (Association (MCS))
formaldehyde S,S'-diamylomercaptal
Puzin, Yu. I.; Leplyanin, G. V.; Spirikhin, L. V.; Parmenova, I. P.; Muslukhov, R. M.; Tolstikov, G. A.; Doklady Chemistry; vol. 279; (1984); p. 422 - 426; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 279; nb. 3; (1984); p. 646 - 650, View in Reaxys 12 of 13
Description (Association NMR spectrum of the complex (MCS)) Solvent (Association (MCS))
CDCl3
Temperature (Association (MCS)) [°C]
24.9
Partner (Association (MCS))
1-(1-Pentylsulfanyl-ethylsulfanyl)-pentane
Puzin, Yu. I.; Leplyanin, G. V.; Spirikhin, L. V.; Parmenova, I. P.; Muslukhov, R. M.; Tolstikov, G. A.; Doklady Chemistry; vol. 279; (1984); p. 422 - 426; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 279; nb. 3; (1984); p. 646 - 650, View in Reaxys 13 of 13
Description (Association NMR spectrum of the complex (MCS)) Solvent (Association (MCS))
CDCl3
Temperature (Association (MCS)) [°C]
24.9
Partner (Association (MCS))
1-(bis(pentylthio)methyl)benzene
Puzin, Yu. I.; Leplyanin, G. V.; Spirikhin, L. V.; Parmenova, I. P.; Muslukhov, R. M.; Tolstikov, G. A.; Doklady Chemistry; vol. 279; (1984); p. 422 - 426; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 279; nb. 3; (1984); p. 646 - 650, View in Reaxys Chromatographic Data (1) Chromatographic References data TLC (Thin layer chromatography)
McDonald, Stacey L.; Hendrick, Charles E.; Bitting, Katie J.; Wang, Qiu; Organic Syntheses; vol. 92; (2016); p. 356 - 372, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
14/162
2018-02-22 00:03:45
Conformation (2) Object of Investi- References gation Energy difference between the conformers
Kikuchi et al.; Bulletin of the Chemical Society of Japan; vol. 51; (1978); p. 11,13, View in Reaxys
Conformation
Jehlicka et al.; Collection of Czechoslovak Chemical Communications; vol. 40; (1975); p. 3004,3005,3006, View in Reaxys; Fayat; Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques; vol. 265; (1967); p. 1406, View in Reaxys
Crystal Phase (5) Description (Crys- Comment (Crystal References tal Phase) Phase) Crystal structure determination
Vary; McBride; Molecular Crystals and Liquid Crystals (1969-1991); vol. 52; (1979); p. 133,134,136,140, View in Reaxys; Sax; McMullan; Acta Crystallographica; vol. 22; (1967); p. 281,284, 286, View in Reaxys; Jeffrey et al.; Journal of the American Chemical Society; vol. 86; (1964); p. 949, View in Reaxys
Solid state structure properties
Vary; McBride; Molecular Crystals and Liquid Crystals (1969-1991); vol. 52; (1979); p. 133,134,136,140, View in Reaxys
Crystal morphology
Morsi et al.; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 71; (1975); p. 1857,1858 - 1863, View in Reaxys; Sax; McMullan; Acta Crystallographica; vol. 22; (1967); p. 281,284, 286, View in Reaxys
Crystal structure determination
.
Sax; McMullan; Acta Crystallographica; vol. 22; (1967); p. 281,284, 286, View in Reaxys
Crystal structure determination
a=8.91 Angstroem, b=9.45 Angstroem, c=14.33 Angstroem, n=4.
Kasatotschkin; Perlina; Ablesowa; Doklady Akademii Nauk SSSR; S.S.S.R.; vol. 47; (1945); p. 36,37, View in Reaxys
Crystal Property Description (2) Colour & Other Location Properties
References
white
Paragraph 0014; 0016; 0018
Patent; Jiangsu Sinobiopharma Co., Ltd.; Huang, Lequn; Chen, Quan; (6 pag.); CN106349139; (2017); (A) Chinese, View in Reaxys
yellow
Paragraph 159
Patent; CONCERT PHARMACEUTICALS, INC.; TUNG, Roger, D.; WO2014/110322; (2014); (A2) English, View in Reaxys
Crystal System (1) Crystal System References rhombic
Kasatotschkin; Perlina; Ablesowa; Doklady Akademii Nauk SSSR; S.S.S.R.; vol. 47; (1945); p. 36,37, View in Reaxys
Decomposition (1) 1 of 1
Rykov; Buchachenko; Doklady Physical Chemistry; vol. 184-189; (1969); p. 233; Doklady Akademii Nauk SSSR; vol. 185; (1969); p. 870, View in Reaxys; Rychly; Andrasik; Staudner; Beniska; Journal of Luminescence; vol. 11; nb. 3-4; (1976); p. 173 - 183, View in Reaxys; Melik-Ogandzhanyan et al.; Kinetics and Catalysis; vol. 15; (1974); p. 509, View in Reaxys; Vary; McBride; Molecular Crystals and Liquid Crystals (1969-1991); vol. 52; (1979); p. 133,134,136,140, View in Reaxys
Dissociation Energy (1) References Kiparisova,E.G.; Rabinovich,I.B.; Doklady Chemistry; vol. 199; (1971); p. 675 - 677; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 199; nb. 5; (1971); p. 1075 - 1077, View in Reaxys Electrical Data (1) 1 of 1
Description (Electrical Data)
Piezoelectricity
Comment (Electrical Da- Dibenzoylperoxid ist piezoelektrisch. ta) Hettich; Steinmetz; Zeitschrift fuer Physik; vol. 76; (1932); p. 688,699, View in Reaxys Electrical Moment (3)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
15/162
2018-02-22 00:03:45
1 of 3
Description (Electrical Moment)
Dipole moment
Jehlicka et al.; Collection of Czechoslovak Chemical Communications; vol. 40; (1975); p. 3004,3005,3006, View in Reaxys 2 of 3
Description (Electrical Moment)
Dipole moment
Moment (Electrical Moment) [D]
1.6
Method (Electrical Moment)
Dielectric constant (ε)
Solvent (Electrical Moment)
benzene
Lobunez et al.; Journal of the American Chemical Society; vol. 80; (1958); p. 3505,3506, View in Reaxys 3 of 3
Description (Electrical Moment)
Dipole moment
Moment (Electrical Moment) [D]
1.58
Method (Electrical Moment)
Dielectric constant (ε)
Solvent (Electrical Moment)
benzene
Oesper; Smyth; Journal of the American Chemical Society; vol. 64; (1942); p. 768,769, View in Reaxys Electrochemical Behaviour (1) Description (Elec- References trochemical Behaviour) Polarography
Fleet et al.; Journal of Electroanalytical Chemistry and Interfacial Electrochemistry; vol. 22; (1969); p. 63, View in Reaxys; Kuta; Quackenbush; Analytical Chemistry; vol. 32; (1960); p. 1069,1070, View in Reaxys; Antonowskii et al.; J. Gen. Chem. USSR (Engl. Transl.); vol. 39; (1969); p. 268,250, View in Reaxys
Electrochemical Characteristics (4) 1 of 4
Description (Electrochemical Characteristics)
polarographic half-wave potential
Kovbuz, M. A.; Gorbachevskaya, K. R.; Artym, I. I.; J. Gen. Chem. USSR (Engl. Transl.); vol. 55; nb. 4; (1985); p. 817 - 820,729 - 732, View in Reaxys 2 of 4
Description (Electrochemical Characteristics)
polarographic half-wave potential
Comment (Electrochem- in Methanol und Benzol. ical Characteristics) Willits et al.; Analytical Chemistry; vol. 24; (1952); p. 785,789, View in Reaxys; Bernard; Annales de Chimie (Cachan, France); vol. <12> 10; (1955); p. 315,324, 328, 333, 338, View in Reaxys; Besugly; Dimitriewa; Zhurnal Prikladnoi Khimii (Sankt-Peterburg, Russian Federation); vol. 31; (1958); p. 298,302; engl. Ausg. S. 283, 285; Zavod. Labor.; vol. 24; (1958); p. 941,945; Chem.Abstr.; (1960); p. 11539, View in Reaxys 3 of 4
Description (Electrochemical Characteristics)
polarographic half-wave potential
Comment (Electrochem- in wss. Aethanol. ical Characteristics) Giguere; Lamontagne; Canadian Journal of Chemistry; vol. 29; (1951); p. 54,56, View in Reaxys 4 of 4
Description (Electrochemical Characteristics)
polarographic current/voltage curve
Lewis; Quackenbush; De Vries; Analytical Chemistry; vol. 21; (1949); p. 762,765, View in Reaxys Electron Binding (1)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
16/162
2018-02-22 00:03:45
Description (Elec- References tron Binding) Electron affinity
Cabildo et al.; Anales de Quimica (1968-1979); vol. 73; (1977); p. 330, View in Reaxys; Kurov, G. N.; Svyatkina, L. I.; Gaintseva, L. L.; Naumova, I. P.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 34; (1985); p. 2542 - 2546; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 12; (1985); p. 2746 - 2749, View in Reaxys
Energy Data (MCS) (5) 1 of 5
Description (Energy Data (MCS))
Enthalpy of solution
Solvent (Energy Data (MCS))
dichloroethane
Rogowin; Nikolajewa; Zhurnal Fizicheskoi Khimii; vol. 20; (1946); p. 753; Chem.Abstr.; (1947); p. 334, View in Reaxys 2 of 5
Description (Energy Data (MCS))
Enthalpy of solution
Solvent (Energy Data (MCS))
benzene
Rogowin; Nikolajewa; Zhurnal Fizicheskoi Khimii; vol. 20; (1946); p. 753; Chem.Abstr.; (1947); p. 334, View in Reaxys 3 of 5
Description (Energy Data (MCS))
Enthalpy of solution
Solvent (Energy Data (MCS))
ethyl acetate
Rogowin; Nikolajewa; Zhurnal Fizicheskoi Khimii; vol. 20; (1946); p. 753; Chem.Abstr.; (1947); p. 334, View in Reaxys 4 of 5
Description (Energy Data (MCS))
Enthalpy of solution
Solvent (Energy Data (MCS))
vinyl acetate
Rogowin; Nikolajewa; Zhurnal Fizicheskoi Khimii; vol. 20; (1946); p. 753; Chem.Abstr.; (1947); p. 334, View in Reaxys 5 of 5
Description (Energy Data (MCS))
Enthalpy of solution
Solvent (Energy Data (MCS))
2-methyl-prop-2-enoic acid methyl ester
Rogowin; Nikolajewa; Zhurnal Fizicheskoi Khimii; vol. 20; (1946); p. 753; Chem.Abstr.; (1947); p. 334, View in Reaxys Enthalpy of Combustion (2) Enthalpy of Com- Comment (Enbustion [Jmol-1] thalpy of Combustion)
References
Kiparisova,E.G.; Rabinovich,I.B.; Doklady Chemistry; vol. 199; (1971); p. 675 - 677; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 199; nb. 5; (1971); p. 1075 - 1077, View in Reaxys -6.55025E+06
Standard.
Enthalpy of Formation (2) Enthalpy of ForComment (Enmation [Jmol-1] thalpy of Formation)
Breitenbach; Derkosch; Monatshefte fuer Chemie; vol. 82; (1951); p. 177; Monatshefte fuer Chemie; vol. 81; (1950); p. 689,694, View in Reaxys References
Kiparisova,E.G.; Rabinovich,I.B.; Doklady Chemistry; vol. 199; (1971); p. 675 - 677; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 199; nb. 5; (1971); p. 1075 - 1077, View in Reaxys; Corson et al.; Journal of Chemical Thermodynamics; vol. 7; (1975); p. 993,994,995, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
17/162
2018-02-22 00:03:45
-391466
Standard.
Breitenbach; Derkosch; Monatshefte fuer Chemie; vol. 82; (1951); p. 177; Monatshefte fuer Chemie; vol. 81; (1950); p. 689,694, View in Reaxys; Breitenbach; Derkosch; Monatshefte fuer Chemie; vol. 81; (1950); p. 689,694, View in Reaxys
Enthalpy of Sublimation (1) References Corson et al.; Journal of Chemical Thermodynamics; vol. 7; (1975); p. 993,994,995, View in Reaxys Further Information (25) Description (Fur- References ther Information) Further information
Melik-Ogandzhanyan et al.; Kinetics and Catalysis; vol. 15; (1974); p. 509, View in Reaxys
Further information
Vartapetyan et al.; Russian Journal of Physical Chemistry; vol. 47; (1973); p. 774; ; p. 1351, View in Reaxys
Further information
Vartapetyan; Khachatryan; Uchenye Zapiski, Erevanskii Gosudarstvennyi Universitet; vol. 2; (1973); p. 50,51-54; Chem.Abstr.; vol. 81; nb. 151933e; Chem. Zentralbl.; 1974, Nr.8, B119B, View in Reaxys
Further information
Byrne et al.; Journal of Chemical and Engineering Data; vol. 17; (1972); p. 507, View in Reaxys
Further information
Fahrenholtz; Trozzolo; Journal of the American Chemical Society; vol. 93; (1971); p. 251, View in Reaxys
Further information
Gream,G.E. et al.; Australian Journal of Chemistry; vol. 22; (1969); p. 1229 - 1247, View in Reaxys
Further information
Antonovskii,V.L. et al.; J. Gen. Chem. USSR (Engl. Transl.); vol. 39; nb. 3; (1969); p. 518 - 522,488 - 491, View in Reaxys
Further information
Stepovik et al.; J. Gen. Chem. USSR (Engl. Transl.); vol. 39; (1969); p. 2043,1996, View in Reaxys
Further information
Livingston; Leonhardt; Journal of Physical Chemistry; vol. 72; (1968); p. 2254, View in Reaxys
Further information
Milowskaja et al.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); (1967); p. 1053; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; (1967); p. 1093, View in Reaxys
Further information
Tvuzard; van Tiggeln; Bulletin des Societes Chimiques Belges; vol. 76; (1967); p. 444,448, 450, View in Reaxys
Further information
Jakobsen et al.; Arkiv foer Kemi; vol. 24; (1965); p. 519,526, View in Reaxys
Further information
Shono et al.; Bulletin of the Chemical Society of Japan; vol. 37; (1964); p. 635, View in Reaxys
Further information
Banerjee; Budke; Analytical Chemistry; vol. 36; (1964); p. 792,794, View in Reaxys
Further information
Patent; Pfizer; Chas and Co.; Inc.; US3438882; (1964); Chem.Abstr.; vol. 71; nb. 12843f; (1969), View in Reaxys
Further information
Trosman; Bagdasar'jan; Russian Journal of Physical Chemistry; vol. 38; (1964); p. 73; Zhurnal Fizicheskoi Khimii; vol. 38; (1964); p. 141, View in Reaxys
Further information
Romanzew; Lewin; J. Anal. Chem. USSR (Engl. Transl.); vol. 18; (1963); p. 1109,957, View in Reaxys
Further information
Beckwith; Evans; Proceedings of the Chemical Society, London; (1962); p. 63, View in Reaxys
Further information
Pobiner; Analytical Chemistry; vol. 33; (1961); p. 1423, View in Reaxys
Further information
Dugan; Analytical Chemistry; vol. 33; (1961); p. 1630, View in Reaxys
Further information
Dugan; Analytical Chemistry; vol. 33; (1961); p. 696,697, 698, View in Reaxys
Further information
Bellamy et al.; Zeitschrift fuer Elektrochemie; vol. 64; (1960); p. 563, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
18/162
2018-02-22 00:03:45
Further information
Dolgoplosk et al.; Vopr. Khim. Kinet., Katal. Reakts. Sposobn., Dokl. Vses. Soveshch.; (1955); p. 810,812; Chem.Abstr.; vol. 50; nb. 9318a; (1956), View in Reaxys
Behaviour as catalyst
Andreson, C. A.; Miller, C. E.; J. Am. pharm. Assoc. sci. Edit.; vol. 37; (1948); p. 204 - 205 ; (from Gmelin), View in Reaxys
Behaviour as catalyst
vol. S: MVol.B3; 33, page 1599 - 1601 ; (from Gmelin), View in Reaxys
Interatomic Distances and Angles (3) Description Comment (Intera- References tomic Distances and Angles) Electron distribution
Kikuchi et al.; Bulletin of the Chemical Society of Japan; vol. 51; (1978); p. 11,13, View in Reaxys
Interatomic distances and angles
Sax; McMullan; Acta Crystallographica; vol. 22; (1967); p. 281,284, 286, View in Reaxys
Interatomic distances and angles
aus dem Roentgen-Diagramm ermittelt.
Kasatotschkin; Perlina; Ablesowa; Doklady Akademii Nauk SSSR; vol. 47; (1945); p. 37; Doklady Akademii Nauk SSSR; vol. 47; (1945); p. 36, View in Reaxys
Liquid/Liquid Systems (MCS) (4) 1 of 4
Description (Liquid/ Liquid Systems (MCS))
Distribution between solvent 1 + 2
Solvent (Liquid/Liquid Systems (MCS))
benzene; H2O
Temperature (Liquid/ Liquid Systems (MCS)) [°C]
25
Jurshenko; Gromowa; Chaizer; Zhurnal Obshchei Khimii; vol. 16; (1946); p. 1505,1508; Chem.Abstr.; (1947); p. 5746, View in Reaxys 2 of 4
Description (Liquid/ Liquid Systems (MCS))
Distribution between solvent 1 + 2
Solvent (Liquid/Liquid Systems (MCS))
H2O
Temperature (Liquid/ Liquid Systems (MCS)) [°C]
60
Jurshenko; Gromowa; Chaizer; Zhurnal Obshchei Khimii; vol. 16; (1946); p. 1505,1508; Chem.Abstr.; (1947); p. 5746, View in Reaxys 3 of 4
Description (Liquid/ Liquid Systems (MCS))
Distribution between solvent 1 + 2
Solvent (Liquid/Liquid Systems (MCS))
aq. NaOH
Temperature (Liquid/ Liquid Systems (MCS)) [°C]
25
Jurshenko; Gromowa; Chaizer; Zhurnal Obshchei Khimii; vol. 16; (1946); p. 1505,1508; Chem.Abstr.; (1947); p. 5746, View in Reaxys 4 of 4
Description (Liquid/ Liquid Systems (MCS))
Distribution between solvent 1 + 2
Solvent (Liquid/Liquid Systems (MCS))
aq. NaOH
Temperature (Liquid/ Liquid Systems (MCS)) [°C]
60
Jurshenko; Gromowa; Chaizer; Zhurnal Obshchei Khimii; vol. 16; (1946); p. 1505,1508; Chem.Abstr.; (1947); p. 5746, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
19/162
2018-02-22 00:03:45
Liquid/Solid Systems (MCS) (3) 1 of 3
Description (Liquid/Solid Melting points Systems (MCS)) Partner (Liquid/Solid Systems (MCS))
bis(2-methylbenzoyl) peroxide; benzoyl(o-toluoyl)peroxide
Moorhoff, Cornelis M.; Braybrook, Carl; Journal of Chemical Research, Miniprint; nb. 3; (2003); p. 339 - 361, View in Reaxys 2 of 3
Description (Liquid/Solid Eutectic Systems (MCS)) Kuhnert-Brandstaetter et al.; Scientia Pharmaceutica; vol. 38; (1970); p. 154,156,162, View in Reaxys
3 of 3
Description (Liquid/Solid Melting diagram Systems (MCS)) Comment (Liquid/Solid Systems (MCS))
Eutektikum.
Partner (Liquid/Solid Systems (MCS))
phenacylacetophenone
Grimm; Guenther; Tittus; Zeitschrift fuer Physikalische Chemie (Leipzig); vol. <B> 14; (1931); p. 169,208, View in Reaxys Molecular Deformation (1) Description (MoReferences lecular Deformation) Force constants
Ivanchev et al.; Russian Journal of Physical Chemistry; vol. 39; (1965); p. 1009; ; p. 1900, View in Reaxys
Optics (2) Description (Optics)
Comment (Optics)
Crystal refractive indices Magnetorotation
References McBride; Gisler; Molecular Crystals and Liquid Crystals (1969-1991); vol. 52; (1979); p. 121,125-127, View in Reaxys
λ: 578 nm.
Other Thermochemical Data (4) Description (Oth- Comment (Other er Thermochemi- Thermochemical cal Data) Data)
Gallais; Wolf; Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences; vol. 236; (1953); p. 2236, View in Reaxys References
Thermodynamic properties
Rychly; Andrasik; Staudner; Beniska; Journal of Luminescence; vol. 11; nb. 3-4; (1976); p. 173 - 183, View in Reaxys; Mikovic; Lazar; Thermochimica Acta; vol. 2; (1971); p. 321, View in Reaxys
Heat of combustion at constant volume
Corson et al.; Journal of Chemical Thermodynamics; vol. 7; (1975); p. 993,994,995, View in Reaxys
Heat of combustion at constant volume
1552 kcal/Mol.
Anonymus; Jber. chem.-tech. Reichsanst.; vol. 4; (1924); p. 92, View in Reaxys
Heat of combustion at constant volume
1553.4 kcal/Mol.
Roth; Lasse; Zeitschrift fuer Elektrochemie und Angewandte Physikalische Chemie; vol. 30; (1924); p. 609 Anm., View in Reaxys; Roth in Landolt-Boernst.; H, 1598, View in Reaxys
Solubility (MCS) (1) 1 of 1
Temperature (Solubility (MCS)) [°C]
15
Solvent (Solubility (MCS))
CS2
Comment (Solubility (MCS))
1 part(s) of substance.dissolves in:39.5 parts of solvent.
Brodie; Jahresbericht ueber die Fortschritte der Chemie und Verwandter Theile Anderer Wissenschaften; (1863); p. 317, View in Reaxys; Brodie; Journal of the Chemical Society; vol. 17; (1864); p. 269; Ann. d. Physik; vol. 121; (1864); p. 377, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
20/162
2018-02-22 00:03:45
Space Group (2) Space Group
References Sax; McMullan; Acta Crystallographica; vol. 22; (1967); p. 281,284, 286, View in Reaxys; Jeffrey et al.; Journal of the American Chemical Society; vol. 86; (1964); p. 949, View in Reaxys
47; 47
Kasatotschkin; Perlina; Ablesowa; Doklady Akademii Nauk SSSR; S.S.S.R.; vol. 47; (1945); p. 36,37, View in Reaxys
NMR Spectroscopy (21) 1 of 21
Description (NMR Spec- Spectrum troscopy) Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- dimethylsulfoxide-d6 scopy) Location
supporting information
Song, Young-Kyu; Lee, Kwang-Hun; Hong, Woo-Sung; Cho, Sung-Youl; Yu, Hwan-Chul; Chung, Chan-Moon; Journal of Materials Chemistry; vol. 22; nb. 4; (2012); p. 1380 - 1386, View in Reaxys 2 of 21
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- CDCl3 scopy) Frequency (NMR Spectroscopy) [MHz]
50
Moorhoff, Cornelis M.; Braybrook, Carl; Journal of Chemical Research, Miniprint; nb. 3; (2003); p. 339 - 361, View in Reaxys 3 of 21
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
17O
Solvents (NMR Spectro- CH2Cl2 scopy) Frequency (NMR Spectroscopy) [MHz]
59.4
Comment (NMR Spectroscopy)
ambient temperature
Ho, Zwei-Chang; Livant, Peter; Lott, William B.; Webb, Thomas R.; Journal of Organic Chemistry; vol. 64; nb. 22; (1999); p. 8226 - 8235, View in Reaxys 4 of 21
Description (NMR Spec- Linewidth of NMR absorption troscopy) Nucleus (NMR Spectroscopy)
17O
Ho, Zwei-Chang; Livant, Peter; Lott, William B.; Webb, Thomas R.; Journal of Organic Chemistry; vol. 64; nb. 22; (1999); p. 8226 - 8235, View in Reaxys 5 of 21
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
17O
Solvents (NMR Spectro- acetone-d6 scopy) Temperature (NMR Spectroscopy) [°C]
29.9
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
21/162
2018-02-22 00:03:45
Antolini, Luciano; Benassi, Rois; Ghelli, Stefano; Folli, Ugo; Sbardellati, Silvia; Taddei, Ferdinando; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); nb. 11; (1992); p. 1907 1913, View in Reaxys 6 of 21
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
17O
Solvents (NMR Spectro- benzene-d6; benzene scopy) Temperature (NMR Spectroscopy) [°C]
29.9
Antolini, Luciano; Benassi, Rois; Ghelli, Stefano; Folli, Ugo; Sbardellati, Silvia; Taddei, Ferdinando; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); nb. 11; (1992); p. 1907 1913, View in Reaxys 7 of 21
Description (NMR Spec- Linewidth of NMR absorption troscopy) Antolini, Luciano; Benassi, Rois; Ghelli, Stefano; Folli, Ugo; Sbardellati, Silvia; Taddei, Ferdinando; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); nb. 11; (1992); p. 1907 1913, View in Reaxys
8 of 21
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
13C
Puzin, Yu. I.; Leplyanin, G.V.; Muslikhov, R.R.; Tolstikov, G.A.; Doklady Chemistry; vol. 320; nb. 1-3; (1991); p. 277 - 281; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 320; nb. 3; (1991); p. 638 - 642, View in Reaxys 9 of 21
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- benzene scopy) Sadykov, R. A.; Shishlov, N. M.; Journal of Organometallic Chemistry; vol. 369; (1989); p. 1 - 8, View in Reaxys 10 of 21
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- dioxane scopy) Sadykov, R. A.; Shishlov, N. M.; Journal of Organometallic Chemistry; vol. 369; (1989); p. 1 - 8, View in Reaxys 11 of 21
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- CDCl3 scopy) Cheng, C. P.; Lin, S. C.; Shaw, Guan-Su; Journal of Magnetic Resonance (1969-1992); vol. 69; nb. 1; (1986); p. 58 - 67, View in Reaxys 12 of 21
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
17O
Solvents (NMR Spectro- CDCl3 scopy)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
22/162
2018-02-22 00:03:45
Cheng, C. P.; Lin, S. C.; Shaw, Guan-Su; Journal of Magnetic Resonance (1969-1992); vol. 69; nb. 1; (1986); p. 58 - 67, View in Reaxys 13 of 21
Description (NMR Spec- Spectrum troscopy) Nucleus (NMR Spectroscopy)
1H
Solvents (NMR Spectro- CCl4 scopy) Temperature (NMR Spectroscopy) [°C]
25
Puzin, Yu. I.; Leplyanin, G. V.; Rafikov, S. R.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 33; (1984); p. 1892 - 1895; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 9; (1984); p. 2073 - 2076, View in Reaxys 14 of 21
Description (NMR Spec- Spectrum troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- CDCl3 scopy) Temperature (NMR Spectroscopy) [°C]
24.9
Puzin, Yu. I.; Leplyanin, G. V.; Spirikhin, L. V.; Parmenova, I. P.; Muslukhov, R. M.; Tolstikov, G. A.; Doklady Chemistry; vol. 279; (1984); p. 422 - 426; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 279; nb. 3; (1984); p. 646 - 650, View in Reaxys 15 of 21
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- 1,2-dichloro-ethane scopy) Takeuchi, Ken'ichi; Murai, Osamu; Matsui, Shin; Inoue, Takeshi; Kitagawa, Toshikazu; Okamoto, Kunio; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); nb. 9; (1983); p. 1301 1310, View in Reaxys 16 of 21
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- acetone scopy) Temperature (NMR Spectroscopy) [°C]
30
Aganov, A. V.; Antonovskii, V. L.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 31; nb. 2; (1982); p. 247 - 250; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 2; (1982); p. 271 - 275, View in Reaxys 17 of 21
Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)
13C
Solvents (NMR Spectro- CDCl3 scopy) Temperature (NMR Spectroscopy) [°C]
-10
Budinger, P. A.; Mooney, J. R.; Grasselli, J. G.; Fay, P. S.; Guttman, A. T.; Analytical Chemistry; vol. 53; nb. 6; (1981); p. 884 - 889, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
23/162
2018-02-22 00:03:45
18 of 21
Description (NMR Spec- CIDNP troscopy) Kaptein et al.; Journal of the Chemical Society, Chemical Communications; (1975); p. 568, View in Reaxys; Levin et al.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); (1970); p. 1593; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; (1970); p. 1680, View in Reaxys; Rykov et al.; Spectroscopy Letters; vol. 3; (1970); p. 55, View in Reaxys; Blank; Fischer; Helvetica Chimica Acta; vol. 54; (1971); p. 905,907,908,911, View in Reaxys; Schaeublin et al.; Journal of Magnetic Resonance (1969-1992); vol. 27; (1977); p. 273,294-299, View in Reaxys; Schwerzel et al.; Chemical Physics Letters; vol. 29; (1974); p. 106, View in Reaxys; Buchachenko et al.; Doklady Chemistry; vol. 190; (1970); p. 101; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 190; (1970); p. 839, View in Reaxys; Rykov et al.; Journal of Structural Chemistry; vol. 10; (1969); p. 814; ; p. 928, View in Reaxys
19 of 21
Description (NMR Spec- NMR troscopy) Swern et al.; Analytical Chemistry; vol. 41; (1969); p. 412, View in Reaxys; Kaptein et al.; Journal of the Chemical Society [Section] D: Chemical Communications; (1970); p. 1687, View in Reaxys
20 of 21
Description (NMR Spec- Spectrum troscopy) Fischer; Accounts of Chemical Research; vol. 2; (1969); p. 110,111, View in Reaxys
21 of 21
Description (NMR Spec- Spectrum troscopy) Comment (NMR Spectroscopy)
1H
Bargon et al.; Zeitschrift fuer Naturforschung, Teil A: Astrophysik, Physik und Physikalische Chemie; vol. 22; (1967); p. 1551, View in Reaxys IR Spectroscopy (19) 1 of 19
Description (IR Spectroscopy)
ATR (attenuated total reflectance); Bands; Spectrum
Bronze-Uhle, Erika S.; Batagin-Neto, Augusto; Xavier, Pedro H. P.; Fernandes, Nicole I.; De Azevedo, Eduardo R.; Graeff, Carlos F. O.; Journal of Molecular Structure; vol. 1047; (2013); p. 102 - 108, View in Reaxys 2 of 19
Description (IR Spectroscopy)
Bands
Solvent (IR Spectroscopy)
CD3CN
Reichardt, Christian; Schroeder, Joerg; Voehringer, Peter; Schwarzer, Dirk; Physical Chemistry Chemical Physics; vol. 10; nb. 12; (2008); p. 1662 - 1668, View in Reaxys 3 of 19
Description (IR Spectroscopy)
Spectrum
Solvent (IR Spectroscopy)
CD3CN
Reichardt, Christian; Schroeder, Joerg; Voehringer, Peter; Schwarzer, Dirk; Physical Chemistry Chemical Physics; vol. 10; nb. 12; (2008); p. 1662 - 1668, View in Reaxys 4 of 19
Description (IR Spectroscopy)
Bands
Solvent (IR Spectroscopy)
acetonitrile
Turovskii; Opeida; Kushch; Russian Journal of Organic Chemistry; vol. 39; nb. 5; (2003); p. 642 - 645, View in Reaxys 5 of 19
Description (IR Spectroscopy)
Spectrum
Temperature (IR Spectroscopy) [°C]
91
Comment (IR Spectroscopy)
polymer matrix. Object(s) of Study: ambient temperature
Mosnacek, Jaroslav; Weiss, Richard G.; Lukac, Ivan; Macromolecules; vol. 35; nb. 10; (2002); p. 3870 - 3875, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
24/162
2018-02-22 00:03:45
6 of 19
Description (IR Spectroscopy)
Spectrum
Solvent (IR Spectroscopy)
acetonitrile
Temperature (IR Spectroscopy) [°C]
25
Opeida; Turovskii; Maksyuta; Russian Journal of Organic Chemistry; vol. 36; nb. 11; (2000); p. 1646 - 1649, View in Reaxys 7 of 19
Description (IR Spectroscopy)
Spectrum
Solvent (IR Spectroscopy)
KBr
Comment (IR Spectroscopy)
2000 - 500 cm**(-1)
Vacque; Sombret; Huvenne; Legrand; Suc; Spectrochimica Acta - Part A Molecular Spectroscopy; vol. 53; nb. 1; (1997); p. 55 - 66, View in Reaxys 8 of 19
Description (IR Spectroscopy)
Spectrum
Solvent (IR Spectroscopy)
KBr
Comment (IR Spectroscopy)
4000 - 2700 cm**(-1)
Grinevich, Oleg; Snavely; Chemical Physics Letters; vol. 267; nb. 3-4; (1997); p. 313 - 317, View in Reaxys 9 of 19
Description (IR Spectroscopy)
Spectrum
Solvent (IR Spectroscopy)
KBr
Comment (IR Spectroscopy)
2000 - 1400 cm**(-1)
Owen, David J.; O'Donnell, Jennifer; Schutt, Wendy; Morrow, Jeffrey; Li, Yuzhuo; Journal of Organic Chemistry; vol. 58; nb. 23; (1993); p. 6203 - 6207, View in Reaxys 10 of 19
Description (IR Spectroscopy)
Spectrum
Solvent (IR Spectroscopy)
acetonitrile
Comment (IR Spectroscopy)
1800 - 1600 cm**(-1)
Chikhacheva, I. P.; Stavrova, S. D.; Efremova, E. P.; Pravednikov, A. N.; Kazakova, V. M.; et al.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 34; (1985); p. 1848 1850; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 9; (1985); p. 2003 - 2006, View in Reaxys 11 of 19
Description (IR Spectroscopy)
Bands
Solvent (IR Spectroscopy)
CCl4
Comment (IR Spectroscopy)
1770 cm**(-1)
Puzin, Yu. I.; Leplyanin, G. V.; Rafikov, S. R.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 33; (1984); p. 1892 - 1895; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 9; (1984); p. 2073 - 2076, View in Reaxys; Puzin, Yu. I.; Leplyanin, G. V.; Spirikhin, L. V.; Parmenova, I. P.; Muslukhov, R. M.; Tolstikov, G. A.; Doklady Chemistry; vol. 279; (1984); p. 422 - 426; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 279; nb. 3; (1984); p. 646 - 650, View in Reaxys 12 of 19
Description (IR Spectroscopy)
Bands
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
25/162
2018-02-22 00:03:45
Solvent (IR Spectroscopy)
paraffin
Comment (IR Spectroscopy)
1781 - 1757 cm**(-1)
Budinger, P. A.; Mooney, J. R.; Grasselli, J. G.; Fay, P. S.; Guttman, A. T.; Analytical Chemistry; vol. 53; nb. 6; (1981); p. 884 - 889, View in Reaxys 13 of 19
Description (IR Spectroscopy)
Bands
Comment (IR Spectroscopy)
1788 - 1760 cm**(-1)
Rakhimov, A. I.; Androsyuk, E. R.; Shelyazhenko, S. V.; Yagupol'skii, L. M.; Journal of Organic Chemistry USSR (English Translation); (1981); p. 1470 - 1475; Zhurnal Organicheskoi Khimii; vol. 17; nb. 8; (1981); p. 1652 - 1657, View in Reaxys 14 of 19
Description (IR Spectroscopy)
Bands
Sorba et al.; Tetrahedron; vol. 35; (1979); p. 1509,1510,1513,1514,1516, View in Reaxys; Fayat; Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques; vol. 265; (1967); p. 1406, View in Reaxys 15 of 19
Description (IR Spectroscopy)
IR
Kul'nevich; Borisova; Journal of Applied Spectroscopy; vol. 14; (1971); p. 480; ; p. 648, View in Reaxys; Ivanchev et al.; Russian Journal of Physical Chemistry; vol. 39; (1965); p. 1009; ; p. 1900, View in Reaxys; Anisimow et al.; J. Anal. Chem. USSR (Engl. Transl.); vol. 21; (1966); p. 113,96, View in Reaxys; Alekseeva et al.; J. Gen. Chem. USSR (Engl. Transl.); vol. 42; (1972); p. 1860,1843, View in Reaxys; Chalfont et al.; Journal of the Chemical Society [Section] B: Physical Organic; (1971); p. 233,242, View in Reaxys; Fayat; Foucaud; Bulletin de la Societe Chimique de France; (1971); p. 3747, View in Reaxys; Filliatre et al.; Bulletin de la Societe Chimique de France; vol. <II>; (1979); p. 473,477, View in Reaxys; Gladyshev et al.; Doklady Physical Chemistry; vol. 166-171; (1966); p. 372; vol. 168; p. 1093, View in Reaxys 16 of 19
Description (IR Spectroscopy)
Spectrum
Milowskaja et al.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); (1967); p. 1053; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; (1967); p. 1093, View in Reaxys 17 of 19
Description (IR Spectroscopy)
Spectrum
Solvent (IR Spectroscopy)
CS2
Comment (IR Spectroscopy)
5000 - 667 cm**(-1)
Shreve et al.; Analytical Chemistry; vol. 23; (1951); p. 282,283, View in Reaxys 18 of 19
Description (IR Spectroscopy)
Spectrum
Solvent (IR Spectroscopy)
CCl4
Comment (IR Spectroscopy)
2000 - 1429 cm**(-1)
Davison; Journal of the Chemical Society; (1951); p. 2456,2459, View in Reaxys 19 of 19
Description (IR Spectroscopy)
Spectrum
Solvent (IR Spectroscopy)
CCl4
Comment (IR Spectroscopy)
2000 - 833 cm**(-1)
Barnes; Liddel; Williams; Industrial and Engineering Chemistry, Analytical Edition; vol. 15; (1943); p. 659,687, View in Reaxys Mass Spectrometry (1)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
26/162
2018-02-22 00:03:45
Description (Mass References Spectrometry) fragmentation pattern; chemical ionization (CI); spectrum
Tu, Ya-Ping; Zou, Da-Peng; Tang, Ming-Sheng; Xin, Bao-Min; Jia, Wei-Ping; Liu, Shu-Ying; Organic Mass Spectrometry; vol. 28; nb. 12; (1993); p. 1435 - 1439, View in Reaxys
UV/VIS Spectroscopy (23) 1 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Solvent (UV/VIS Spectroscopy)
tetrahydrofuran
Location
supporting information
Zhao, Baodong; Zhao, Weidong; Yu, Liujian; Li, Jie; Zhao, Yuming; Wang, Tao; New Journal of Chemistry; vol. 41; nb. 21; (2017); p. 13156 - 13165, View in Reaxys 2 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Solvent (UV/VIS Spectroscopy)
N,N-dimethyl-formamide
Location
supporting information
Absorption Maxima (UV/ 294 VIS) [nm] Li, Qingrui; Zhao, Xiuli; Li, Yabo; Huang, Mengmeng; Kim, Jung Keun; Wu, Yangjie; Organic and Biomolecular Chemistry; vol. 15; nb. 46; (2017); p. 9775 - 9778, View in Reaxys 3 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Absorption Maxima (UV/ 195 VIS) [nm] He, Minghui; Jiang, Shun; Xu, Ruixin; Yang, Jianwen; Zeng, Zhaohua; Chen, Guangxue; Journal of Polymer Science, Part A: Polymer Chemistry; vol. 52; nb. 11; (2014); p. 1560 - 1569, View in Reaxys 4 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Solvent (UV/VIS Spectroscopy)
ethanol
Location
supporting information
Ouchi, Akihiko; Liu, Chuanxiang; Kaneda, Masayuki; Hyugano, Takeshi; European Journal of Organic Chemistry; nb. 18; (2013); p. 3807 - 3816, View in Reaxys 5 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Solvent (UV/VIS Spectroscopy)
various solvents
Xie, Hui; Wang, Huai You; Ma, Li Ying; Xiao, Yan; Han, Juan; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 62; nb. 1-3; (2005); p. 197 - 202, View in Reaxys 6 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Solvent (UV/VIS Spectroscopy)
CHCl3
Mosnacek, Jaroslav; Weiss, Richard G.; Lukac, Ivan; Macromolecules; vol. 35; nb. 10; (2002); p. 3870 - 3875, View in Reaxys 7 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Solvent (UV/VIS Spectroscopy)
CCl4
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
27/162
2018-02-22 00:03:45
Comment (UV/VIS Spectroscopy)
2500 - 714.29 nm
Grinevich, Oleg; Snavely; Chemical Physics Letters; vol. 267; nb. 3-4; (1997); p. 313 - 317, View in Reaxys 8 of 23
Description (UV/VIS Spectroscopy)
Absorption maxima
Solvent (UV/VIS Spectroscopy)
benzene
Absorption Maxima (UV/ 254 VIS) [nm] Ext./Abs. Coefficient [l·mol-1cm-1]
21000
Owen, David J.; O'Donnell, Jennifer; Schutt, Wendy; Morrow, Jeffrey; Li, Yuzhuo; Journal of Organic Chemistry; vol. 58; nb. 23; (1993); p. 6203 - 6207, View in Reaxys 9 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Comment (UV/VIS Spectroscopy)
200 - 300 nm
Malkin, Ya. N.; Shepelin, E. V.; J. Gen. Chem. USSR (Engl. Transl.); vol. 57; nb. 5; (1987); p. 1176 - 1182,1052 1058, View in Reaxys 10 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Solvent (UV/VIS Spectroscopy)
benzene
Comment (UV/VIS Spectroscopy)
400 - 600 nm
Al-Abidin, Kusai M. Z.; Jones, Richard G.; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 78; (1982); p. 513 - 518, View in Reaxys 11 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Solvent (UV/VIS Spectroscopy)
CH2Cl2
Comment (UV/VIS Spectroscopy)
400 - 600 nm
Al-Abidin, Kusai M. Z.; Jones, Richard G.; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 78; (1982); p. 513 - 518, View in Reaxys 12 of 23
Description (UV/VIS Spectroscopy)
Absorption maxima
Solvent (UV/VIS Spectroscopy)
benzene
Absorption Maxima (UV/ 500 VIS) [nm] Al-Abidin, Kusai M. Z.; Jones, Richard G.; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 78; (1982); p. 513 - 518, View in Reaxys 13 of 23
Description (UV/VIS Spectroscopy)
Absorption maxima
Solvent (UV/VIS Spectroscopy)
CH2Cl2
Absorption Maxima (UV/ 500 VIS) [nm] Al-Abidin, Kusai M. Z.; Jones, Richard G.; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 78; (1982); p. 513 - 518, View in Reaxys 14 of 23
Description (UV/VIS Spectroscopy)
UV/VIS
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
28/162
2018-02-22 00:03:45
Kuhnert-Brandstaetter et al.; Scientia Pharmaceutica; vol. 38; (1970); p. 154,156,162, View in Reaxys; McBride; Gisler; Molecular Crystals and Liquid Crystals (1969-1991); vol. 52; (1979); p. 121,125-127, View in Reaxys; Fayat; Foucaud; Bulletin de la Societe Chimique de France; (1971); p. 3747, View in Reaxys 15 of 23
Description (UV/VIS Spectroscopy)
Absorption maxima
Polumbrik et al.; J. Anal. Chem. USSR (Engl. Transl.); vol. 31; (1976); p. 2436,1792,1793, View in Reaxys 16 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Cohen et al.; Journal of Polymer Science; vol. 3; (1948); p. 278, View in Reaxys; Lebourgeois et al.; Journal de Chimie Physique et de Physico-Chimie Biologique; vol. 69; (1972); p. 1633,1634-1637, 1639-1641, View in Reaxys 17 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Solvent (UV/VIS Spectroscopy)
ethyl acetate
Comment (UV/VIS Spectroscopy)
250 - 350 nm
Kinell; Arkiv foer Kemi; vol. 14; (1959); p. 353,366, View in Reaxys 18 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Solvent (UV/VIS Spectroscopy)
ethanol
Comment (UV/VIS Spectroscopy)
240 - 460 nm; nach Bestrahlung mit UV-Licht (λ: 253.7 nm) bei 77 K.
Symons; Townsend; Journal of the Chemical Society; (1959); p. 263,265, View in Reaxys 19 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Solvent (UV/VIS Spectroscopy)
CHCl3
Comment (UV/VIS Spectroscopy)
260 - 300 nm
Takayama; Japan Analyst; vol. 4; (1955); p. 290,291; Chem.Abstr.; (1956); p. 12756, View in Reaxys 20 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Solvent (UV/VIS Spectroscopy)
CHCl3
Comment (UV/VIS Spectroscopy)
220 - 330 nm
Breitenbach; Derkosch; Monatshefte fuer Chemie; vol. 81; (1950); p. 530,531, 532, View in Reaxys 21 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Solvent (UV/VIS Spectroscopy)
light petroleum
Comment (UV/VIS Spectroscopy)
220 - 290 nm
Breitenbach; Derkosch; Monatshefte fuer Chemie; vol. 81; (1950); p. 530,531, 532, View in Reaxys 22 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Solvent (UV/VIS Spectroscopy)
cyclohexane
Comment (UV/VIS Spectroscopy)
200 - 390 nm
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
29/162
2018-02-22 00:03:45
Melville; Valentine; Proceedings of the Royal Society of London, Series A: Mathematical, Physical and Engineering Sciences; vol. 200; (1950); p. 358,360, 361, View in Reaxys 23 of 23
Description (UV/VIS Spectroscopy)
Spectrum
Solvent (UV/VIS Spectroscopy)
ethanol
Purvis; Journal of the Chemical Society; (1927); p. 782; Journal of the Chemical Society; vol. 127; (1925); p. 2773, View in Reaxys ESR Spectroscopy (5) 1 of 5
Description (ESR Spectroscopy)
Spectrum
Temperature (ESR Spectroscopy) [°C]
-196.2
Comment (ESR Spectroscopy)
Solvent(s): further solvent(s)
Kupfer, Michael; Stoesser, Reinhard; Proesch, Ullrich; Kolditz, Lothar; Journal of Fluorine Chemistry; vol. 43; (1989); p. 1 - 14, View in Reaxys 2 of 5
Description (ESR Spectroscopy)
g-factor
Yamauchi, Seigo; Hirota, Noboru; Journal of the American Chemical Society; vol. 107; nb. 17; (1985); p. 5021 5022, View in Reaxys; Kupfer, Michael; Stoesser, Reinhard; Proesch, Ullrich; Kolditz, Lothar; Journal of Fluorine Chemistry; vol. 43; (1989); p. 1 - 14, View in Reaxys 3 of 5
Description (ESR Spectroscopy)
Spectrum
Solvents (ESR Spectroscopy)
CCl4
Yamauchi, Seigo; Hirota, Noboru; Journal of the American Chemical Society; vol. 107; nb. 17; (1985); p. 5021 5022, View in Reaxys 4 of 5
Description (ESR Spectroscopy)
ESR
McBride; Gisler; Molecular Crystals and Liquid Crystals (1969-1991); vol. 52; (1979); p. 121,125-127, View in Reaxys; Box et al.; Journal of the American Chemical Society; vol. 92; (1970); p. 5305,5306, View in Reaxys 5 of 5
Description (ESR Spectroscopy)
Spectrum
Shapiro et al.; Doklady Chemistry; vol. 195; (1970); p. 794; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 195; (1970); p. 104, View in Reaxys NQR Spectroscopy (1) Description (NQR References Spectroscopy) Nuclear quadrupole resonance
Cheng; Brown; Journal of the American Chemical Society; vol. 101; (1979); p. 2327,2329, View in Reaxys
Raman Spectroscopy (8) Description (Ram- Comment (Raman Spectroscopy) an Spectroscopy) Spectrum; Bands
References Wang, Xiaobin; Huang, Wenqian; Wang, Qingyan; Liu, Chen; Wang, Chaopeng; Yang, Guiyan; Zhao, Chunjiang; Journal of Molecular Structure; vol. 1138; (2017); p. 6 - 11, View in Reaxys
Spectrum
neat (no solvent)
Vacque; Sombret; Huvenne; Legrand; Suc; Spectrochimica Acta - Part A Molecular Spectroscopy; vol. 53; nb. 1; (1997); p. 55 - 66, View in Reaxys
Bands
CH2Cl2
Kosnikov, A. Yu.; Antonovskii, V. L.; Lindeman, S. V.; Struchkov, Yu. T.; Zyat'kov, I. P.; et al.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 34; nb. 4; (1985); p. 855 - 857; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 4; (1985); p. 937 - 940, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
30/162
2018-02-22 00:03:45
Raman
Fayat; Foucaud; Bulletin de la Societe Chimique de France; (1971); p. 3747, View in Reaxys
Spectrum
der Krystalle
Susz; Berenstein; C. r. Soc. Phys. Geneve; vol. 59; (1942); p. 182,184, View in Reaxys
Spectrum
von Loesungen in Beresowskaja; Kurnosowa; Zhurnal Fizicheskoi Khimii; vol. 6; (1935); p. 125, Chloroform View in Reaxys
Spectrum
von Loesungen in Beresowskaja; Kurnosowa; Zhurnal Fizicheskoi Khimii; vol. 6; (1935); p. 125, Tetrachlormethan View in Reaxys
Spectrum
einer Loesung in Chloroform
Kohlrausch; Pongratz; Seka; Chemische Berichte; vol. 66; (1933); p. 9, View in Reaxys
Luminescence Spectroscopy (2) Description (LuReferences minescence Spectroscopy) Luminescence quantum yield
Thijs et al.; Journal of Organic Chemistry; vol. 44; (1979); p. 4123,4124, 4125, 4127, View in Reaxys
Luminescence
Hercules; Spectrochimica Acta; vol. 19; (1963); p. 788, View in Reaxys; Panasenko et al.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 26; (1977); p. 425; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; vol. 26; (1977); p. 470, View in Reaxys; Ivanchev; Selivanov; Journal of Applied Spectroscopy; vol. 19; (1973); p. 1504; ; p. 920, View in Reaxys; Rychly; Andrasik; Staudner; Beniska; Journal of Luminescence; vol. 11; nb. 3-4; (1976); p. 173 - 183, View in Reaxys; Lloyd; Transactions of the Faraday Society; vol. 61; (1965); p. 2182,2187, View in Reaxys
Phosphorescence Spectroscopy (1) Description References (Phosphorescence Spectroscopy) Phosphorescence Hercules; Spectrochimica Acta; vol. 19; (1963); p. 788, View in Reaxys Abiotic Degradation, Photolysis (1) 1 of 1
Type (Abiotic Degradation, Photolysis)
thermolysis
Temperature (Abiotic 91 Degradation, Photolysis) [°C] Rate Constant
0.245 per hour
Method, Remarks (Abio- title comp. in polystyrene film (10 wtpercent); heated in air up to 8 h; FT-IR analysis; neartic Degradation, Photol- ly complete degradation after 8 h; figure ysis) Mosnacek, Jaroslav; Weiss, Richard G.; Lukac, Ivan; Macromolecules; vol. 35; nb. 10; (2002); p. 3870 - 3875, View in Reaxys Use (740) Laboratory Use and Handling
Use Pattern
Location
References
Cosmetics/dental/ Page/Page colPatent; Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; toilet umn title page; 27 Yasman, Yuri; Privalova, Olga; Benaltabet, Lior; (39 pag.); US9682031; (2017); (B2) English, View in Reaxys microcapsule for treatment of acne
Page/Page colPatent; Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; umn title page; 27 Yasman, Yuri; Privalova, Olga; Benaltabet, Lior; (39 pag.); US9682031; (2017); (B2) English, View in Reaxys
Pharmaceuticals
Page/Page column title page; 34-35
Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys
acne
Page/Page column title page; 34-35
Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys
acne scars
Page/Page column title page; 34-35
Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
31/162
2018-02-22 00:03:45
inflammatory skin disorder
Page/Page column title page; 34-35
Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys
skin moisture by minimizing transepidermal water loss
Page/Page column title page; 34-35
Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys
topical composition in combination with one or more silicone and zinc compounds
Page/Page column title page; 34-35
Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys
Explosive
He, Benzhao; Wu, Yongwei; Qin, Anjun; Tang, Ben Zhong; Macromolecules; vol. 50; nb. 15; (2017); p. 5719 - 5728, View in Reaxys
Explosive
supporting information
Qian, Bo; Xiong, Haigen; Zhu, Nengbo; Ye, Changqing; Jian, Wujun; Bao, Hongli; Tetrahedron Letters; vol. 57; nb. 30; (2016); p. 3400 - 3403, View in Reaxys
Page/Page column 6-7
Patent; Koenig, David William; Hoffman, Douglas Robert; Huang, Yang; He, Aimin; US2015/110893; (2015); (A1) English, View in Reaxys
water insoluble Page/Page coloxidant for a spor- umn 6-7 icidal formulation
Patent; Koenig, David William; Hoffman, Douglas Robert; Huang, Yang; He, Aimin; US2015/110893; (2015); (A1) English, View in Reaxys
Pharmaceuticals
Page/Page column 43; 46
Patent; GALDERMA RESEARCH and DEVELOPMENT; AUDIBERT, Fabien; KERROUCHE, Nabil; SOTO, Pascale; WO2015/91828; (2015); (A1) English, View in Reaxys
inhibiting or treating severe acne related diseases in combination with the retinoid and the antibiotic
Page/Page column 43; 46
Patent; GALDERMA RESEARCH and DEVELOPMENT; AUDIBERT, Fabien; KERROUCHE, Nabil; SOTO, Pascale; WO2015/91828; (2015); (A1) English, View in Reaxys
Pharmaceuticals
Page/Page column 31; 32
Patent; RANBAXY LABORATORIES LIMITED; DUBEY, Vaibhav; JENA, Simon Santosh; MADAN, Sumit; ARORA, Vinod Kumar; WO2015/92602; (2015); (A1) English, View in Reaxys
component in free-form, in form of microcapsules or in form of microspheres in pharmaceutical composition comprising microspheres and microcapsules of retinoid coated with a polymeric layer
Page/Page column 31; 32
Patent; RANBAXY LABORATORIES LIMITED; DUBEY, Vaibhav; JENA, Simon Santosh; MADAN, Sumit; ARORA, Vinod Kumar; WO2015/92602; (2015); (A1) English, View in Reaxys
in combination with retinoid
Page/Page column 31; 32
Patent; RANBAXY LABORATORIES LIMITED; DUBEY, Vaibhav; JENA, Simon Santosh; MADAN, Sumit; ARORA, Vinod Kumar; WO2015/92602; (2015); (A1) English, View in Reaxys
Polymers/polymer Page/Page colapplications umn 11
Patent; Premier Dental Products Company; Gross, Stephen M.; Latta, Mark A.; US9119774; (2015); (B2) English, View in Reaxys
radical initiator suitable for preparing a dental restorative formulation
Patent; Premier Dental Products Company; Gross, Stephen M.; Latta, Mark A.; US9119774; (2015); (B2) English, View in Reaxys
Detergents/disinfections
Page/Page column 11
Cosmetics/dental/ Page/Page coltoilet umn title page; 13; 14
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
Patent; Weisenfluh, Scott Alan; Desai, Ketan; Kroposky, Sandra; US9138446; (2015); (B2) English, View in Reaxys
32/162
2018-02-22 00:03:45
as active ingredient of composition in combination with Emu oil for treating skin imperfections
Page/Page column title page; 13; 14
Patent; Weisenfluh, Scott Alan; Desai, Ketan; Kroposky, Sandra; US9138446; (2015); (B2) English, View in Reaxys
for treating acne
Page/Page column title page; 13; 14
Patent; Weisenfluh, Scott Alan; Desai, Ketan; Kroposky, Sandra; US9138446; (2015); (B2) English, View in Reaxys
for treating hair loss
Page/Page column title page; 13; 14
Patent; Weisenfluh, Scott Alan; Desai, Ketan; Kroposky, Sandra; US9138446; (2015); (B2) English, View in Reaxys
for treating wrinkles
Page/Page column title page; 13; 14
Patent; Weisenfluh, Scott Alan; Desai, Ketan; Kroposky, Sandra; US9138446; (2015); (B2) English, View in Reaxys
Pharmaceuticals
Page/Page column 33-36
Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys
acne-rosacea type of rosacea
Page/Page column 33-36
Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys
alone or in combi- Page/Page colnation with antibi- umn 33-36 otic agent
Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys
alone or in combi- Page/Page colnation with antimi- umn 33-36 crobial agent
Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys
alone or in combi- Page/Page colnation with retiumn 33-36 noid
Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys
alone or in combi- Page/Page colnation with tetra- umn 33-36 cycline agent
Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys
papularpostular rosacea
Page/Page column 33-36
Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys
rosacea
Page/Page column 33-36
Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys
Pharmaceuticals
Page/Page column 7; 8
Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys
anti-acne agent
Page/Page column 7; 8
Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys
for treating acne
Page/Page column 7; 8
Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys
inflammatory lesions
Page/Page column 7; 8
Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys
non-inflammatory lesions
Page/Page column 7; 8
Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
33/162
2018-02-22 00:03:45
reducing dryness
Page/Page column 7; 8
Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys
reducing erythema
Page/Page column 7; 8
Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys
reducing itching
Page/Page column 7; 8
Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys
reducing local irri- Page/Page coltation umn 7; 8
Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys
reducing photosensitivity
Page/Page column 7; 8
Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys
reducing the inci- Page/Page coldence and severi- umn 7; 8 ty of acne lesions on the skin
Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys
reducing total number of acne lesions on the skin
Page/Page column 7; 8
Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys
supporting information
Lifchits, Olga; Demoulin, Nicolas; List, Benjamin; Angewandte Chemie - International Edition; vol. 50; nb. 41; (2011); p. 9680 9683, View in Reaxys
avoid contact with heat harmful
Caravano, Audrey; Field, Robert A.; Percy, Jonathan M.; Rinaudo, Giuseppe; Roig, Ricard; Singh, Kuldip; Organic and Biomolecular Chemistry; vol. 7; nb. 5; (2009); p. 996 - 1008, View in Reaxys Bactericidal
Patent; TopoTarget Germany AG; EP1839656; (2007); (A1) English, View in Reaxys; Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
Dermatological conditions
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
Anti-inflammatory/ antipyretic/analgetic drug
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
keratolytic
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
dermatological conditions associated with a keratinization disorder
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
comedonal acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
polymorphous acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
rosacea acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
nodulocystic acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
acne conglobara
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
34/162
2018-02-22 00:03:45
senile acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
secondary acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
solar acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
drug acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
occupational acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
keratinization disorders
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
ichthyosiform states
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
Carrier' s disease
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
palmoplantar keratoderma
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
leukoplakia state
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
leucoplakiform state
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
cutaneous lichen
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
mucous (buccal) lichen
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
dermatological conditions associated with a keratinization disorder having an inflammatory component
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
dermatological conditions associated with a keratinization disorder having immunoallergic component
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
cutaneous psoriasis
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
mucous psoriasis
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
ungula psoriasis
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
psoriatic rheumatism
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
cutaneous atopy
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
respiratory atopy
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
gingival hypertrophy
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
inflammatory conditions that do not
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
35/162
2018-02-22 00:03:45
exhibit keratinization disorders dermal proliferation
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
epidermal proliferation
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
benign dermal proliferation
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
malignant dermal proliferation
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
benign epidermal proliferation
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
malignant epidermal proliferation
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
verrucas
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
plane warts
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
epidermodysplasia verruciformis
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
oral papillomatoses
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
floride papillomatoses
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
proliferations induced by ultraviolet light
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
actinic keratose
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
skin aging
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
light-induced skin aging
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
chronological skin aging
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
skin pigmentation
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
pathologies associated with chronological aging
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
pathologies associated with actinic aging
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
wound-healing disorders
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
striae atrophicae
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
wound healing
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
sebaceous gland disorders
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
hyperseborrhea of acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
36/162
2018-02-22 00:03:45
simple seborrhea
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
skin condition of fungal origin
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
tinea pedis
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
tinea versicolor
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
skin disorders due to exposure to UV radiation
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
dermatological conditions associated with an inflammation of the tissues surrounding the hair follicle
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
microbial colonization
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
microbial infection
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
sycosis barbae
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
body hygiene
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
hair hygiene
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
acne-prone skin
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
hair regrowth
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
greasy appearance of the skin
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
greasy appearance of the hair
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
damaging effects of the sun
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
light-induced aging
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
chronological aging
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys
Acne lesions
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Non-inflammatory lesions
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Open comedones
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Closed comedones
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Inflammatory lesions
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Papules
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
37/162
2018-02-22 00:03:45
Pustules
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Nodules
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Cysts
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Common acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Comedones
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Polymorphs
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Nodulocystic acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Acne conglobata
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Secondary acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Solar acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Medicational acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Occupational acne
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Dermatoses sensitive to retinoids
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
Non-inflammatory acne lesions
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys
drug deliver system
Patent; STIEFEL LABORATORIES, INC.; US2008/26039; (2008); (A1) English, View in Reaxys
Skin disoders
Patent; STIEFEL LABORATORIES, INC.; US2008/26039; (2008); (A1) English, View in Reaxys
active ingredient of an antiacne topical preparation
Patent; AHUMADA AYALA, Fernando; WO2008/17914; (2008); (A2) English, View in Reaxys
keratolytic agent
Patent; AHUMADA AYALA, Fernando; WO2008/17914; (2008); (A2) English, View in Reaxys
Initiator for hair treatment
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for producing desired hair characteristics
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for improving hair strength
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for improving hair shine
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
38/162
2018-02-22 00:03:45
Initiator for improving hair color
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for improving hair elasticity
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for improving hair optical properties
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for generating a particular hairstyle
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for preserving a particular hairstyle
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for improving hair luster
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for improving hair smoothness
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for improving hair slip
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for improving hair static control
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for improving hair distinct feel
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for styling hair
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for restoring damaged hair
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for curling hair
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for giving hair a wave
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Initiator for giving hair a body
Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
39/162
2018-02-22 00:03:45
initiator
Patent; Pulpdent Corporation; US7371782; (2008); (B2) English, View in Reaxys
dermatological disorders
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
disturbed keratinization
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
defective syntheses of dermal components
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
xerosis
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
palmar hyperkeratoses
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
plantar hyperkeratoses
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
Darier's disease
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
keratoses
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
eczema
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
pruritus
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
herpes
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
lentigines
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
melasmas
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
hyperkeratoses
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
hyperpigmented skin
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
diminished syntheses of collagen
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
Abnormal syntheses of collagen
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
Abnormal syntheses of glycosatinoglycans
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
Abnormal syntheses of proteoglycans
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
Abnormal syntheses of elastin
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
diminished levels of components in the dermis
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
Irritation
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
Erythema
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
40/162
2018-02-22 00:03:45
cosmetic conditions
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
changes associated with aging of skin
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
changes associated with aging of nail
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
changes associated with aging of hair
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
Dryness of skin
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
Dryness of nails
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
Dryness of hair
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
rough surface of skin
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
rough surface of nail
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
rough surface of hair
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
dandruff
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
itchy scalp
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
itchy skin
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
age spots
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
blemished skin
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
stretch marks
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
skin lines
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
fine lines
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
thinning of skin
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
nail plate and hair
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
skin thickening due to elastosis of photoaging
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
skin thickening due to reduction of skin
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
skin thickening due to reduction of nail
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
hair resiliency
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
41/162
2018-02-22 00:03:45
elasticity
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
lack of skin
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
nail and hair lubricants and luster
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
dull and olderlooking skin
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
dull and olderlooking nail
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
dull and olderlooking hair
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
fragility
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
splitting of nail
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
splitting of hair
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
recoilability
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
Dryness
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
Damage of skin
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys
anti-acne
Patent; Watson, Dana M.; US2006/19935; (2006); (A1) English, View in Reaxys; Patent; SKINVISIBLE PHARMACEUTICALS, INC.; WO2008/51461; (2008); (A2) English, View in Reaxys
anti-seborrhoeic agent
Patent; Galderma Research and Development, S.N.C.; US2007/269524; (2007); (A1) English, View in Reaxys; Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys
disorders associated with greasiness of a dark skin
Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys
skin disorders associated with hyperseborrhoea of dark skin
Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys
greasy skin
Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys
hyperseborrhoea
Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys
acne lesions
Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys
aesthetic disorders associated with the overproduction of sebum
Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys
imperfections associated with the overproduction of sebum
Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys
reducing the number of comedones, inflammatory papules, pus-
Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
42/162
2018-02-22 00:03:45
tules, cysts and lesions; reducing the microbial count associated with the secondary infection skin disorders
Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys
perioral dermatitis
Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys
impetigo
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys
secondary skin infections
Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys
seborrhea
Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys
skin lesions
Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys
inflammatory skin conditions
Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys
oxidizing agent
Patent; Hofmann, Robert F.; US2006/14732; (2006); (A1) English, View in Reaxys; Patent; Watson, Dana M.; US2006/19935; (2006); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys
Anti-acne agent in composition with extract of Primula denticulata
Patent; Johnson and Johnson Consumer Companies, Inc.; US7381433; (2008); (B1) English, View in Reaxys
cosmetic dermatological preparation
Patent; Brunese, Maria Rosaria; Brunese, Julie; Brunese, Roberto; US2008/63737; (2008); (A1) English, View in Reaxys
in combination with α2-adrenoceptor agonists and anti-muscarinic agent for treatment of condition associated with excess sebum production or excretion
Patent; DANIOLABS LTD.; WO2008/59190; (2008); (A1) English, View in Reaxys
bacteriostatic effect on Corynebacterium acnes, reduces the level of free fatty acids in sebaceous secretions; has keratolytic and strong oxidizing properties
Patent; GALDERMA S.A.; US2008/153901; (2008); (A1) English, View in Reaxys
manufacture of a medicament for treating skin conditions
Patent; GALDERMA S.A.; US2008/153901; (2008); (A1) English, View in Reaxys
common acne
Patent; GALDERMA S.A.; US2008/153901; (2008); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
43/162
2018-02-22 00:03:45
anti-infectious agent
Patent; Galderma Research and Development, S.N.C.; US2007/269524; (2007); (A1) English, View in Reaxys; Patent; GALDERMA S.A.; US2008/153901; (2008); (A1) English, View in Reaxys
dermatological composition
Patent; GALDERMA S.A.; US2008/153901; (2008); (A1) English, View in Reaxys
composition comprising a hydroxycinnamic acid or methoxycinnamic acid, or mixtures thereof, useful for the treating aging human skin to maintain or improve at least visible indicia of aging
Patent; LIPO CHEMICALS INC.; WO2008/73684; (2008); (A1) English, View in Reaxys
exfoliation promoter for cosmetic nanocomposite pigment composition effective in improving aesthetic and natural appearance of skin and other biological surfaces
Patent; AVON PRODUCTS, INC.; WO2008/79760; (2008); (A2) English, View in Reaxys
composition comprising colloidal metals suitable for the treatment and prevention of skin diseases
Patent; PHARMWEST, INC.; WO2008/79898; (2008); (A1) English, View in Reaxys
composition comprising colloidal metals suitable for the treatment and prevention of skin conditions
Patent; PHARMWEST, INC.; WO2008/79898; (2008); (A1) English, View in Reaxys
Personal care composition
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Color cosmetic
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Lipstick
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Foundation
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Shampoo
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Hair conditioner
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Hair fixative
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Shower gel
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Skin moisturizer
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Skin conditioner
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
44/162
2018-02-22 00:03:45
Body conditioner
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Sun protection product
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Antiperspirant
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Deodorant
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Insect repellants
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Sunscreens
Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys
Acne vulgaris
Patent; ASPEN BENEFITS GROUP, LLC; WO2007/53422; (2007); (A1) English, View in Reaxys; Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys; Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/92911; (2008); (A1) English, View in Reaxys
Disorders of keratinisation
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/92911; (2008); (A1) English, View in Reaxys
Disorders of proliferation
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/92911; (2008); (A1) English, View in Reaxys
Disorders of differentiation
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/92911; (2008); (A1) English, View in Reaxys
Retinoid-sensitive dermatoses
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/92911; (2008); (A1) English, View in Reaxys
Treating a surface condition
Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys
Acne
Patent; ALPHARX INC.; US2005/255133; (2005); (A1) English, View in Reaxys; Patent; MIDWEST RESEARCH LABORATORIES, LLC; WO2005/112872; (2005); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys; Patent; ASPEN BENEFITS GROUP, LLC; WO2007/53422; (2007); (A1) English, View in Reaxys; Patent; Imaginative Research Associates, Inc.; EP1813277; (2007); (A1) English, View in Reaxys; Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys; Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; US2008/26039; (2008); (A1) English, View in Reaxys; Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys; Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys; Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/92911; (2008); (A1) English, View in Reaxys; Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys
Rosacea
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys; Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys
Psoriasis
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys; Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys
Photoaging skin
Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys
Hyperpigmented skin
Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys
Mucosal infected areas
Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
45/162
2018-02-22 00:03:45
Inflamed dermatitis
Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys
free radical initiator of polymerization
Patent; Godwin, Allen D.; Buturla, Kenneth J.; Colle, Karla S.; Kiss, Gabor; Nadler, Kirk C.; Patil, Abhimanyu O.; Pike, Edris Eileen; Saleh, Ramzi Y.; Stanat, Jon E.; Varma-Nair, Manika; Zushma, Stephen; US2008/242895; (2008); (A1) English, View in Reaxys
in combination with a retinoid receptor agonist as active ingredients of a composition suitable for treating acne
Patent; ALMIRALL HERMAL GMBH; WO2008/107193; (2008); (A1) English, View in Reaxys
polymerisation initiator for preparing a cross-linked gelatin suitable for the prepation of controlled release compositions
Patent; FUJIFILM Manufacturing Europe B.V.; EP1961411; (2008); (A1) English, View in Reaxys
greasy seborrhoea
Patent; CARDON PHAMACEUTICALS NV; US2008/103117; (2008); (A1) English, View in Reaxys
ingredient of a composition suitable for the treatment of animals
Patent; CARDON PHAMACEUTICALS NV; US2008/103117; (2008); (A1) English, View in Reaxys
seborrheic dermatitis
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
lichen simplex chronicus
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
pseudofolliculitis barbae
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
antimicrobial agent
Patent; ECOLAB, INC.; EP1738758; (2007); (A1) English, View in Reaxys; Patent; Lane, Jonathan Douglas; US2008/269222; (2008); (A1) English, View in Reaxys
photosensitizer of dental composition for making dental prostheses and for dental restoration
Patent; RHODIA CHIMIE; US2008/287562; (2008); (A1) English, View in Reaxys
acne
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys; Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys; Patent; Medpak LLC; US2005/208153; (2005); (A1) English, View in Reaxys; Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; JR CHEM, LLC; US2006/204530; (2006); (A1) English, View in Reaxys; Patent; Lane, Jonathan Douglas; US2008/269222; (2008); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
46/162
2018-02-22 00:03:45
bacterial skin infections
Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
folliculitis
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys; Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
hidradenitis suppurativa
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
warts
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
molluscum contagiosum
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
psoriasis
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys; Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
ichthyosis
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
skin ulcers
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
atopic dermatitis
Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
rosacea
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys; Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys; Patent; Galderma Research and Development, S.N.C.; US2007/269524; (2007); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys; Patent; GALDERMA S.A.; US2008/153901; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
hair loss
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; Phar-
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
47/162
2018-02-22 00:03:45
macia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys wrinkles
Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
acne vulgaris
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
initiator for preparation of bone cement
Patent; DISC-O-TECH MEDICAL TECHNOLOGIES LTD.; WO2008/32322; (2008); (A2) English, View in Reaxys
Skin disorders
Patent; ALPHARX INC.; US2005/255133; (2005); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
radical initiator
Patent; Sumitomo Chemical Company, Limited; EP1683777; (2006); (A1) English, View in Reaxys; Patent; UNIVERSITY OF SOUTH CAROLINA; WO2007/8927; (2007); (A2) English, View in Reaxys; Patent; Solvay SA; EP1757570; (2007); (A1) English, View in Reaxys
oxygen component of antimicrobial composition
Patent; ECOLAB, INC.; EP1738758; (2007); (A1) English, View in Reaxys
auto cure initiator used to create a two-part system that cures when the components are mixed together
Patent; Pulpdent Corporation; US7157502; (2007); (B2) English, View in Reaxys
Microbial infections
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
Inflammation of tissue
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
P. acnes
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
Strep. pyogenes
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
E. coli
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
Pseudomonas aeruginosa
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
Staph. aureus
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
Impetigo
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
Dermatitis
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
Secondary skin infectionss
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
Responsive dermatoses
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
Seborrhea
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
Skin lesions
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
48/162
2018-02-22 00:03:45
Atopic dermatitis
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
Bacterial skin infections
Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys
tablets with reinforcement depressions on the upper side
Patent; Holderbaum, Thomas; Pegelow, Ulrich; Nitsch, Christian; Steffen-Holderbaum, Uta; US2007/9561; (2007); (A1) English, View in Reaxys
compressed particulate washing or cleaning composition
Patent; Holderbaum, Thomas; Pegelow, Ulrich; Nitsch, Christian; Steffen-Holderbaum, Uta; US2007/9561; (2007); (A1) English, View in Reaxys
organic bleache
Patent; Holderbaum, Thomas; Pegelow, Ulrich; Nitsch, Christian; Steffen-Holderbaum, Uta; US2007/9561; (2007); (A1) English, View in Reaxys
antibacterial composition for skin infection
Patent; Jones, George; US2007/9607; (2007); (A1) English, View in Reaxys
anti-inflammatory composition for skin infection
Patent; Jones, George; US2007/9607; (2007); (A1) English, View in Reaxys
manufacture of biodegradable and crosslinkable polymer
Patent; UNIVERSITY OF SOUTH CAROLINA; WO2007/8927; (2007); (A2) English, View in Reaxys
polymerization initiator for dental material
Patent; Dodiuk-Kenig, Hanna; Zalsman, Barry; Lisenboim, Kira; McHale, William A.; US2007/43142; (2007); (A1) English, View in Reaxys
radiopaque acrylic bone cement for orthopaedic use
Patent; Tecres, S.p.A.; US7186761; (2007); (B2) English, View in Reaxys
pharmaceutical composition comprising alkanolamine, soy and/or feverfew for mitigating redness or inflammation of skin
Patent; Tierney, Neena; Martin, Katharine; Mitchell, Phyllis; Southall, Michael; US2007/59259; (2007); (A1) English, View in Reaxys
Therapeutic agent for an orally-dissolvable, edible film
Patent; Maibach, Todd; US2007/59346; (2007); (A1) English, View in Reaxys
Dermatological agent
Patent; Maibach, Todd; US2007/59346; (2007); (A1) English, View in Reaxys
Crosslinking agent
Patent; Sumitomo Rubber Industries, Ltd.; US2007/78218; (2007); (A1) English, View in Reaxys
skin care agent
Patent; ENGINEERED RELEASE SYSTEMS, INC.; WO2007/9023; (2007); (A2) English, View in Reaxys
Reduces side effects associated with the ingredients used
Patent; ASPEN BENEFITS GROUP, LLC; WO2007/53422; (2007); (A1) English, View in Reaxys
Symptoms associated with acne
Patent; ASPEN BENEFITS GROUP, LLC; WO2007/53422; (2007); (A1) English, View in Reaxys
Propionibacterium acnes
Patent; ASPEN BENEFITS GROUP, LLC; WO2007/53422; (2007); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
49/162
2018-02-22 00:03:45
Acne causation factors due to oxidative effect
Patent; ASPEN BENEFITS GROUP, LLC; WO2007/53422; (2007); (A1) English, View in Reaxys
Anti-acne
Patent; Liegeois, Nanette; US2007/207115; (2007); (A1) English, View in Reaxys; Patent; THE BOOTS COMPANY PLC; WO2006/51246; (2006); (A1) English, View in Reaxys
free-radical polymerization initiator
Patent; Li, Zhi; Iqbal, Rifat; Wang, Jun; US2006/241220; (2006); (A1) English, View in Reaxys; Patent; Tecres, S.p.A.; US7186761; (2007); (B2) English, View in Reaxys
Initiator for BaylisHillman reaction for prudusing coating materials containing α-(1'hydroxyalkyl)acrylates
Patent; Schwalm, Reinhold; Beck, Erich; Heischkel, Yvonee; Gruber, Nick; Larbig, Harald; US2007/135556; (2007); (A1) English, View in Reaxys
initiator for manufacturing an ionomeric resin suitable for manufacturing a flexible wound dressing
Patent; Den-Mat Corporation; US2007/154528; (2007); (A1) English, View in Reaxys
Crosslinking initiator in an injectable bone cement for fixing bone fractures
Patent; Goupil, Dennis W.; Asfaw, Bruktawit T.; US2007/149641; (2007); (A1) English, View in Reaxys
Crosslinking initiator in an injectable bone cement to treat porous bone
Patent; Goupil, Dennis W.; Asfaw, Bruktawit T.; US2007/149641; (2007); (A1) English, View in Reaxys
Crosslinking initiator in an injectable bone cement to treat osteoporotic bone
Patent; Goupil, Dennis W.; Asfaw, Bruktawit T.; US2007/149641; (2007); (A1) English, View in Reaxys
Temporary dental restorative
Patent; Tiba, Amer; Charlton, David G.; Ragain, James C.; US2007/173559; (2007); (A1) English, View in Reaxys
Oxidizing agent for solid biocide composition
Patent; SANDERSON, William, D.; WO2007/78838; (2007); (A2) English, View in Reaxys
Comedonalbased acne
Patent; Liegeois, Nanette; US2007/207115; (2007); (A1) English, View in Reaxys
Acne/rosacea combination
Patent; Liegeois, Nanette; US2007/207115; (2007); (A1) English, View in Reaxys
Pustular variants of acne
Patent; Liegeois, Nanette; US2007/207115; (2007); (A1) English, View in Reaxys
Severe acne
Patent; Liegeois, Nanette; US2007/207115; (2007); (A1) English, View in Reaxys
Anti-inflammatory
Patent; Liegeois, Nanette; US2007/207115; (2007); (A1) English, View in Reaxys
Follicular based beard acne
Patent; Liegeois, Nanette; US2007/207115; (2007); (A1) English, View in Reaxys
anti-acne medicament
Patent; LUBRIZOL ADVANCED MATERIALS, INC.; WO2007/101059; (2007); (A2) English, View in Reaxys
Dermatological condition
Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
50/162
2018-02-22 00:03:45
Rashes
Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys
Eczema
Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys
Contact dermatitis
Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys
Acne rosacea
Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys
Fungal infections
Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys
Bacterial infections
Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys
Anti-acne agent
Patent; AMCOL INTERNATIONAL CORPORATION; WO2007/114904; (2007); (A2) English, View in Reaxys
Skin treatment
Patent; AMCOL INTERNATIONAL CORPORATION; WO2007/114904; (2007); (A2) English, View in Reaxys
Controlling excess skin oil
Patent; AMCOL INTERNATIONAL CORPORATION; WO2007/114904; (2007); (A2) English, View in Reaxys
Adsorption of moisture
Patent; AMCOL INTERNATIONAL CORPORATION; WO2007/114904; (2007); (A2) English, View in Reaxys
heat cure initiator of polymeric matrix of dental material
Patent; Jia, Weitao; Jin, Shuhua; US2007/232718; (2007); (A1) English, View in Reaxys
fibrosis inhibitor; inflammation inhibitor; acute inflammatory response inhibitor; migration or proliferation of connective tissue cells inhibitor; angiogenesis inhibitor; tissue remodelling inhibitor; reduces extracellular matrix (ECM) production; promotes ECM breakdown; collagen production inhibitor; collagen release inhibitor
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
Excessive scarring
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
Surgical adhesion
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
Fibrosis
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
Hypertrophic scar
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
Abdominal surgery
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
gynecological surgery
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
Hysterectomies
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
51/162
2018-02-22 00:03:45
Suture granulomas
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
Stitch abscess
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
Local irritation
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
Tissue necrosis
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
Side effects of surgical adhesion
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
Scarring
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
Tissue irritation
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
Improving skin retention time
Patent; CRODA, INC; WO2007/127158; (2007); (A2) English, View in Reaxys
Decreasing flux
Patent; CRODA, INC; WO2007/127158; (2007); (A2) English, View in Reaxys
keloid
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
Polymerization initiator
Patent; Toumi, Beatrice; US2005/281769; (2005); (A1) English, View in Reaxys; Patent; ROHMAX ADDITIVES GMBH; US2007/191238; (2007); (A1) English, View in Reaxys; Patent; Great Lakes Chemical (Europe) GmbH; EP1124787; (2003); (B1) English, View in Reaxys; Patent; QUICK-MED TECHNOLOGIES, INC.; WO2005/84436; (2005); (A1) English, View in Reaxys
Anti-microbial agent for cosmetic compositions
Page/Page column 9; 12
Patent; General Electric Company; US2007/134283; (2007); (A1) English, View in Reaxys
anti-acne agent
Patent; Estanislao, Roderico B.; Lambino, Danilo L.; Lim, Connie; Sugimoto, Maki; US2005/74484; (2005); (A1) English, View in Reaxys; Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/8537; (2006); (A1) English, View in Reaxys; Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; Or-Le-Or Ltd.; EP1685824; (2006); (A1) English, View in Reaxys; Patent; REVANCE THERAPEUTICS, INC.; WO2006/105450; (2006); (A2) English, View in Reaxys; Patent; Bhatnagar, Rajendra S.; US2006/293227; (2006); (A1) English, View in Reaxys; Patent; Bhatnagar, Rajendra S.; US2006/293228; (2006); (A1) English, View in Reaxys
papulo-pustular inflammatory acne
Patent; Watson, Dana M.; US2006/19935; (2006); (A1) English, View in Reaxys
Oxidizing agent for cracking hydrocarbon feedstock
Patent; Keusenkothen, Paul F.; US2006/14994; (2006); (A1) English, View in Reaxys
thermal free radical initiator
Patent; Pearson, Jason Clay; Weaver, Max Allen; Fleischer, Jean Carroll; King, Gregory Allan; US2006/115516; (2006); (A1) English, View in Reaxys
radical polymerization initiator
Patent; ASAHI GLASS COMPANY LTD.; EP1679311; (2006); (A1) English, View in Reaxys
halogenation of aralkyl compounds
Patent; Sumitomo Chemical Company, Limited; EP1683777; (2006); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
52/162
2018-02-22 00:03:45
Free radical initiator
Patent; THE GOODYEAR TIRE and RUBBER COMPANY; EP1681293; (2006); (A1) English, View in Reaxys
Topical acne drug
Patent; Leonard, Todd; US2006/122282; (2006); (A1) English, View in Reaxys
Skin and mucous membrane miscellaneous antiinfective
Patent; Leonard, Todd; US2006/122282; (2006); (A1) English, View in Reaxys
thermal radical initiator for synthesis of carbon-isotope labeled compounds
Patent; Langstrom, Bengt; Itsenko, Oleksiy; Kihlberg, Tor; US2006/171882; (2006); (A1) English, View in Reaxys
ingredient of topical composition beneficial for skin care
Patent; Or-Le-Or Ltd.; EP1685824; (2006); (A1) English, View in Reaxys
chemical initiator of polymerization
Patent; Abels, Norbert; Fischer, Dan E.; Backes, Claus-H; US2006/189707; (2006); (A1) English, View in Reaxys
Initiator of polymerization for dental sealant composition
Patent; DENTSPLY DE TREY GMBH; WO2006/10631; (2006); (A1) English, View in Reaxys
Antidandruff
Patent; L'OREAL; US2006/159730; (2006); (A1) English, View in Reaxys
topical application to the skin
Patent; JR CHEM, LLC; US2006/204530; (2006); (A1) English, View in Reaxys
Acne Vulgaris
Patent; JR CHEM, LLC; US2006/204530; (2006); (A1) English, View in Reaxys
Polymerization initiator for dental self-curing resin cement composition
Patent; Dentkist, Inc.; US7115674; (2006); (B2) English, View in Reaxys
Component for skin lotions of invention
Patent; HY-GENE BIOMEDICAL CORPORATION; WO2006/31230; (2006); (A1) English, View in Reaxys
Initiator of radical polymerisation
Patent; CELANESE EMULSIONS GMBH; WO2006/34762; (2006); (A2) German, View in Reaxys
keratolytic agent that removes the dead and damaged skin cells
Patent; TARO PHARMACEUTICALS U.S.A., INC.; RAO, Srinivasa; DIXIT, Suresh; OBE, Folusho; GOYAL, Sandhya; YACOBI, Avraham; WO2006/102004; (2006); (A2) English, View in Reaxys
anti-acne drug
Patent; ZYMES, LLC; WO2006/107825; (2006); (A2) English, View in Reaxys
Component of skin-health-improving formulations
Patent; ZYMES, LLC; WO2006/107825; (2006); (A2) English, View in Reaxys
Polymerization initiator for an uncured dental composition
Patent; Anton, Douglas Robert; Jaycox, Gary Delmar; US2006/258771; (2006); (A1) English, View in Reaxys
free radical crosslinker
Patent; Pluyter, Johan Gerwin Lodewijk; anastasiou, Theodore James; US2006/248665; (2006); (A1) English, View in Reaxys
Oxygen component for preparation of the antimi-
Patent; ECOLAB INC.; US2006/257498; (2006); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
53/162
2018-02-22 00:03:45
crobial composition Oil control agent
Patent; Bissett, Donald Lynn; Mitra, Shekhar; US2006/275237; (2006); (A1) English, View in Reaxys
cosmetic composition comprising transforming growth factor-β (TGF-β) mimic used for treatment of skin
Patent; Bhatnagar, Rajendra S.; US2006/293227; (2006); (A1) English, View in Reaxys
in combination with peptide useful for teatment of dermatitis, psoriasis, acne, urticaria, mucositis, and a wound
Patent; Bhatnagar, Rajendra S.; US2006/293228; (2006); (A1) English, View in Reaxys
chemical initiator
Patent; KANCA, John, III; WO2006/91855; (2006); (A1) English, View in Reaxys
Tooth whitening agent
Patent; CORIUM INTERNATIONAL, INC.; A.V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESIS; WO2006/69236; (2006); (A2) English, View in Reaxys
organic peroxide initiator for the peroxide curing system
Patent; 3M INNOVATIVE PROPERTIES COMPANY; WO2006/55220; (2006); (A1) English, View in Reaxys; Patent; 3M INNOVATIVE PROPERTIES COMPANY; WO2006/55274; (2006); (A1) English, View in Reaxys
Reducing agent for skin cleansing system
Patent; Kimberly-Clark Worldwide, Inc.; US2006/140899; (2006); (A1) English, View in Reaxys
topical acne drug for adhesive skin patch
Patent; NU-TEIN CO., INC.; LEONARD, Todd; WO2006/62740; (2006); (A2) English, View in Reaxys
mucous membrane miscellaneous anti-infective
Patent; NU-TEIN CO., INC.; LEONARD, Todd; WO2006/62740; (2006); (A2) English, View in Reaxys
skin miscellaneous anti-infective
Patent; NU-TEIN CO., INC.; LEONARD, Todd; WO2006/62740; (2006); (A2) English, View in Reaxys
Antibacterial drug
Patent; THE BOOTS COMPANY PLC; WO2006/51246; (2006); (A1) English, View in Reaxys
Antimicrobial agent
Patent; THE BOOTS COMPANY PLC; WO2006/51246; (2006); (A1) English, View in Reaxys
Initiator
Patent; Myung, David; Noolandi, Jaan; Smith, Alan J.; Frank, Curtis W.; Ta, Christopher; Hu, Yin; Koh, Won-Gun; Carrasco, Michael R.; US2006/83773; (2006); (A1) English, View in Reaxys
producing a hydrogel composition comprising crosslinked poly(ethylene oxide) useful for wound dressing
Patent; DePuy Products, Inc.; EP1642595; (2006); (A1) English, View in Reaxys
crosslinking agent
Patent; DePuy Products, Inc.; EP1642595; (2006); (A1) English, View in Reaxys
component comosition for the treating mammalian skin and hair
Patent; LIPO CHEMICALS, INC.; WO2006/36557; (2006); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
54/162
2018-02-22 00:03:45
polymerization initiator for transparent resin matrix for temporary cosmetic dental coating
Patent; Hurwitz, Mami Markell; Narasimhan, Dave; US2006/63853; (2006); (A1) English, View in Reaxys
curable composition
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
restorative material
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
prosthesis
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
cement
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
cavity liner
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
varnish
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
sealer
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
hip prostheses
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
dental fissure sealers
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
temporary or permanent crowns
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
temporary or permanent bridges
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
cemented orthodontic appliances
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
veneer
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
bonding material
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
diseased tooth
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
cavity
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
caries
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
broken tooth
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
discolored tooth
Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys
follicular diseases
Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys
follicular rash
Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys
follicular infections
Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys
psudofolliculitis barbe
Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys
follicular ketarosis
Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
55/162
2018-02-22 00:03:45
phrynoderma
Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys
ichthyosis follicularis
Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys
follicular dysplasia
Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys
antimicrobial agent of cleansing composition
Patent; L'OREAL; US2006/18865; (2006); (A1) English, View in Reaxys
formulation for resolve scar tissue
Patent; Hofmann, Robert F.; US2006/14732; (2006); (A1) English, View in Reaxys
scar tissue resulting from a burn
Patent; Hofmann, Robert F.; US2006/14732; (2006); (A1) English, View in Reaxys
burn-related injuries
Patent; Hofmann, Robert F.; US2006/14732; (2006); (A1) English, View in Reaxys
hypertrichosis
Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
hirsutism
Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
polymerization initiator
Patent; BASF AKTIENGESELLSCHAFT; US2005/196444; (2005); (A1) English, View in Reaxys; Patent; Ahn, Sung Hee; Yang, Jae Ho; Hong, Sang Hyun; Bae, Su Hak; Ryu, Young Sik; US2006/183825; (2006); (A1) English, View in Reaxys
keratosis pilaris
Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
alopecia
Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
free radical polymerization initiator
Patent; Farcet, Celine; US2006/8431; (2006); (A1) English, View in Reaxys
free-radical polymerization initiator
Page/Page column 11
Patent; Mougin, Nathalie; US2006/88487; (2006); (A1) English, View in Reaxys
polymerization ini- Page/Page coltiator umn 14
Patent; L'OREAL; WO2006/106487; (2006); (A1) English, View in Reaxys
source of peroxide for conducting a chemiluminescent assay of detecting complexbound microorganisms
Patent; Olstein, Alan D.; Feirtag, Joellen; US2005/26813; (2005); (A1) English, View in Reaxys
component of emulsion for topical application to the skin
Patent; Hy-Gene Biomedical Corporation; US2005/36972; (2005); (A1) English, View in Reaxys
component of spray for application to surfaces
Patent; Hy-Gene Biomedical Corporation; US2005/36972; (2005); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
56/162
2018-02-22 00:03:45
treatment of blemishes
Patent; Fusco, Normajean; US2005/53595; (2005); (A1) English, View in Reaxys
anti-acne agent for medicinal compositions
Patent; GALDERMA RESEARCH and DEVELOPMENT, S.N.C.; WO2005/58312; (2005); (A1) English, View in Reaxys
polymerization thermal initiator
Patent; Burtscher, Peter; Madler, Lutz; Moszner, Nobert; Pratsinis, Sotiris E.; Rheinberger, Volker M.; US2005/176843; (2005); (A1) English, View in Reaxys
chlorination catalyst
Patent; Central Glass Co., Ltd; JP2005/200396; (2005); (A) Japanese, View in Reaxys
Component for pharmaceutical composition for the treatment of acne vulgaris
Patent; Bernstein, Joel E.; US2005/169948; (2005); (A1) English, View in Reaxys
Component for pharmaceutical composition for the treatment of acne rosacea
Patent; Bernstein, Joel E.; US2005/169948; (2005); (A1) English, View in Reaxys
bleach solution
Patent; Brennen Medical, Inc.; Carbon Medical Technologies, Inc.; US6933103; (2005); (B1) English, View in Reaxys
medicament
Patent; Medpak LLC; US2005/208153; (2005); (A1) English, View in Reaxys
therapy
Patent; Medpak LLC; US2005/208153; (2005); (A1) English, View in Reaxys
dental material
Patent; Ivoclar Vivadent AG; US6953832; (2005); (B2) English, View in Reaxys
thermal initiator
Patent; Ivoclar Vivadent AG; US6953832; (2005); (B2) English, View in Reaxys
elimination of allergen(s) from the skin's surface
Patent; ALPHARX INC.; US2005/255133; (2005); (A1) English, View in Reaxys
viral infection
Patent; ALPHARX INC.; US2005/255133; (2005); (A1) English, View in Reaxys
Microbial infection
Patent; ALPHARX INC.; US2005/255133; (2005); (A1) English, View in Reaxys
Radical initiator in the reactions of chlorination
Patent; SOLVAY FLUOR GMBH; WO2005/123636; (2005); (A1) German, View in Reaxys
Initiator of a freeradical polymerization reaction
Patent; Lemoine, Guy; Youssef, Boulos; Bunel, Claude; Jolivet, Yannick; Pinoche, Jean-Marie; US2005/256350; (2005); (A1) English, View in Reaxys
oxidizing agent for removing a biocompatible hydrogel from a patient
Patent; Pritchard, Wilson; Flowers, Cedric; Prescott, Tony; Mendius, Rick; Hallam, Clive; US2005/220882; (2005); (A1) English, View in Reaxys
sexual dysfunction
Patent; MIDWEST RESEARCH LABORATORIES, LLC; WO2005/112872; (2005); (A1) English, View in Reaxys
Human sexual dysfunction
Patent; MIDWEST RESEARCH LABORATORIES, LLC; WO2005/112872; (2005); (A1) English, View in Reaxys
sexual arousal
Patent; MIDWEST RESEARCH LABORATORIES, LLC; WO2005/112872; (2005); (A1) English, View in Reaxys
whitening agent
Patent; Hassan, Mahmoud; Xu, Guofeng; Viscio, David; Gaffar, Abdul; US2005/249678; (2005); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
57/162
2018-02-22 00:03:45
Oxidizing agent for sinthesis of drug for effectively stimulate bone regeneration and increase osteoblastic activity
Patent; Hofmann, Robert F.; US2005/250755; (2005); (A1) English, View in Reaxys
Oxidizing agent for sinthesis of drug against agerelated macular degeneration
Patent; Hofmann, Robert F.; US2005/250756; (2005); (A1) English, View in Reaxys
Oxidizing agent for sinthesis of drug against lymphoma
Patent; Hofmann, Robert F.; US2005/250757; (2005); (A1) English, View in Reaxys
initiator for preparing silver/polymer composite nanospheres for preservation of cosmetics
Patent; AMOREPACIFIC CORPORATION; WO2005/77329; (2005); (A1) English, View in Reaxys
antiacne component of treatment composition
Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys
discreet erythema of the skin
Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys
skin redness
Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys
chronic sun damage
Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys
allergic rhinitis
Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys
skin exfoliant as component of the topical preparation for reducing an occurrence of irritation and/or inflammatory reaction in human skin
Patent; PCR TECHNOLOGY HOLDINGS, LC; WO2005/79775; (2005); (A1) English, View in Reaxys
antibacterial agent
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
dermatological or mucosal disorder
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
disorder of the skin, mucosal membrane, vagina and rectum
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
Pain
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
nummular dermatitis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
chronic dermatitis of the hands and feet
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
generalized exfoliative dermatitis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
58/162
2018-02-22 00:03:45
stasis dermatitis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
diaper rash
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
bacterial infections
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
staphylococcal scalded skin syndrome
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
fungal infections
Patent; ALPHARX INC.; US2005/255133; (2005); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
dermatophyte infections
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
yeast infections
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
parasitic infections
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
viral infections
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
disorders of hair follicles and sebaceous glands
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
peroral dermatitis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
male pattern baldness
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
alopecia areata
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
alopecia universalis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
alopecia totalis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
keratinous cyst
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
scaling papular diseases
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
benign tumors
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
dysplastic nevi
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
skin tags
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
lipomas
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
angiomas
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
pyogenic granuloma
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
seborrheic keratoses
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
dermatofibroma
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
59/162
2018-02-22 00:03:45
keratoacanthoma
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
malignant tumors
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
Paget's disease of the nipples
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
reactions to sunlight
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
bullous diseases
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
linear immunoglobulin A disease
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
vitiligo
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
albinism
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
postinflammatory hypopigmentation
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
hyperpigmentation
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
melasma
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
chloasma
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
drug-induced hyperpigmentation
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
postinflammatory hyperpigmentation
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
calluses
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
actinic keratosis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
pressure sores
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
disorders of sweating
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
granuloma annulare
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
non-dermatological disorders, which respond to topical/ transdermal delivery of an active agent
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
localized pain
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
joint pain
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
muscle pain
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
back pain
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
60/162
2018-02-22 00:03:45
rheumatic pain
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
arthritis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
ostheoarthritis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
acute soft tissue injuries and sports injuries
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
conditions, which respond to hormone therapy
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
hormone replacement therapy
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
transdermal nicotine administration
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
pelvic pain
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
premenstrual syndrome (PMS)
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
mittelschmerz
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
dysmenorrhea
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
endometriosis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
ectopic pregnancy
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
ovarian cysts and masses
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
acute pelvic inflammatory disease
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
pelvic congestion syndrome
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
vulvodynia
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
vulvovaginal infections
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
bacterial vaginosis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
candidal vaginitis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
trichomonas vaginalis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
herpes simplex
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
genital ulcers and warts
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
pelvic inflammatory disease (PID)
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
cervicitis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
61/162
2018-02-22 00:03:45
acute and chronic salpingitis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
gynecological neoplasms
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
endometrial cancer
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
ovarian cancer
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
cervical cancer
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
vulvar cancer
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
vaginal cancer
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
fallopian tube cancer
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
gestational trophoblastic disease
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
sexually transmitted diseases
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
sexual dysfunction disorders that respond to pharmacological therapy
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
sexual arousal disorder
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
female orgasmic disorder
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
dyspareunia
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
vaginismus
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
anal abscess/ fistula
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
anal cancer
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
anal warts
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
Crohn's disease
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
haemorrhoids
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
perianal thrush
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
anal fissures
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
fecal incontinence
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
constipation
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
polyps of the colon and rectum
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
62/162
2018-02-22 00:03:45
sexually-transmitted disease
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
non-sexuallytransmitted vaginal and genital infectious disease
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
wounds
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
burns
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
cuts
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
ulcers
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys
photosensitizer in a dental composition
Patent; RHODIA CHIMIE; US2005/59752; (2005); (A1) English, View in Reaxys
decellularizing agent
Patent; DEPUY SPINE, INC.; WO2005/32473; (2005); (A2) English, View in Reaxys
sequential decellurization of an isolated tissue
Patent; DEPUY SPINE, INC.; WO2005/32473; (2005); (A2) English, View in Reaxys
tissue regeneration
Patent; DEPUY SPINE, INC.; WO2005/32473; (2005); (A2) English, View in Reaxys
biocompatible tissue implant
Patent; DEPUY SPINE, INC.; WO2005/32473; (2005); (A2) English, View in Reaxys
injured or diseased joints
Patent; DEPUY SPINE, INC.; WO2005/32473; (2005); (A2) English, View in Reaxys
creation artificial tissue (kidney, liver, bladder, skin, and the like)
Patent; DEPUY SPINE, INC.; WO2005/32473; (2005); (A2) English, View in Reaxys
dermatological disorders and dermatological disorder-related complications
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
comedones
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
papules, pustules
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
inflamed nodules
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
superficial pus-filled cysts
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
skin lesions and dermal inflammation
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
dermal scarring
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
disfigurement, cellulitis
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
dermal abscesses
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
63/162
2018-02-22 00:03:45
secondary bacterial infection (impetigo)
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
herpes simplex or zoster
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
dermatological pain
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
dermatological inflammation
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
dermatitis
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
fungal skin infections
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
skin neoplasia
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
viral skin infections
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
parasitic skin infections
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
skin neoplasms
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
pruritis
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
cellulitis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
acute lymphangitis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
lymphadenitis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
erysipelas
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
cutaneous abscesses
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
necrotizing subcutaneous infections
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
scalded skin syndrome
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
furuncles
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
carbuncles
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
paronychial infections
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
64/162
2018-02-22 00:03:45
rashes
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
erythrasma
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
ecthyma
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
yeast skin infections
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
trauma or injury to the skin
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
post-operative or post-surgical skin conditions
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
scabies
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
pediculosis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
creeping eruption
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
eczemas
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
pityriasis rosea
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
lichen planus
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
pityriasis rubra pilaris
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
edematous
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
erythema multiforme
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
erythema nodosum
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
grannuloma annulare
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
epidermal necrolysis
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
sunburn
Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
photosensitivity
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
pemphigus
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
65/162
2018-02-22 00:03:45
bullous pemphigoid
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
dermatitis herpetiformis
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
callouses
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
corns
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
ischemic necrosis
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
miliaria
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
hyperhidrosis
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
moles
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
Kaposi's sarcoma
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
melanoma
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
malignant melanoma
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
basal cell carcinoma
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
squamous cell carcinoma
Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
poison ivy
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
poison oak
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
contact dermatitis
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
purpura
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
moniliasis
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
candidiasis
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
baldness
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
Behcet's syndrome
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
cholesteatoma
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
Dercum disease
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
66/162
2018-02-22 00:03:45
ectodermal dysplasia
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
gustatory sweating
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
nail patella syndrome
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
lupus
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
hives
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
Hailey-Hailey disease
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
chemical or thermal skin burns
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
scleroderma
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
aging skin
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
sun spots
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
necrotizing fasciitis
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
necrotizing myositis
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
gangrene
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
scarring and vitiligo
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
inflammatory acne
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
non-inflammatory acne
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
acne fulminans
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
nodular papulopustular acne
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
acne conglobata
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
dermatological treatment agent
Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys
keratoplastic effect
Patent; CIBA SPECIALTY CHEMICALS HOLDING INC.; WO2005/40284; (2005); (A1) English, View in Reaxys
Ingredient of cosmetics
Patent; CIBA SPECIALTY CHEMICALS HOLDING INC.; WO2005/40284; (2005); (A1) English, View in Reaxys
radical generator
Patent; TAISHO PHARMACEUTICAL CO., LTD; Sato, Fumie; EP1598335; (2005); (A1) English, View in Reaxys
initiator for polymerization of MIP for reducing dietary phosphate
Patent; Ross, Edward Allan; Batich, Christopher D.; US2005/276781; (2005); (A1) English, View in Reaxys
Initiator of radical polymerization
Patent; ASAHI GLASS COMPANY, LIMITED; WO2005/121118; (2005); (A1) Japanese, View in Reaxys
inhibition of anaerobotic microbial
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
67/162
2018-02-22 00:03:45
growth and establishment of a healthier membrane microflora; enhanced tissue immunological activity reduction the visible signs of skin aging
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys
pseudo-folliculitis barbae
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys
lesions
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys
sebum regulations
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys
pigmentation regulation
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys
hair growth retardation
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys
hair stimulation
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys
vaginal candidiasis
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys
vaginosis
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys
genital herpes
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys
blood vasoconstriction
Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys
oxidation of iron(II) to iron(III), which precipitates.
Patent; BP CORPORATION NORTH AMERICA INC.; WO2003/91195; (2003); (A1) English, View in Reaxys
Removal of dissolved iron from liquid streams during aromatic acid manufacture
Patent; BP CORPORATION NORTH AMERICA INC.; WO2003/91195; (2003); (A1) English, View in Reaxys
polymerization ini- Page/Page coltiator umn 22
Patent; Mitsubishi Rayon Co., Ltd.; EP1352904; (2003); (A1) English, View in Reaxys
Medchem (289) 1 of 289
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : |transport Bioassay : control: without title comp. hydrated nail clippings incubated with title comp. for 20 h; excess moisture removed; title comp. penetration activity measured as nail swelling and increase in nail weight
Biological Species/NCBI human ID Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title comp. did not significantly increase nail weight; table
Measurement Parameter
Qualitative
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
68/162
2018-02-22 00:03:45
Khengar; Jones; Turner; Forbes; Brown; Pharmaceutical Research; vol. 24; nb. 12; (2007); p. 2207 - 2212, View in Reaxys 2 of 289
Substance Effect
Cytotoxic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : T1 cell lineBioassay : in Dulbecco's modified Eagle's medium with 10 percent FCS, HEPES and antibiotics; positive control: 0.5 ng/ml mezerein; 1E4 cells/ml; lowest conc. at which no sign. increase in foci compared to unexposed control determined; compared with Ames and SHE tests bovine papillomavirus DNA-carrying C3H/10T1/2 cell line; 200 cells from T1 passages 26-35 cocultured with 5E4 untransfected C3H/10T1/2 cells passages 16-19; incubated at 37 deg C for 72 hr; prediction of carcinogenicity; foci counted
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Dose
0.00500000 µM
Qualitative Results
title comp. showed positive response; lowest transforming dose: 0.1 μmol/l
Measurement Parameter
Qualitative
Kowalski; Assi; Wee; Madden Vera Genics; Environmental and Molecular Mutagenesis; vol. 37; nb. 3; (2001); p. 231 - 240, View in Reaxys 3 of 289
Bioassay Category
In Vivo (Animal models)
Bioassay Name
In vivo Measurement
Bioassay Details
Effect : cutaneous iron levels; increase ofBioassay : control: untreated mice mice pretreated with 7,12-dimethylbenz(a)anthracene and iron-dextran; administered with title comp.; sacrificed at termination of tumor induction; dorsal skin removed; cutaneous iron levels were estimated by dipyridyl method
Biological Species/NCBI Mus musculus ID Substance RN
984320View in Reaxys
Substance Name
230913
Substance Route of Adm.
transdermal administration
Qualitative Results
non-tumor-bearing, tumor-bearing skin of mice treated with title comp. showed increase in cutaneous iron levels
Measurement Parameter
Qualitative
Bhasin, Gayatri; Kauser, Hina; Athar, Mohammad; Archives of Toxicology; vol. 78; nb. 3; (2004); p. 139 - 146, View in Reaxys 4 of 289
Bioassay Category
In Vivo (Animal models)
Bioassay Name
In vivo Measurement
Bioassay Details
Effect : tumor-promotingBioassay : mice pretreated with 7,12-dimethylbenz(a)anthracene in presence or absence of iron-dextran; administered with title comp.; carcinomas formed were counted and verified by histopathological examination
Biological Species/NCBI Mus musculus ID Substance RN
984320View in Reaxys
Substance Name
230913
Substance Route of Adm.
transdermal administration
Qualitative Results
tumor size of title comp.-treated mice was 62.3 mm2 and in iron-overloaded mice treated with title comp. was 74 mm2; fig.
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
69/162
2018-02-22 00:03:45
Measurement Parameter
Qualitative
Bhasin, Gayatri; Kauser, Hina; Athar, Mohammad; Archives of Toxicology; vol. 78; nb. 3; (2004); p. 139 - 146, View in Reaxys 5 of 289
Bioassay Category
In Vivo (Animal models)
Bioassay Name
In vivo Measurement
Bioassay Details
Effect : tumor-promotingBioassay : DMBA: 7,12-dimethylbenz(a)anthracene mice pretreated with DMBA in presence or absence of iron-dextran; administered with title comp.; carcinomas formed were counted and verified by histopathological examination; percent of malignant conversion of benign papillomas into carcinomas was determined
Biological Species/NCBI Mus musculus ID Substance RN
984320View in Reaxys
Substance Name
230913
Substance Route of Adm.
transdermal administration
Qualitative Results
percent of incidence of carcinomas was 85 and 90 percent in normal and iron-overloaded mice treated with title comp., resp.; fig.
Measurement Parameter
Qualitative
Bhasin, Gayatri; Kauser, Hina; Athar, Mohammad; Archives of Toxicology; vol. 78; nb. 3; (2004); p. 139 - 146, View in Reaxys 6 of 289
Bioassay Category
In Vivo (Animal models)
Bioassay Name
In vivo Measurement
Bioassay Details
Effect : tumor-promotingBioassay : DMBA: 7,12-dimethylbenz(a)anthracene mice pretreated with DMBA in presence or absence of iron-dextran; mice administered with title comp.; mice sacrificed at termination of tumor induction; tissues removed; sections were stained with hematoxylin, eosin stains and examined microscopically
Biological Species/NCBI Mus musculus ID Substance RN
984320View in Reaxys
Substance Name
230913
Substance Route of Adm.
transdermal administration
Qualitative Results
epidermal ulceration was observed in tumor samples treated with iron and title comp.; table
Measurement Parameter
Qualitative
Bhasin, Gayatri; Kauser, Hina; Athar, Mohammad; Archives of Toxicology; vol. 78; nb. 3; (2004); p. 139 - 146, View in Reaxys 7 of 289
Substance Effect
Antimicrobial
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Bioassay : This example illustrates antimicrobial efficacy of topical benzoyl peroxide compositions in accordance with the present disclosure in skin during a three day study. Materials and Methods A split-face, randomized study of 24 patients was conducted. Patients were randomly divided into two groups of 12
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Substance Name
230913
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
70/162
2018-02-22 00:03:45
Qualitative Results
The 5% test compound in accordance with the present disclosure yielded a 0.2 log greater reduction in P. acnes than the 5% benzoyl peroxide gel and a 0.7 log greater reduction in P. acnes that the 5% benzoyl peroxide/1% clindamycin gel after 3 and 8
Measurement Parameter
Qualitative
Patent; JR CHEM, LLC; US2006/204530; (2006); (A1) English, View in Reaxys 8 of 289
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : inflammatory lesion; effect onBioassay : This example illustrates lesion reduction using topical 5% benzoyl peroxide compositions in accordance with the present disclosure. Materials and Methods Subjects were randomly assigned to receive 5% benzoyl peroxide compositions (meeting the U.S. Pharmacopoeia labeling requirements) in accordance with
Biological Species/NCBI human ID Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
inflammatory lesion counts over treatment course: ~55.0% (4 week); ~35% (10week); figure given
Measurement Parameter
Qualitative
Patent; JR CHEM, LLC; US2006/204530; (2006); (A1) English, View in Reaxys 9 of 289
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : non-inflammatory lesion; effect onBioassay : This example illustrates lesion reduction using topical 5% benzoyl peroxide compositions in accordance with the present disclosure. Materials and Methods Subjects were randomly assigned to receive 5% benzoyl peroxide compositions (meeting the U.S. Pharmacopoeia labeling requirements) in accordance with
Biological Species/NCBI human ID Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
non-inflammatory lesion counts over treatment course: 40.0% (4 week); ~38% (10week); figure given
Measurement Parameter
Qualitative
Patent; JR CHEM, LLC; US2006/204530; (2006); (A1) English, View in Reaxys 10 of 289
Target Name
Myeloperoxidase
Target Synonyms
mpo; myeloperoxidase; uncleaved myeloperoxidase
Target, Subunit, Species Myeloperoxidase Target Mutant/Chimera Details
Myeloperoxidase:Wild
Target Transfection
Non Transfected
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : |enzyme; examination of Bioassay : 20 mg in 0.2 ml acetone; applied topically to female mice CD-1; after killing MPO extraction from 22-mm diameter dorsal skin from polymorphonuclear leucocytes (PMNs) spectrophotometrically; MPO accumulation in mouse skin
Substance RN
984320View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
71/162
2018-02-22 00:03:45
11 of 289
Substance Name
230913
Qualitative Results
ability to elicit the accumulation of MPO as MPO activity: 0.04 +/- 0.01 (units/22 mm skin punch); 1 unit of MPO activity is equivalent to 8.6*106 murine PMNs
Measurement Parameter
Qualitative
Substance Effect
Antimicrobial
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
reducing the number of P.acnes, figure 4 is given
Measurement Parameter
Qualitative
Patent; KIM, Jenny; FRIEDMAN, Adam; MODLIN, Robert; WO2007/149868; (A2); (2007), View in Reaxys 12 of 289
Bioassay Category
In Vivo (Animal models)
Bioassay Name
In vivo Measurement
Bioassay Details
Effect : TPA-induced ear edema; reduction ofTarget : Balb/c ByJIc mouseBioassay : Example 2 : Evaluation of the anti-inflammatory in ear oedema model on Balb/c miceThe study was carried out with 45 (5 par groups) female9 weeks aged Balb/c ByJIc mice.The Edema was induced by a single application of 20μl of TPA dissolved in acetone at 0.01%.The treatment was administrated by single
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Route of Adm.
cutaneous administration
Qualitative Results
2.5%, 5% and 10% title compound has a slight anti-inflammatory effect, reducing the TPAinduced ear edema by 16%, 24% and 40%, respectively; figure is given
Measurement Parameter
Qualitative
Patent; GROSS, Denis; LOESCHE, Christian; PONCET, Michel; ABOU-CHACRA VERNET, Marie-line; WO2008/6888; (A1); (2008), View in Reaxys 13 of 289
Bioassay Category
In Vivo (Animal models)
Bioassay Name
In vivo Measurement
Bioassay Details
Effect : lesions; reduction ofBioassay : Example 1: Clinical study results A clinical study for confirmation of efficacy was performed for a topical gel combining adapalene + benzoyl peroxide (BPO) . <n="13"/>This gel has the following formulation (expressed as % weight/ total weight) :Adapalene 0.10%Benzoyl peroxide 2.50% Copolymer of acrylamide
Biological Species/NCBI human ID Substance RN
984320View in Reaxys
Substance Name
230913
Substance Route of Adm.
cutaneous administration
Qualitative Results
2.5% title compound treatment resulted in 15.4% degree of success, -43.6% number of inflammatory lesions, -36.4% number of non-inflammatory lesions, -35.6% total number of lesions, -13.0 number of inflammatory lesions, -16.0 number of non-inflammatory
Measurement Parameter
Qualitative
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
72/162
2018-02-22 00:03:45
Patent; GROSS, Denis; LOESCHE, Christian; PONCET, Michel; ABOU-CHACRA VERNET, Marie-line; WO2008/6888; (A1); (2008), View in Reaxys 14 of 289
Bioassay Category
Toxicity/Safety Pharmacology
Bioassay Name
Cell/tumor cell: proliferation/viability/growth
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Substance Name
Bezoyl peroxide
Substance Dose
1.95000 mg/L
Measurement Parameter
MIC
Unit
mg/L
Quantitative value
31.25
Measurement pX
3.89
Patent; ROACH, Alan George; GOLDSMITH, Paul; (12 pag.); WO2007/141530; (2007); (A2), View in Reaxys 15 of 289
Bioassay Category
Toxicity/Safety Pharmacology
Bioassay Name
Cell/tumor cell: proliferation/viability/growth
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Substance Name
Bezoyl peroxide
Substance Dose
1.95000 mg/L
Measurement Parameter
Concentration
Unit
mg/L
Measurement Object
minimum bactericidal concentration (MBC)
Quantitative value
62.5
Patent; ROACH, Alan George; GOLDSMITH, Paul; (12 pag.); WO2007/141530; (2007); (A2), View in Reaxys 16 of 289
Substance Effect
Antiproliferative
Bioassay Category
Toxicity/Safety Pharmacology
Bioassay Name
Cell/tumor cell: proliferation/viability/growth
Bioassay Details
Effect : cell proliferation; inhibition ofEXAMPLE 13SCREENING ASSAY FOR ASSESSING THE EFFECT OF COMPOUNDS ON CELLPROLIFERATIONA screening assay was conducted on numerous compounds to determing their effect on cell proliferation (In vitro toxicol. (1990) 3: 219; Biotech. Histochem. (1993) 68: 29; Anal Biochem. (1993) 213: 426).Fibroblasts at
Biological Species/NCBI human ID Cells/Cell Lines
fibroblast
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
IC50
Unit
nM
Quantitative value
1200 - 10000
Measurement pX
5.92
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
73/162
2018-02-22 00:03:45
17 of 289
Substance Effect
Antimicrobial
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : anti-microbial
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
reducing the number of P.acnes, figure 4 is given
Measurement Parameter
Qualitative
Patent; SK CHEMICALS CO., LTD.; WO2007/49868; (2007); (A1) English, View in Reaxys 18 of 289
Substance Effect
Antimicrobial
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : anti-microbial
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
reducing the number of P.acnes, figure 4 is given
Measurement Parameter
Qualitative
Patent; KIM, Jenny; FRIEDMAN, Adam; MODLIN, Robert; (43 pag.); WO2007/149868; (A2); (2007), View in Reaxys 19 of 289
Substance Effect
Antimicrobial
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : anti-microbial
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
reducing the number of P.acnes, figure 4 is given
Measurement Parameter
Qualitative
Patent; KIM, Jenny; FRIEDMAN, Adam; MODLIN, Robert; (43 pag.); WO2007/149868; (A2); (2007), View in Reaxys 20 of 289
Bioassay Category
In Vivo (Animal models)
Bioassay Name
In vivo Measurement
Bioassay Details
Effect : TPA-induced ear edema; reduction of Example 2 : Evaluation of the anti-inflammatory in ear oedema model on Balb/c miceThe study was carried out with 45 (5 par groups) female9 weeks aged Balb/c ByJIc mice.The Edema was induced by a single application of 20μl of TPA dissolved in acetone at 0.01%.The treatment was administrated by single
Biological Species/NCBI Mus musculus ID Substance RN
984320View in Reaxys
Substance Name
230913
Substance Route of Adm.
cutaneous administration
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
74/162
2018-02-22 00:03:45
Qualitative Results
2.5%, 5% and 10% title compound has a slight anti-inflammatory effect, reducing the TPAinduced ear edema by 16%, 24% and 40%, respectively; figure is given
Measurement Parameter
Qualitative
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys 21 of 289
Bioassay Category
In Vivo (Animal models)
Bioassay Name
In vivo Measurement
Bioassay Details
Effect : lesions; reduction of Example 1: Clinical study results A clinical study for confirmation of efficacy was performed for a topical gel combining adapalene + benzoyl peroxide (BPO) . <n="13"/>This gel has the following formulation (expressed as % weight/total weight) :Adapalene 0.10%Benzoyl peroxide 2.50% Copolymer of acrylamide
Biological Species/NCBI human ID Substance RN
984320View in Reaxys
Substance Name
230913
Substance Route of Adm.
cutaneous administration
Qualitative Results
2.5% title compound treatment resulted in 15.4% degree of success, -43.6% number of inflammatory lesions, -36.4% number of non-inflammatory lesions, -35.6% total number of lesions, -13.0 number of inflammatory lesions, -16.0 number of non-inflammatory
Measurement Parameter
Qualitative
Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys 22 of 289
Substance Effect
Antiproliferative
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : fibroblasts of humanBioassay : EXAMPLE 13SCREENING ASSAY FOR ASSESSING THE EFFECT OF COMPOUNDS ON CELLPROLIFERATIONA screening assay was conducted on numerous compounds to determing their effect on cell proliferation (In vitro toxicol. (1990) 3: 219; Biotech. Histochem. (1993) 68: 29; Anal Biochem. (1993) 213: 426).Fibroblasts at
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
IC50
Unit
nM
Quantitative value
1200 - 10000
Measurement pX
5.92
Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys 23 of 289
Substance Effect
Antiacne
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : with Grade 2-3 facial acne of humanBioassay : B. Acne Clinical Trial Using Inventive FormulationFifteen panelists exhibiting Grade 2-3 facial acne were recruited for participation in this study. Panelists were randomized into three equal groups corresponding to the three different products they were using: Lotion 1, 2, and 3.Lotion 1 contained
Substance RN
984320View in Reaxys
Substance Name
230913
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
75/162
2018-02-22 00:03:45
Qualitative Results
title compound treatment resulted in a significant reduction in the acne lesion counts; title compound demonstrated a decrease in the total number of lesions observed on days 3(10%), 7(18%), 14(37%), 28(55%); title compound performed better in reducing
Measurement Parameter
Qualitative
Patent; CONCERT, LLC; US2008/139518; (2008); (A1) English, View in Reaxys 24 of 289
Substance Effect
Sensitizing
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CBA mouseBioassay : 6-12 wk old animals; housed under standard conitions with food and tap water ad libitum; international interlaboratory trial (5 participants) local lymph node assay; exposed on dorsum of both ears to 25 μl of 1 of 5 conc.; 5 d after the start of treatment injected i.v. with PSB cont. 20 μCi of <3H>methylthymidine (spec. act. 2 Ci/ mmol); proliferative act. of draining auricular LNC measured
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
elicited strong LLNA respnses in each participating laboratory; dpm: 658-9110 to 715-8595 (acetone: 27-463), SI: 14.6-24.4 to 16.1 to 26.5
Measurement Parameter
Qualitative
Kimber; Hilton; Dearman; Gerberick; Ryan; Basketter; Lea; House; Ladics; Loveless; Hastings; Journal of Toxicology and Environmental Health; vol. 53; nb. 7; (1998); p. 563 - 579, View in Reaxys 25 of 289
Substance Effect
Mutagenic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Bioassay : preincubation protocol; in the absence and presence of Aroclor 1254-induced male Fischer 344 rat or male B6C3F1 mouse liver S9 mix
Biological Species/NCBI Salmonella enterica serovar Typhimurium ID Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
Qualitative
Qualitative value
NA
Measurement pX
1
Dillon, Deborah; Combes, Robert; Zeiger, Errol; Mutagenesis; vol. 13; nb. 1; (1998); p. 19 - 26, View in Reaxys 26 of 289
Substance Effect
Mutagenic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : Salmonella typhimurium TA102Bioassay : preincubation protocol; in the absence and presence of Aroclor 1254-induced male Fischer 344 rat or male B6C3F1 mouse liver S9 mix
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
Qualitative
Qualitative value
NA
Measurement pX
1
Dillon, Deborah; Combes, Robert; Zeiger, Errol; Mutagenesis; vol. 13; nb. 1; (1998); p. 19 - 26, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
76/162
2018-02-22 00:03:45
27 of 289
Substance Effect
Mutagenic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : Salmonella typhimurium TA104Bioassay : preincubation protocol; in the absence and presence of Aroclor 1254-induced male Fischer 344 rat or male B6C3F1 mouse liver S9 mix
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
Qualitative
Qualitative value
NA
Measurement pX
1
Dillon, Deborah; Combes, Robert; Zeiger, Errol; Mutagenesis; vol. 13; nb. 1; (1998); p. 19 - 26, View in Reaxys 28 of 289
Substance Effect
Mutagenic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : Salmonella typhimurium TA97aBioassay : preincubation protocol; in the absence and presence of Aroclor 1254-induced male Fischer 344 rat or male B6C3F1 mouse liver S9 mix
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
Qualitative
Qualitative value
NA
Measurement pX
1
Dillon, Deborah; Combes, Robert; Zeiger, Errol; Mutagenesis; vol. 13; nb. 1; (1998); p. 19 - 26, View in Reaxys 29 of 289
Substance Effect
Cytotoxic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Bioassay : control: 1 percent ethanol cells cult. in 75 cm2 plastic flask in DMEM med. with 10 percent FCS, antibiotics at 37 deg C; 5 percent CO2; seeded 75E3 cell/cm2 in 6-well plates for 24 h; confluent 90 percent; treat. for 24 h; Neutral red assay; neutral red dye uptake as measure of cell viablity
Biological Species/NCBI human ID Cells/Cell Lines
HaCat
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Dose
100 µM
Qualitative Results
min. cytotoxicity at doses from 100 to 200 μmol/l ( cell viability ca. 99 percent); significant cytotoxicity at doses 250 and 300 μmol/l (cell viability 70 and 50 percent resp.) (fig.)
Measurement Parameter
Qualitative
Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester; Toxicology; vol. 165; nb. 2-3; (2001); p. 225 - 234, View in Reaxys 30 of 289
Substance Effect
Genotoxic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
77/162
2018-02-22 00:03:45
Bioassay Details
Bioassay : control: untreated and 1 percent ethanol treated cells cells cult. in 75 cm2 plastic flask in DMEM medium with 10 percent FCS, antibiotics at 37 deg C; 5 percent CO2; seeded 75E3 cell/cm2 in 6-well plates for 24 h; confluent 90 percent; treat. for 24 h; flow cytometry, with propidium iodide (PI) staining; DNA fragmentat.
Biological Species/NCBI human ID Cells/Cell Lines
HaCat
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Dose
100 µM
Qualitative Results
little dose dependent DNA fragmentation from 1.1 to 4.9 percent
Measurement Parameter
Qualitative
Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester; Toxicology; vol. 165; nb. 2-3; (2001); p. 225 - 234, View in Reaxys 31 of 289
Target Name
cytokine
Target Synonyms
cytokine
Target, Subunit, Species cytokine Target Mutant/Chimera Details
cytokine:Wild
Target Transfection
Non Transfected
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : cytokines; expression ofBioassay : EPh: electrophoresis; internal control: β-actin cells cult. in 75 cm2 pl. flask in DMEM med. with 10 percent FCS, antibiot. at 37 deg C; 5 percent CO2; seeded 2E5 cell/cm2 in 12-well plates for 24 h; confl. 90 percent; treat. for 6, 12, 24 h; total RNA extr.; rev. transcrip.; IL-1α, IL-8, β-actin PCR ampl.; EPh
Biological Species/NCBI human ID Cells/Cell Lines
HaCat
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Dose
50 µM
Qualitative Results
dose-dependent increase of IL-1α mRNA steady state levels; more significant after 6 h incubation 2.8, 3.8 and 5-fold at doses 50, 100 and 200 μmol/l resp.; no effect on IL-8 mRNA level (fig.)
Measurement Parameter
Qualitative
Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester; Toxicology; vol. 165; nb. 2-3; (2001); p. 225 - 234, View in Reaxys 32 of 289
Target Name
NF-kappaB
Target Synonyms
nf-kappab
Target, Subunit, Species NF-kappaB Target Mutant/Chimera Details
NF-kappaB:Wild
Target Transfection
Non Transfected
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
78/162
2018-02-22 00:03:45
Bioassay Details
Effect : NF-κB activationBioassay : pGL3-4κB-Luc and pRL-TK plasmids; dual-luciferase reporter assay system; positive control: TNFα (5 and 20 ng/ml) treatment cells cult. in 75 cm2 plastic flask in DMEM med. with 10 percent FCS, antibiot. at 37 deg C; 5 percent CO2; seeded 2E5 cell/cm2 in 12-well plates for 24 h; confl. 90 percent; co-transfect.; incub. for 18 h; treat. for 24 h; cell lysis 12 h after tr.; luciferase act.
Biological Species/NCBI human ID Cells/Cell Lines
HaCat
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Dose
10 µM
Measurement Parameter
Qualitative
Qualitative value
NA
Measurement pX
1
Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester; Toxicology; vol. 165; nb. 2-3; (2001); p. 225 - 234, View in Reaxys 33 of 289
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : |metabolic Bioassay : GSH: reduced glutathione; GSSG: oxidized glutathione; control: untreated and 1 percent ethanol treated cells cells cult. in 75 cm2 plastic flask in DMEM med. with 10 percent FCS, antibiot. at 37 deg C; 5 percent CO2; seeded 75E3 cell/cm2 in 6-well plates for 24 h; confluent 90 percent; treat. for 24 h and from 30 min to 6 h at dose 300 μmol/l; HPLC; GSH, GSSG, vit. E lev.
Biological Species/NCBI human ID Cells/Cell Lines
HaCat
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Dose
100 µM
Qualitative Results
dose-dependent decrease of vit. E and GSH levels from 8 to 4 pmol/E6 cells and from 10.7 to 0.4 nmol/E6 cells; increase of GSSG/GSH ratio from 2.3 to 90.4 percent; time course study: 50 percent decrease of vit. E and GSH level at 30 min and 6 h resp.
Measurement Parameter
Qualitative
Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester; Toxicology; vol. 165; nb. 2-3; (2001); p. 225 - 234, View in Reaxys 34 of 289
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : smooth muscle cell proliferation; effect onBioassay : SCREENING ASSAY FOR ASSESSING THE EFFECT OF COMPOUNDS ON SMOOTHMUSCLE CELL PROLIFERATIONThis example describes a screening assay for assessing the effect of an agent on smooth muscle cell proliferation (In vitro toxicol. (1990) 3: 219; Biotech. Histochem. (1993) 68: 29; Anal. Biochem. (1993) 213: 426).
Cells/Cell Lines
smooth muscle cell
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
IC50
Unit
nM
Quantitative value
0.01
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
79/162
2018-02-22 00:03:45
Measurement pX
11
Patent; HUNTER, William, L.; TOLEIKIS, Philip, M.; GRAVETT, David, M.; MAITI, Arpita; LIGGINS, Richard T.; TAKACS-COX, Aniko; AVELAR, Rui; SIGNORE, Pierre, E.; LOSS, Troy, A. E.; HUTCHINSON, Anne; MCDONALD-JONES, Gaye; LAKHANI, Fara; (2278 pag.); WO2006/121518; (A2); (2006), View in Reaxys 35 of 289
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
no mutagenicity in test on Salmonella typhimurium TA 98 and TA 100
Measurement Parameter
Qualitative
Yamaguchi; Yamashita; Agricultural and Biological Chemistry; vol. 44; nb. 7; (1980); p. 1675 - 1678, View in Reaxys 36 of 289
Substance Effect
Keratolytic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Bioassay : SC: stratum corneum randomized, blinded and placebo-controlled study; TEWL measurements taken using closed-chamber evaporimeter; 25 tape stripping and protein assay
Biological Species/NCBI human ID Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
mean SC removed (μg/cm2) after 3 h of treatment: 1.46 (control: 1.01), after 6 h: 1.64 (control: 1.31); mean TEWL taken 5 times over 30 min at 3 h after stripping: 30.08 and at 6 h: 28.76 (control: 9.68 and 11.65)
Measurement Parameter
Qualitative
Waller; Dreher; Behnam; Ford; Lee; Tiet; Weinstein; Maibach; Skin Pharmacology and Physiology; vol. 19; nb. 5; (2006); p. 283 - 289, View in Reaxys 37 of 289
Substance Effect
Mutagenic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : Escherichia coli IC188Bioassay : parent WP2 uvrA/pKM101 bacterial strain in vitro; plate incorporation assay; Difco agar; minimal ET4 plates; 37 deg C; 2 d; number of revertants per plates counted
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
Qualitative
Qualitative value
NA
Measurement pX
1
Martinez, A.; Urios, A.; Blanco, M.; Mutation research; vol. 467; nb. 1; (2000); p. 41 - 53, View in Reaxys 38 of 289
Substance Effect
Mutagenic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : Escherichia coli IC203Bioassay : WP2 uvrA/pKM101 bacterial strain deficient in OxyR in vitro; plate incorporation assay; Difco agar; minimal ET4 plates; 37 deg C; 2 d; number of revertants per plates counted
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
80/162
2018-02-22 00:03:45
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
Qualitative
Qualitative value
NA
Measurement pX
1
Martinez, A.; Urios, A.; Blanco, M.; Mutation research; vol. 467; nb. 1; (2000); p. 41 - 53, View in Reaxys 39 of 289
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : |DNA; examination of Target : supercoiled pBR 322 DNA (form I, MW of 2.9E6 Da, 4365 bp)Bioassay : Reactivity of benzoyloxyl versus tert-butoxyl radicals was assessed by comparison with tert-butyl perbenzoate; ssb=single-strand breaks The title comp. in water with DNA in KH2PO4 buffer (pH 7.4) were irradiated (UV, λ=300 nm); 0 deg C; 2 min or 10 min; the DNA-cleaving activity of the title comp. assessed; gel electrophoresis analysis
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Dose
1 mM
Qualitative Results
The blank value of open circular DNA: without irrad. 0.04 ssb, after 10 min irrad. 0.06 ssb per DNA molecule 4E3 bp; irradiation with the title comp.: 0.06 ssb (2 min) and 0.09 ssb (10 min) per DNA molecule; the moderate activity of title comp.
Measurement Parameter
Qualitative
Adam, Waldemar; Grimm, Guenther N.; Saha-Moeller, Chantu R.; Dall'Acqua, Francesco; Miolo, Gorgia; Vedaldi, Daniela; Chemical Research in Toxicology; vol. 11; nb. 9; (1998); p. 1089 - 1097, View in Reaxys 40 of 289
Substance Effect
Antiacne
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : anti-acneExample 27; Inhibition of Propionibacterium acnes Growth; [00308] The present example demonstrates that certain AFC complexes of the present invention exhibit superior or similar anti-microbial activity when compared to benzoyl peroxide, a wellknown anti-microbial and anti-acne agent. The assay for
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
IC50
Unit
µg/mL
Quantitative value
161
Measurement pX
3.18
Patent; SIGNUM BIOSCIENCES, INC.; VORONKOV, Michael; STOCK, Jeffry, B.; STOCK, Maxwell; LEE, Seung-Yub; PEREZ, Eduardo; GORDON, Joel, S.; WO2010/90845; (2010); (A1) English, View in Reaxys 41 of 289
Substance Effect
Antiacne
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : anti-acneExample 27; Inhibition of Propionibacterium acnes Growth; [00308] The present example demonstrates that certain AFC complexes of the present invention exhibit superior or similar anti-microbial activity when compared to benzoyl peroxide, a wellknown anti-microbial and anti-acne agent. The assay for
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
81/162
2018-02-22 00:03:45
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
IC50
Unit
µg/mL
Quantitative value
161
Measurement pX
3.18
Patent; VORONKOV, Michael; STOCK, Jeffry, B.; STOCK, Maxwell; LEE, Seung-Yub; PEREZ, Eduardo; GORDON, Joel, S.; (135 pag.); WO2010/90845; (A1); (2010), View in Reaxys 42 of 289
Substance Effect
Antiacne
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : anti-acneExample 27; Inhibition of Propionibacterium acnes Growth; [00308] The present example demonstrates that certain AFC complexes of the present invention exhibit superior or similar anti-microbial activity when compared to benzoyl peroxide, a wellknown anti-microbial and anti-acne agent. The assay for
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
IC50
Unit
µg/mL
Quantitative value
161
Measurement pX
3.18
Patent; VORONKOV, Michael; STOCK, Jeffry, B.; STOCK, Maxwell; LEE, Seung-Yub; PEREZ, Eduardo; GORDON, Joel, S.; (135 pag.); WO2010/90845; (A1); (2010), View in Reaxys 43 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATC 25577 of Propionibacterium avidumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 25.83 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 44 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12600 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combina-
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
82/162
2018-02-22 00:03:45
tions of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 11.99 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 45 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12600-U of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 12.20 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 46 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12601 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 11.68 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 47 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12602 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 12.73 mm disc diffusion assay (DDA)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
83/162
2018-02-22 00:03:45
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 48 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12604 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 12.52 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 49 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12605 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 12.20 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 50 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12606 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 11.68 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 51 of 289
Substance Effect
Antibiotic
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
84/162
2018-02-22 00:03:45
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12607 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 12.31 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 52 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 25923 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 10.86 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 53 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 27836 of Staphylococcus warneriBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 12.04 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 54 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 27848 of Staphylococcus capitisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
85/162
2018-02-22 00:03:45
with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 12.46 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 55 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 27848 of Staphylococcus hominisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 11.83 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 56 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 27848 of Staphylococcus simulansBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 9.94 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 57 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29212 of Enterococcus faecalisBioassay : Example 10 - activity against E. faecalisThe activities of BP, TBHQ and combinations of the two were tested against E. faecalis ATCC 29212, using MIC, MBC and (S)DDA assays as described above.For the (S)DDA assays, 200 μg of each compound was loaded onto each disc. The solvents used were DMSO for
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
Qualitative
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
86/162
2018-02-22 00:03:45
Qualitative value
NA
Measurement pX
1
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 58 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29213 of Staphylococcus aureusBioassay : Example 1 - activity against S. aureus -MIC, MBC & (S)DDA assaysThe following experiments all used S. aureus ATCC 29213 as the test organism.MIC, MBC and DDA assays, as described above, were carried out using the test compound benzoyl peroxide (BP) and a range of different benzoquinones and hydroquinones.
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 11.03 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 59 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29213 of Staphylococcus aureusBioassay : Example 3 - activity against S. aureus - TTK assaysTTK assays were then conducted, as described above, on samples of BP, TBHQ and a BP/TBHQ mixture, using S. aureus ATCC 29213 as the test organism. The solvents used were DMSO for the BP and ethanol for the TBHQ. The results are shown in Table 3. cfu
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
125 μg/ml of title compound resulted in a 3.67E4-7.63E5 CFU/ml t=0-1.0 wherein time to kill was >1 h
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 60 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29213 of Staphylococcus aureusBioassay : Example 4 - activity against S aureus - MTTK assaysSamples containing BP, TBHQ and BP/TBHQ mixtures were also subjected to MTTK assays as described above, using S. aureus ATCC 29213 as the test organism The BP was dissolved in DMSO and the TBHQ in ethanolThe results, after 24 hours, are shown in Table
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
mixture of BP and TBHQ showed reduction in microbial activity greater (after 24 hours) than that obtained using title compound alone
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
87/162
2018-02-22 00:03:45
61 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29970 of Staphylococcus haemolyticusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 11.10 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 62 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29971 of Staphylococcus xylosusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 10.99 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 63 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29974 of Staphylococcus cohniiBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 11.51 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 64 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 33753 of Staphylococcus auricularisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
88/162
2018-02-22 00:03:45
with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 21.56 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 65 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL EMRSA 15 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 10.17 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 66 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL EMRSA 16 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 10.80 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 67 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL EMRSA 17 of Staphylococcus simulans methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 11.74 mm disc diffusion assay (DDA)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
89/162
2018-02-22 00:03:45
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 68 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL GISA HO41340156 of Staphylococcus aureus vancomycin (Van)/teicoplanin (Tec)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 12.16 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 69 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL VISA Mu3 of Staphylococcus aureus vancomycin (Van)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 10.90 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 70 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL VISA Mu50 of Staphylococcus aureus vancomycin (Van)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 11.64 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 71 of 289
Substance Effect
Antibiotic
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
90/162
2018-02-22 00:03:45
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : NCTC 11047 of Staphylococcus epidermidisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 10.65 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 72 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : NCTC 11865 of Propionibacterium granulosumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 24.19 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 73 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : NCTC 7292 of Staphylococcus saprophyticusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 11.38 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 74 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : NCTC 737 of Propionibacterium acnesBioassay : Example 6 - activity against P. acnes -MIC, MBC & (S)DDA assaysThe following experiments all used P. acnes NCTC 737 as the test organism.MIC, MBC and DDA assays, as described above, were carried
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
91/162
2018-02-22 00:03:45
out using BP and a range of different benzoquinones and hydroquinones. Supplemented DDA assays, in the presence Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in a 24.25 mm disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 75 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : NCTC 737 of Propionibacterium acnesBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 19.25 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 76 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-002 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 25.69 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 77 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-003 of Propionibacterium acnes tetracycline (Tet)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 25.69 mm in disc diffusion assay (DDA)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
92/162
2018-02-22 00:03:45
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 78 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-004 of Propionibacterium acnes tetracycline (Tet)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 31.17 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 79 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-005 of Propionibacterium granulosum macrolide-lincosamide-streptograminketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 22.95 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 80 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-007 of Propionibacterium acnes clindamycin (Clin)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 23.88 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 81 of 289
Substance Effect
Antibiotic
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
93/162
2018-02-22 00:03:45
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-008 of Propionibacterium acnes clindamycin (Clin)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 27.80 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 82 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-010 of Propionibacterium acnes macrolide-lincosamide-streptogramin-ketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 30.39 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 83 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-017 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 23.28 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 84 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-023 of Propionibacterium acnes macrolide-lincosamide-streptogramin-ketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tes-
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
94/162
2018-02-22 00:03:45
ted against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 24.11 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 85 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-026 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 26.52 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 86 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-043 of Propionibacterium granulosum macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 22.48 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 87 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-044 of Propionibacterium granulosum macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 29.31 mm in disc diffusion assay (DDA)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
95/162
2018-02-22 00:03:45
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 88 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-046 of Propionibacterium acnesBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 24.36 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 89 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-053 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 29.72 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 90 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-055 of Propionibacterium granulosumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 21.52 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 91 of 289
Substance Effect
Antibiotic
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
96/162
2018-02-22 00:03:45
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-059 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 23.49 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 92 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-068 of Propionibacterium acnes erythromycin (Ery)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 28.79 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 93 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-101 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 25.73 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 94 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-102 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
97/162
2018-02-22 00:03:45
were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
title compound resulted in 29.62 mm in disc diffusion assay (DDA)
Measurement Parameter
Qualitative
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 95 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATC 25577 of Propionibacterium avidumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
62.5
Measurement pX
3.59
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 96 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12600 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 97 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12600-U of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
98/162
2018-02-22 00:03:45
with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 98 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12601 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 99 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12602 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
125
Measurement pX
3.29
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 100 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
99/162
2018-02-22 00:03:45
Bioassay Details
Target : ATCC 12604 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 101 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12605 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 102 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12606 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 103 of 289 Substance Effect Bioassay Category
Antibiotic In Vitro (Efficacy)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
100/162
2018-02-22 00:03:45
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12607 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 104 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 25923 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 105 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 27836 of Staphylococcus warneriBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 106 of 289 Substance Effect
Antibiotic
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
101/162
2018-02-22 00:03:45
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 27840 of Staphylococcus capitisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 107 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 27844 of Staphylococcus hominisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 108 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 27848 of Staphylococcus simulansBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
102/162
2018-02-22 00:03:45
109 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29213 of Staphylococcus aureusBioassay : Example 1 - activity against S. aureus -MIC, MBC & (S)DDA assaysThe following experiments all used S. aureus ATCC 29213 as the test organism.MIC, MBC and DDA assays, as described above, were carried out using the test compound benzoyl peroxide (BP) and a range of different benzoquinones and hydroquinones.
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 110 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29970 of Staphylococcus haemolyticusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 111 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29971 of Staphylococcus xylosusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
103/162
2018-02-22 00:03:45
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 112 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29974 of Staphylococcus cohniiBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
125
Measurement pX
3.29
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 113 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 33753 of Staphylococcus auricularisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
62.5
Measurement pX
3.59
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 114 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL EMRSA 16 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
104/162
2018-02-22 00:03:45
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 115 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL GISA HO42340156 of Staphylococcus aureus vancomycin (Van)/teicoplanin (Tec)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 116 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL VISA Mu50 of Staphylococcus aureus vancomycin (Van)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 117 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : NCTC 11047 of Staphylococcus epidermidisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
105/162
2018-02-22 00:03:45
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 118 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : NCTC 11865 of Propionibacterium granulosumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
15.6
Measurement pX
4.19
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 119 of 289
Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : NCTC 7292 of Staphylococcus saprophyticusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 120 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : NCTC 737 of Propionibacterium acnesBioassay : Example 6 - activity against P. acnes -MIC, MBC & (S)DDA assaysThe following experiments all used P. acnes NCTC 737 as the test organism.MIC, MBC and DDA assays, as described above, were carried out using BP and a range of different benzoquinones and hydroquinones. Supplemented DDA assays, in the presence
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
106/162
2018-02-22 00:03:45
Unit
µg/mL
Quantitative value
62.5
Measurement pX
3.59
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 121 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : NCTC 737 of Propionibacterium acnesBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 122 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-002 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 123 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-003 of Propionibacterium acnes tetracycline (Tet)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
107/162
2018-02-22 00:03:45
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 124 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-004 of Propionibacterium acnes tetracycline (Tet)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
15.6
Measurement pX
4.19
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 125 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-005 of Propionibacterium granulosum macrolide-lincosamide-streptograminketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
15.6
Measurement pX
4.19
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 126 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-007 of Propionibacterium acnes clindamycin (Clin)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
108/162
2018-02-22 00:03:45
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
62.5
Measurement pX
3.59
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 127 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-008 of Propionibacterium acnes clindamycin (Clin)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 128 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-010 of Propionibacterium acnes macrolide-lincosamide-streptogramin-ketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 129 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-017 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
109/162
2018-02-22 00:03:45
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
62.5
Measurement pX
3.59
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 130 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-023 of Propionibacterium acnes macrolide-lincosamide-streptogramin-ketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
62.5
Measurement pX
3.59
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 131 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-026 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 132 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-043 of Propionibacterium granulosum macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
110/162
2018-02-22 00:03:45
against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
62.5
Measurement pX
3.59
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 133 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-044 of Propionibacterium granulosum macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 134 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-046 of Propionibacterium acnesBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
62.5
Measurement pX
3.59
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 135 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
111/162
2018-02-22 00:03:45
Bioassay Details
Target : PRP-053 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
62.5
Measurement pX
3.59
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 136 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-055 of Propionibacterium granulosumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
15.6
Measurement pX
4.19
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 137 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-059 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
125
Measurement pX
3.29
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 138 of 289 Substance Effect Bioassay Category
Antibiotic In Vitro (Efficacy)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
112/162
2018-02-22 00:03:45
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-068 of Propionibacterium acnes erythromycin (Ery)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
125
Measurement pX
3.29
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 139 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-101 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 140 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-102 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
62.5
Measurement pX
3.59
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 141 of 289 Substance Effect
Antibiotic
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
113/162
2018-02-22 00:03:45
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATC 25577 of Propionibacterium avidumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 142 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12600 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
125
Measurement pX
3.29
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 143 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12600-U of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
114/162
2018-02-22 00:03:45
144 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12601 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 145 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12602 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
125
Measurement pX
3.29
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 146 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12604 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
125
Measurement pX
3.29
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
115/162
2018-02-22 00:03:45
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 147 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12605 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 148 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12606 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 149 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 12607 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
250
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
116/162
2018-02-22 00:03:45
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 150 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 25923 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 151 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 27836 of Staphylococcus warneriBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 152 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 27840 of Staphylococcus capitisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
117/162
2018-02-22 00:03:45
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 153 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 27844 of Staphylococcus hominisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 154 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 27848 of Staphylococcus simulansBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 155 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29212 of Enterococcus faecalisBioassay : Example 10 - activity against E. faecalisThe activities of BP, TBHQ and combinations of the two were tested against E. faecalis ATCC 29212, using MIC, MBC and (S)DDA assays as described above.For the (S)DDA assays, 200 μg of each compound was loaded onto each disc. The solvents used were DMSO for
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
118/162
2018-02-22 00:03:45
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 156 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29213 of Staphylococcus aureusBioassay : Example 1 - activity against S. aureus -MIC, MBC & (S)DDA assaysThe following experiments all used S. aureus ATCC 29213 as the test organism.MIC, MBC and DDA assays, as described above, were carried out using the test compound benzoyl peroxide (BP) and a range of different benzoquinones and hydroquinones.
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 157 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29970 of Staphylococcus haemolyticusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 158 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29971 of Staphylococcus xylosusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
119/162
2018-02-22 00:03:45
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 159 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 29974 of Staphylococcus cohniiBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
62.5
Measurement pX
3.59
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 160 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : ATCC 33753 of Staphylococcus auricularisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
15.6
Measurement pX
4.19
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 161 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL EMRSA 15 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
120/162
2018-02-22 00:03:45
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
125
Measurement pX
3.29
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 162 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL EMRSA 16 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
125
Measurement pX
3.29
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 163 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL EMRSA 17 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
125
Measurement pX
3.29
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 164 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL GISA HO41340156 of Staphylococcus aureus vancomycin (Van)/teicoplanin (Tec)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
121/162
2018-02-22 00:03:45
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
125
Measurement pX
3.29
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 165 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL VISA Mu3 of Staphylococcus aureus vancomycin (Van)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
125
Measurement pX
3.29
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 166 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL VISA Mu50 of Staphylococcus aureus vancomycin (Van)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
125
Measurement pX
3.29
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 167 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : NCTC 11047 of Staphylococcus epidermidisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, includ-
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
122/162
2018-02-22 00:03:45
ing some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 168 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : NCTC 11865 of Propionibacterium granulosumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
15.6
Measurement pX
4.19
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 169 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : NCTC 7292 of Staphylococcus saprophyticusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
250
Measurement pX
2.99
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 170 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
123/162
2018-02-22 00:03:45
Bioassay Details
Target : NCTC 737 of Propionibacterium acnesBioassay : Example 6 - activity against P. acnes -MIC, MBC & (S)DDA assaysThe following experiments all used P. acnes NCTC 737 as the test organism.MIC, MBC and DDA assays, as described above, were carried out using BP and a range of different benzoquinones and hydroquinones. Supplemented DDA assays, in the presence
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 171 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : NCTC 737 of Propionibacterium acnesBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
15.6
Measurement pX
4.19
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 172 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-002 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
15.6
Measurement pX
4.19
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 173 of 289 Substance Effect Bioassay Category
Antibiotic In Vitro (Efficacy)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
124/162
2018-02-22 00:03:45
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-003 of Propionibacterium acnes tetracycline (Tet)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 174 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-004 of Propionibacterium acnes tetracycline (Tet)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
7.8
Measurement pX
4.49
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 175 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-005 of Propionibacterium granulosum macrolide-lincosamide-streptograminketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
15.6
Measurement pX
4.19
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 176 of 289 Substance Effect
Antibiotic
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
125/162
2018-02-22 00:03:45
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-007 of Propionibacterium acnes clindamycin (Clin)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 177 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-008 of Propionibacterium acnes clindamycin (Clin)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 178 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-010 of Propionibacterium acnes macrolide-lincosamide-streptogramin-ketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
126/162
2018-02-22 00:03:45
179 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-017 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 180 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-023 of Propionibacterium acnes macrolide-lincosamide-streptogramin-ketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 181 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-026 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
15.6
Measurement pX
4.19
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
127/162
2018-02-22 00:03:45
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 182 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-043 of Propionibacterium granulosum macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
62.5
Measurement pX
3.59
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 183 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-044 of Propionibacterium granulosum macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 184 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-046 of Propionibacterium acnesBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
31.25
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
128/162
2018-02-22 00:03:45
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 185 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-053 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
31.25
Measurement pX
3.89
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 186 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-055 of Propionibacterium granulosumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
15.6
Measurement pX
4.19
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 187 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-059 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
129/162
2018-02-22 00:03:45
Quantitative value
62.5
Measurement pX
3.59
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 188 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-068 of Propionibacterium acnes erythromycin (Ery)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
62.5
Measurement pX
3.59
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 189 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-101 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Unit
µg/mL
Quantitative value
15.6
Measurement pX
4.19
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 190 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : PRP-102 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MIC
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
130/162
2018-02-22 00:03:45
Unit
µg/mL
Quantitative value
62.5
Measurement pX
3.59
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 191 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL EMRSA 15 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
125 - 150
Measurement pX
3.29
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 192 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL EMRSA 17 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
125 - 250
Measurement pX
3.29
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 193 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : CPHL VISA Mu3 of Staphylococcus aureus vancomycin (Van)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Substance RN
984320View in Reaxys
Substance Name
230913
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
131/162
2018-02-22 00:03:45
Measurement Parameter
MBC
Unit
µg/mL
Quantitative value
125 - 250
Measurement pX
3.29
Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 194 of 289 Substance Effect
Antiinflammatory
Bioassay Category
In Vivo (Animal models)
Bioassay Name
In vivo Measurement
Bioassay Details
Effect : anti-inflammatoryBioassay : TPA-induced ear oedemic animalEvaluation of the anti-inflammatory activity of the peroxides after a single topical administration in TPA- induced ear oedema.Principle of the test: the aim is to evaluate the anti&not; inflammatory activity of the peroxides by measuring the thickness of mouse ear after TPA topical application.
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Route of Adm.
transdermal administration
Measurement Parameter
MIC
Unit
mg/mL
Quantitative value
80
Patent; GALDERMA RESEARCH and DEVELOPMENT; BOUIX-PETER, Claire; PASCAL, Jean-Claude; RODEVILLE, Nicolas; WO2011/70170; (2011); (A1) English, View in Reaxys 195 of 289 Target Name Target Synonyms
enzyme catalytic; enzyme
Target, Subunit, Species enzyme Target Mutant/Chimera Details
enzyme:Wild
Target Transfection
Non Transfected
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : |enzyme; inhib. of Bioassay : protein kinase C (PKC) activity measured after 24 h of exposure; immunoblot analysis cultured cells from adult breast skin were grown and maintained in serum-free medium with var. Ca(2+) conc.; cells treated with soln. of title comp. in acetone; cell proliferation, phorbol ester-induced differentiation determined using <3H>-thymidine
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Dose
100 nM
Qualitative Results
title comp. does not downregulate subcellular levels of PKC activity after 24 h expos.; does not significantly antagonize phorbol ester-induced inhib. of prolife. and differentiation; inhibits both human and murine PKC activity in vitro
Measurement Parameter
Qualitative
Matsui; Mintz; DeLeo; Skin Pharmacology; vol. 8; nb. 3; (1995); p. 130 - 138, View in Reaxys 196 of 289 Target Name Target Synonyms
enzyme catalytic; enzyme
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
132/162
2018-02-22 00:03:45
Target, Subunit, Species enzyme Target Mutant/Chimera Details
enzyme:Wild
Target Transfection
Non Transfected
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Effect : |enzyme; examination of Bioassay : in PBS; compared to untreated control in vitro; cells maintained with or without pretreatment CDNB (chlorodinitrobenzene) for 1 h; treated title comp.; exposed; measured cellular reduced glutathione (GSH) spectrophotometrically at 412 nm according to Anderson
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Dose
0.0100000 mM
Qualitative Results
title comp. reduced intracellular GSH level at conc. 0.5 mM and higher (75, 54, 31, 31 percent at 0.5, 1.0, 1.5, 2.0 mM); pretreatment with CDNB lowered intracellular level of GSH to 15 percent of control cells and enhanced their subsequent sensitivity
Measurement Parameter
Qualitative
Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 196, View in Reaxys 197 of 289 Substance Effect
Cytotoxic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : human keratinocyte cell line, RHEK-1Bioassay : exposure medium: DMEM, 10 percent Serum Plus, 2 percent EBS and antibiotics; compared to untreated control in vitro; cells incubated with growth medium 24 or 48 h; treated title comp.; exposed; assessed cell proliferation using quantitative determination of DNA with the fluorochrome, bisbenzimidazole
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Dose
0.0200000 mM
Qualitative Results
time required for the DNA content to double, h: 20 (control), 23, 24, 38, 48 at 0.02, 0.04, 0.06, 0.08 mM title comp., respect; after 7 d of exposure cell population, percent of control: 86, 76, 69, 61 at 0.02, 0.04, 0.06, 0.08 mM title comp., respect.
Measurement Parameter
Qualitative
Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 196, View in Reaxys 198 of 289 Substance Effect
Cytotoxic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : human keratinocyte cell line, RHEK-1Bioassay : exposure medium: DMEM, 10 percent Serum Plus, 2 percent EBS and antibiotics; compared to untreated control in vitro; cells incubated with growth medium 48-72 h; treated varied conc. title comp.; exposed: for 24 h, or 1 h followed by 48 h in title comp.-free medium; fixed; stained with Giemsa's solut.; examined miroscopically for cellular aberrations
Substance RN
984320View in Reaxys
Substance Name
230913
Qualitative Results
at all tested conditions title comp. resulted in an increase in multinucleation and in extensive vacuolization; initially appeared vacuolization then spread throughout the cytoplasm
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
133/162
2018-02-22 00:03:45
Measurement Parameter
Qualitative
Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 196, View in Reaxys 199 of 289 Substance Effect
Cytotoxic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : human keratinocyte cell line, RHEK-1Bioassay : exposure medium: DMEM, 10 percent Serum Plus, 2 percent EBS and antibiotics; incubated cells with NR 3 h at 37 deg C; calculated NR50 (reduced uptake NR by 50 percent); compared to untreated control in vitro; cells incubated with growth medium 24 or 48 h; treated exposure medium amended with varied conc. title comp.; exposed; assessed cytotoxicity with neutral red (NR), which is based on the uptake and lysosomal accumulation of supravital dye, NR
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Dose
0.0500000 mM
Qualitative Results
NR50 0.11 mmol/l
Measurement Parameter
Qualitative
Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 196, View in Reaxys 200 of 289 Substance Effect
Cytotoxic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : human keratinocyte cell line, RHEK-1Bioassay : exposure medium: DMEM, 10 percent Serum Plus, 2 percent EBS and antibiotics; incubated cells with NR 3 h at 37 deg C; compared to untreated control in vitro; cells incubated with growth medium 24 or 48 h; treated title comp.; exposed for 1 h or 1 h followed by 48 h in title comp.-free medium; assessed cytotoxicity with neutral red (NR): uptake and lysosomal accumulation of supravital dye, NR
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Dose
0.0100000 mM
Qualitative Results
title comp. caused irreversible damage for cells exposed 1-h at conc. > 0.15 mM; response cells to 1-h exposure followed by 48 h in title comp.-free medium 20 percent of control, while to only 1 h exposure - ca. 42 percent of control
Measurement Parameter
Qualitative
Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 196, View in Reaxys 201 of 289 Substance Effect
Cytotoxic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : human keratinocyte cell line, RHEK-1Bioassay : in PBS in vitro; cells incubated with growth medium 24 or 48 h; treated title comp.; exposed; determined lactic acid dehydrogenase (LDH) release in supernatant using the CytoTox 96<R> Nonradiactive Cytotoxicity Assay Kit
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Dose
0.0100000 mM
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
134/162
2018-02-22 00:03:45
Qualitative Results
title comp. evoked signif. LDH release in supernatant at conc. 0.5 mM and higher; presented as graph
Measurement Parameter
Qualitative
Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 196, View in Reaxys 202 of 289 Substance Effect
Cytotoxic
Bioassay Category
In Vitro (Efficacy)
Bioassay Name
In Vitro (others)
Bioassay Details
Target : human keratinocyte cell line, RHEK-1Bioassay : in PBS; lipid peroxidation by conc. malondialdehyde and thiobarbituric acid reactive substances (TBARS); LDH reliase using CytoTox 96<R> Nonradioactive Cytotoxicity Assay Kit in vitro; cells maintained or not in vitamin E 24; treated title comp.; with or without 1 mM Fe(2+); exposed; estimated lipid peroxidation in supernatant and lactic acid dehydrogenase (LDH) release; compared to untreated control
Substance RN
984320View in Reaxys
Substance Name
230913
Substance Dose
2 mM
Qualitative Results
title comp. or Fe(2+) alone did not exhibit peroxidation; title comp.+Fe(2+) caused formation 0.7 or 2.3 nmol TBARS/mg cellular protein in cells maintained or not in vitamin E; LDH release: 71 percent and 74 percent without and with Fe(2+) and title
Measurement Parameter
Qualitative
Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 196, View in Reaxys 203 of 289 Bioassay Category Bioassay Details
Metabolism/Transport Percutaneous penetration of benzoyl peroxide in monkey is low
Biological Species/NCBI Cercopithecidae ID Substance RN
984320View in Reaxys
Qualitative Results
Low
Measurement Parameter
Absorption
Qualitative value
NA
Measurement pX
1
Galderma Laboratories, L.P., Benzac¿ (benzoyl peroxide) Gel & AC wash, Product Leaflet, View in Reaxys 204 of 289 Bioassay Category Bioassay Details
Pharmacokinetic In vivo, benzoic acid recovered from urine following topical administration of small amounts of 14C-benzoyl peroxide
Biological Species/NCBI Cercopithecidae ID Substance RN
984320View in Reaxys
Substance Route of Adm.
topical administration
Qualitative Results
45
Measurement Parameter
Ue (%)
Unit
%
Measurement Object
Excretion
Quantitative value
45
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
135/162
2018-02-22 00:03:45
Nacht; Yeung; Beasley Jr.; Anjo; Maibach; Journal of the American Academy of Dermatology; vol. 4; nb. 1; (1981); p. 31 - 37, View in Reaxys 205 of 289 Target Name Target Synonyms
protein kinase C atp:protein phosphotransferase (diacylglycerol-dependent); diacylglycerol-activated phospholipid-dependent pkc; diacylglycerol-activated phospholipid-dependent protein kinase c; pkc (protein kinase c); pkc1 (protein kinase c); protein kinase c
Target, Subunit, Species protein kinase C Target Mutant/Chimera Details
protein kinase C:Wild
Substance Action on Target
Inhibitor
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Inhibitory concentration of the compound against Protein Kinase C
Substance RN
984320View in Reaxys
Measurement Parameter
IC50
Unit
nM
Qualitative value
=
Quantitative value
500
Measurement pX
6.3
206 of 289 Bioassay Category Bioassay Details
Metabolism/Transport Percutaneous absorption in rhesus monkey in a 24 Hr period study
Biological Species/NCBI Cercopithecidae ID Substance RN
984320View in Reaxys
Qualitative Results
45
Measurement Parameter
Absorption
Unit
%
Quantitative value
45
Galderma Laboratories, L.P., Benzac¿ (benzoyl peroxide) Gel & AC wash, Product Leaflet, View in Reaxys 207 of 289 Bioassay Category Bioassay Details
Metabolism/Transport Percutaneous penetration of benzoyl peroxide in rat is low
Biological Species/NCBI Rattus norvegicus ID Substance RN
984320View in Reaxys
Qualitative Results
Low
Measurement Parameter
Absorption
Qualitative value
NA
Measurement pX
1
Galderma Laboratories, L.P., Benzac¿ (benzoyl peroxide) Gel & AC wash, Product Leaflet, View in Reaxys 208 of 289 Bioassay Category Bioassay Details
Metabolism/Transport Percutaneous penetration of benzoyl peroxide in rabbit is low
Biological Species/NCBI rabbit ID Substance RN
984320View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
136/162
2018-02-22 00:03:45
Qualitative Results
Low
Measurement Parameter
Absorption
Qualitative value
NA
Measurement pX
1
Galderma Laboratories, L.P., Benzac¿ (benzoyl peroxide) Gel & AC wash, Product Leaflet, View in Reaxys 209 of 289 Bioassay Category Bioassay Details
Metabolism/Transport Percutaneous penetration of benzoyl peroxide in man is low
Biological Species/NCBI human ID Substance RN
984320View in Reaxys
Qualitative Results
Low
Measurement Parameter
Absorption
Qualitative value
NA
Measurement pX
1
Galderma Laboratories, L.P., Benzac¿ (benzoyl peroxide) Gel & AC wash, Product Leaflet, View in Reaxys 210 of 289 Bioassay Category Bioassay Details
Pharmacokinetic In vivo, benzoic acid recovered from urine following intramuscular administration of small amounts of 14C-benzoyl peroxide
Biological Species/NCBI Cercopithecidae ID Substance RN
984320View in Reaxys
Substance Route of Adm.
intramuscular administration
Qualitative Results
98
Measurement Parameter
Ue (%)
Unit
%
Measurement Object
Excretion
Quantitative value
98
Nacht; Yeung; Beasley Jr.; Anjo; Maibach; Journal of the American Academy of Dermatology; vol. 4; nb. 1; (1981); p. 31 - 37, View in Reaxys 211 of 289
Substance Action on Target
Inhibitor
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
In vitro inhibitory concentration against mouse ehrlich ascites tumor (EAT) cells upon incubation at 37 degree C for 3 h 45 min and pH 7.4 with compound dissolved in DMSO (0.25) using MTT assay
Biological Species/NCBI Mus musculus ID Cells/Cell Lines
Ehrlich ascites carcinoma cell line
Substance RN
984320View in Reaxys
Measurement Parameter
IC80
Unit
µM
Qualitative value
=
Quantitative value
415
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
137/162
2018-02-22 00:03:45
Deviation
9
Measurement pX
3.98
Woerdenbag; Moskal; Pras; Malingre; El-Feraly; Kampinga; Konings; Journal of Natural Products (Lloydia); vol. 56; nb. 6; (1993); p. 849 - 856, View in Reaxys 212 of 289 Substance Action on Target
Inhibitor
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
In vitro inhibitory concentration against mouse ehrlich ascites tumor (EAT) cells upon incubation at 37 degree C for 3 h 45 min and pH 7.4 with compound dissolved in DMSO (0.25) using MTT assay
Biological Species/NCBI Mus musculus ID Cells/Cell Lines
Ehrlich ascites carcinoma cell line
Substance RN
984320View in Reaxys
Measurement Parameter
IC50
Unit
µM
Qualitative value
=
Quantitative value
337
Deviation
43
Measurement pX
3.47
Woerdenbag; Moskal; Pras; Malingre; El-Feraly; Kampinga; Konings; Journal of Natural Products (Lloydia); vol. 56; nb. 6; (1993); p. 849 - 856, View in Reaxys 213 of 289 Bioassay Category Bioassay Details
In Vitro (Efficacy) Percent increase in serum production on the forehead in human with localized acne on face determined upon administration of the compound
Biological Species/NCBI human ID Substance RN
984320View in Reaxys
Measurement Parameter
Activity
Unit
%
Measurement Object
Percent increase in serum production on the forehead in human
Qualitative value
=
Quantitative value
10.5
Stinco, Guiseppe; Bragadin; Trotter; Pillon; Patrone; Journal of the European Academy of Dermatology and Venereology; vol. 21; nb. 3; (2007); p. 320 - 325, View in Reaxys 214 of 289 Bioassay Category Bioassay Details
In Vitro (Efficacy) Percent increase in serum production on the cheek in human with localized acne on face determined upon administration of the compound
Biological Species/NCBI human ID Substance RN
984320View in Reaxys
Measurement Parameter
Activity
Unit
%
Measurement Object
Percent increase in serum production on the cheek in human
Qualitative value
=
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
138/162
2018-02-22 00:03:45
Quantitative value
25.4
Stinco, Guiseppe; Bragadin; Trotter; Pillon; Patrone; Journal of the European Academy of Dermatology and Venereology; vol. 21; nb. 3; (2007); p. 320 - 325, View in Reaxys 215 of 289 Bioassay Category Bioassay Details
In Vitro (Efficacy) Percent increase in serum production on the chin in human with localized acne on face determined upon administration of the compound
Biological Species/NCBI human ID Substance RN
984320View in Reaxys
Measurement Parameter
Activity
Unit
%
Measurement Object
Percent increase in serum production on the chin in human
Qualitative value
=
Quantitative value
10.3
Stinco, Guiseppe; Bragadin; Trotter; Pillon; Patrone; Journal of the European Academy of Dermatology and Venereology; vol. 21; nb. 3; (2007); p. 320 - 325, View in Reaxys 216 of 289 Bioassay Category
Toxicity/Safety Pharmacology
Bioassay Details
Lethal dose (LD50) in mammal after application on skin
Substance RN
984320View in Reaxys
Qualitative Results
> 1000
Measurement Parameter
LD50
Unit
mg/kg
Quantitative value
1000
Material Safety Data Sheet, View in Reaxys 217 of 289 Bioassay Category Bioassay Details
Toxicity/Safety Pharmacology Intraperitoneal lethal dose in mouse
Biological Species/NCBI Mus musculus ID Substance RN
984320View in Reaxys
Measurement Parameter
LD50
Unit
mg/kg
Qualitative value
=
Quantitative value
250
Material Safety Data Sheet, View in Reaxys 218 of 289 Bioassay Category Bioassay Details
Toxicity/Safety Pharmacology Oral lethal dose in mouse
Biological Species/NCBI Mus musculus ID Substance RN
984320View in Reaxys
Substance Route of Adm.
oral administration
Measurement Parameter
LD50
Unit
mg/kg
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
139/162
2018-02-22 00:03:45
Qualitative value
=
Quantitative value
5700
Material Safety Data Sheet, View in Reaxys 219 of 289 Bioassay Category Bioassay Details
Toxicity/Safety Pharmacology Oral lethal dose in rats
Biological Species/NCBI Rattus norvegicus ID Substance RN
984320View in Reaxys
Measurement Parameter
LD50
Unit
mg/kg
Qualitative value
=
Quantitative value
7710
Material Safety Data Sheet, View in Reaxys 220 of 289 Bioassay Category Bioassay Details
Toxicity/Safety Pharmacology Intraperitoneal lethal dose (LD50) in mouse
Biological Species/NCBI Mus musculus ID Substance RN
984320View in Reaxys
Qualitative Results
250
Measurement Parameter
LD50
Unit
mg/kg
Quantitative value
250
Material Safety Data Sheet, View in Reaxys 221 of 289 Bioassay Category Bioassay Details
Toxicity/Safety Pharmacology Oral lethal dose (LD50) in mouse
Biological Species/NCBI Mus musculus ID Substance RN
984320View in Reaxys
Qualitative Results
5700
Measurement Parameter
LD50
Unit
mg/kg
Quantitative value
5700
Material Safety Data Sheet, View in Reaxys 222 of 289 Bioassay Category Bioassay Details
Toxicity/Safety Pharmacology Lethal dose in mammal after application on skin; Value is >1000;Dermal
Biological Species/NCBI mammal ID Substance RN
984320View in Reaxys
Substance Route of Adm.
topical administration
Measurement Parameter
LD50
Unit
mg/kg
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
140/162
2018-02-22 00:03:45
Qualitative value
=
Quantitative value
1000
Material Safety Data Sheet, View in Reaxys 223 of 289 Bioassay Category Bioassay Details
Toxicity/Safety Pharmacology Oral lethal dose (LD50) in rats
Biological Species/NCBI Rattus norvegicus ID Substance RN
984320View in Reaxys
Substance Route of Adm.
oral administration
Qualitative Results
7710
Measurement Parameter
LD50
Unit
mg/kg
Quantitative value
7710
Material Safety Data Sheet, View in Reaxys 224 of 289 Substance Effect
Antineoplastic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.01 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
Experiment 1
Measurement Parameter
MIC
Unit
mg/mL
Measurement Object
Growth inhibition
Qualitative value
>
Quantitative value
0.6
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 225 of 289 Substance Effect
Antineoplastic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.01 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
Experiment 2
Measurement Parameter
MIC
Unit
mg/mL
Measurement Object
Growth inhibition
Qualitative value
<=
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
141/162
2018-02-22 00:03:45
Quantitative value
0.8
Measurement pX
2.48
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 226 of 289 Substance Effect
Antineoplastic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Measurement Parameter
MIC
Unit
mg/mL
Measurement Object
Growth inhibition
Qualitative value
<
Quantitative value
0.2
Measurement pX
3.08
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 227 of 289 Substance Effect
Antineoplastic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 1.0 mg/mL Dihomo-gamma-linolenic acid (DGLA)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
Experiment 1
Measurement Parameter
MIC
Unit
mg/mL
Measurement Object
Growth inhibition
Qualitative value
>
Quantitative value
0.2
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 228 of 289 Substance Effect
Antineoplastic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 1.0 mg/mL Dihomo-gamma-linolenic acid (DGLA)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
Experiment 2
Measurement Parameter
MIC
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
142/162
2018-02-22 00:03:45
Unit
mg/mL
Measurement Object
Growth inhibition
Qualitative value
<=
Quantitative value
0.4
Measurement pX
2.78
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 229 of 289 Substance Effect
Antineoplastic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.4 mg/mL Dihomo-gamma-linolenic acid (DGLA)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
Experiment 1
Measurement Parameter
MIC
Unit
mg/mL
Measurement Object
Growth inhibition
Qualitative value
>
Quantitative value
0.2
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 230 of 289 Substance Effect
Antineoplastic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.4 mg/mL Dihomo-gamma-linolenic acid (DGLA)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
Experiment 2
Measurement Parameter
MIC
Unit
mg/mL
Measurement Object
Growth inhibition
Qualitative value
<=
Quantitative value
0.4
Measurement pX
2.78
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 231 of 289 Substance Effect
Antineoplastic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.1 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid
Biological Species/NCBI Propionibacterium acnes ID
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
143/162
2018-02-22 00:03:45
Substance RN
984320View in Reaxys
Measurement Parameter
MIC
Unit
mg/mL
Measurement Object
Growth inhibition
Qualitative value
<
Quantitative value
0.2
Measurement pX
3.08
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 232 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.2 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.4 mg/mL Dihomo-gamma-linolenic acid (DGLA)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
+++ = Confluent growth
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
@
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 233 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.4 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.4 mg/mL Dihomo-gamma-linolenic acid (DGLA)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 234 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.6 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.4 mg/mL Dihomo-gamma-linolenic acid (DGLA)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
144/162
2018-02-22 00:03:45
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 235 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.6 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
+ = Marked reduction in growth to multiple tiny, single colonies
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
@
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 236 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.8 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 237 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 1.0 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
145/162
2018-02-22 00:03:45
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 238 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.2 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.1 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 239 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.2 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
+++ = Confluent growth
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
@
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 240 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.2 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 241 of 289 Substance Effect Bioassay Category
Antibiotic In Vitro (Efficacy)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
146/162
2018-02-22 00:03:45
Bioassay Details
Antibacterial activity of 1.0 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 242 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.6 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
++ = Less confluent growth
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
@
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 243 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.8 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
+ = Marked reduction in growth to multiple tiny, single colonies
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
@
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 244 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.4 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
+++ = Confluent growth
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
147/162
2018-02-22 00:03:45
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
@
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 245 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.4 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.1 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 246 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.6 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.1 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 247 of 289 Substance Effect
Antineoplastic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
Experiment 1
Measurement Parameter
MIC
Unit
mg/mL
Measurement Object
Growth inhibition
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
148/162
2018-02-22 00:03:45
Qualitative value
>
Quantitative value
0.4
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 248 of 289 Substance Effect
Antineoplastic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
Experiment 2
Measurement Parameter
MIC
Unit
mg/mL
Measurement Object
Growth inhibition
Qualitative value
<=
Quantitative value
0.6
Measurement pX
2.61
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 249 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.8 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.4 mg/mL Dihomo-gamma-linolenic acid (DGLA)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 250 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.2 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 1.0 mg/mL Dihomo-gamma-linolenic acid (DGLA)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
++ = Less confluent growth
Measurement Parameter
Activity
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
149/162
2018-02-22 00:03:45
Measurement Object
Growth index
Qualitative value
@
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 251 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.4 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 1.0 mg/mL Dihomo-gamma-linolenic acid (DGLA)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 252 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.6 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 1.0 mg/mL Dihomo-gamma-linolenic acid (DGLA)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 253 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.8 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 1.0 mg/mL Dihomo-gamma-linolenic acid (DGLA)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
150/162
2018-02-22 00:03:45
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 254 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.4 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.01 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
+++ = Confluent growth
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
@
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 255 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.6 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.01 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
++ = Less confluent growth
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
@
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 256 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.8 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.01 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
+ = Marked reduction in growth to multiple tiny, single colonies
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
@
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 257 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.8 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.1 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
151/162
2018-02-22 00:03:45
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 258 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.2 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.01 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
+++ = Confluent growth
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
@
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 259 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 1 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.4 mg/mL Dihomo-gamma-linolenic acid (DGLA)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 260 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 1.0 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.01 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
152/162
2018-02-22 00:03:45
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 261 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.4 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 262 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.6 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 263 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.8 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
- = No growth present
Measurement Parameter
Activity
Measurement Object
Growth index
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
153/162
2018-02-22 00:03:45
Qualitative value
NA
Measurement pX
1
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 264 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.2 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
+++ = Confluent growth
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
@
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 265 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Antibacterial activity of 0.4 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
++ = Less confluent growth
Measurement Parameter
Activity
Measurement Object
Growth index
Qualitative value
@
Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 266 of 289 Substance Effect
Antimicrobial
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Minimum inhibitory concentration of compound against PROPIONIBACTERIUM ACNES NCTC 737 at pH 7.1 +/- 0.2 using BROTH MICRODILUTION ASSAY
Biological Species/NCBI Propionibacterium acnes ATCC 6919 ID Substance RN
984320View in Reaxys
Measurement Parameter
MIC
Unit
mg/L
Measurement Object
BACTERIAL GROWTH
Qualitative value
=
Quantitative value
31.25
Measurement pX
3.89
Patent; SUMMIT (CAMBRIDGE) LIMITED; US2010/184727; (2010); (A1) English, View in Reaxys 267 of 289 Substance Effect
Antimicrobial
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
154/162
2018-02-22 00:03:45
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Minimum bactericidal concentration of compound against PROPIONIBACTERIUM ACNES NCTC 737 at pH 7.1 +/- 0.2 using BROTH MICRODILUTION ASSAY
Biological Species/NCBI Propionibacterium acnes ATCC 6919 ID Substance RN
984320View in Reaxys
Measurement Parameter
MBC
Unit
mg/L
Measurement Object
BACTERIAL GROWTH
Qualitative value
=
Quantitative value
62.5
Measurement pX
3.59
Patent; SUMMIT (CAMBRIDGE) LIMITED; US2010/184727; (2010); (A1) English, View in Reaxys 268 of 289 Substance Effect
Antimicrobial
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Minimum bactericidal concentration of compound against PROPIONIBACTERIUM ACNES NCTC 737 at pH 6 using BROTH MICRODILUTION ASSAY
Biological Species/NCBI Propionibacterium acnes ATCC 6919 ID Substance RN
984320View in Reaxys
Measurement Parameter
MBC
Unit
mg/L
Measurement Object
BACTERIAL GROWTH
Qualitative value
=
Quantitative value
62.5
Measurement pX
3.59
Patent; SUMMIT (CAMBRIDGE) LIMITED; US2010/184727; (2010); (A1) English, View in Reaxys 269 of 289 Substance Effect
Antimicrobial
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
Minimum inhibitory concentration of compound against PROPIONIBACTERIUM ACNES NCTC 737 at pH 6 using BROTH MICRODILUTION ASSAY
Biological Species/NCBI Propionibacterium acnes ATCC 6919 ID Substance RN
984320View in Reaxys
Measurement Parameter
MIC
Unit
mg/L
Measurement Object
BACTERIAL GROWTH
Qualitative value
=
Quantitative value
31.25
Measurement pX
3.89
Patent; SUMMIT (CAMBRIDGE) LIMITED; US2010/184727; (2010); (A1) English, View in Reaxys 270 of 289 Substance Effect Bioassay Category
Antibiotic In Vitro (Efficacy)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
155/162
2018-02-22 00:03:45
Bioassay Details
In vitro minimum bactericidal concentration (MBC90) of compound against growth of Propionibacterium acnes upon incubation at 35 degree C for 72 hours in the presence of 50 sebum by Microtiter assay
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Measurement Parameter
MBC90
Unit
µg/mL
Measurement Object
BACTERIAL GROWTH
Qualitative value
=
Quantitative value
1600
Measurement pX
3.13
Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 271 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
In vitro minimum inhibitory concentration (MIC90) of compound against growth of Propionibacterium acnes upon incubation at 35-37 degree C for 48 hours in the presence of 50 sebum by Microtiter assay
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Measurement Parameter
MIC90
Unit
µg/mL
Measurement Object
BACTERIAL GROWTH
Qualitative value
=
Quantitative value
400
Measurement pX
3.74
Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 272 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
In vitro minimum bactericidal concentration (MBC50) of compound against growth of Propionibacterium acnes upon incubation at 35 degree C for 72 hours in the absence of 50 sebum by Microtiter assay
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Measurement Parameter
MBC50
Unit
µg/mL
Measurement Object
BACTERIAL GROWTH
Qualitative value
=
Quantitative value
200
Measurement pX
3.08
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
156/162
2018-02-22 00:03:45
Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 273 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
In vitro minimum inhibitory concentration (MIC90) of compound against growth of Propionibacterium acnes upon incubation at 35-37 degree C for 48 hours in the absence of 50 sebum by Microtiter assay
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Measurement Parameter
MIC90
Unit
µg/mL
Measurement Object
BACTERIAL GROWTH
Qualitative value
=
Quantitative value
50
Measurement pX
4.64
Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 274 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
In vitro minimum inhibitory concentration (MIC) of compound against growth of Propionibacterium acnes upon incubation at 35-37 degree C for 48 hours in the absence of 50 sebum by Microtiter assay
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
Range = <=50 ug/ml to 100 ug/ml
Measurement Parameter
MIC
Unit
µg/ml
Measurement Object
BACTERIAL GROWTH
Qualitative value
<=
Quantitative value
50 - 100
Measurement pX
3.69
Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 275 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
In vitro minimum inhibitory concentration (MIC50) of compound against growth of Propionibacterium acnes upon incubation at 35-37 degree C for 48 hours in the absence of 50 sebum by Microtiter assay
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Measurement Parameter
MIC50
Unit
µg/mL
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
157/162
2018-02-22 00:03:45
Measurement Object
BACTERIAL GROWTH
Qualitative value
=
Quantitative value
50
Measurement pX
3.69
Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 276 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
In vitro minimum bactericidal concentration (MBC90) of compound against growth of Propionibacterium acnes upon incubation at 35 degree C for 72 hours in the absence of 50 sebum by Microtiter assay
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Measurement Parameter
MBC90
Unit
µg/mL
Measurement Object
BACTERIAL GROWTH
Qualitative value
=
Quantitative value
200
Measurement pX
4.04
Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 277 of 289 Substance Effect
Antibiotic
Bioassay Category
In Vitro (Efficacy)
Bioassay Details
In vitro minimum bactericidal concentration (MBC) of compound against growth of Propionibacterium acnes upon incubation at 35 degree C for 72 hours in the absence of 50 sebum by Microtiter assay
Biological Species/NCBI Propionibacterium acnes ID Substance RN
984320View in Reaxys
Qualitative Results
Range = 100 ug/ml to 400 ug/ml
Measurement Parameter
MBC
Unit
µg/ml
Measurement Object
BACTERIAL GROWTH
Quantitative value
100 - 400
Measurement pX
3.38
Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 278 of 289 Substance Effect
Antibiotic
Bioassay Category
Toxicity/Safety Pharmacology
Bioassay Name
Cell/tumor cell: proliferation/viability/growth
Biological Species/NCBI Propionibacterium acnes ATCC 6919 ID Substance RN
984320View in Reaxys
Substance Name
BPO-Table 3, Entry 1; Table 4, Entry 1; Table 5, Entry 1
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
158/162
2018-02-22 00:03:45
Measurement Parameter
MIC
Unit
mg/L
Quantitative value
64
Measurement pX
3.58
Concomitants: Compound RN
1718733; 506008
Concomitants: Compound name
Ethanol; DMSO
Concomitants: Compound role
COM; COM
Desbois, Andrew P.; Lawlor, Keelan C.; Marine Drugs; vol. 11; nb. 11; (2013); p. 4544 - 4557, View in Reaxys 279 of 289 Substance Effect
Antibiotic
Bioassay Category
Toxicity/Safety Pharmacology
Bioassay Name
Cell/tumor cell: proliferation/viability/growth
Biological Species/NCBI Propionibacterium acnes ATCC 6919 ID Substance RN
984320View in Reaxys
Substance Name
BPO-Table 3, Entry 1; Table 4, Entry 1; Table 5, Entry 1
Measurement Parameter
MBC
Unit
mg/L
Qualitative value
>
Quantitative value
4096
Measurement pX
1
Concomitants: Compound RN
1718733; 506008
Concomitants: Compound name
Ethanol; DMSO
Concomitants: Compound role
COM; COM
Desbois, Andrew P.; Lawlor, Keelan C.; Marine Drugs; vol. 11; nb. 11; (2013); p. 4544 - 4557, View in Reaxys 280 of 289 Substance Effect
Antibiotic
Bioassay Category
Toxicity/Safety Pharmacology
Bioassay Name
Cell/tumor cell: proliferation/viability/growth
Biological Species/NCBI Staphylococcus aureus subsp. aureus ATCC 43300 ID Substance RN
984320View in Reaxys
Substance Name
BPO-Table 3, Entry 1; Table 4, Entry 1; Table 5, Entry 1
Measurement Parameter
MIC
Unit
mg/L
Quantitative value
512
Measurement pX
2.68
Concomitants: Compound RN
1718733; 506008
Concomitants: Compound name
Ethanol; DMSO
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
159/162
2018-02-22 00:03:45
Concomitants: Compound role
COM; COM
Desbois, Andrew P.; Lawlor, Keelan C.; Marine Drugs; vol. 11; nb. 11; (2013); p. 4544 - 4557, View in Reaxys 281 of 289 Substance Effect
Antibiotic
Bioassay Category
Toxicity/Safety Pharmacology
Bioassay Name
Cell/tumor cell: proliferation/viability/growth
Biological Species/NCBI Staphylococcus aureus subsp. aureus ATCC 43300 ID Substance RN
984320View in Reaxys
Substance Name
BPO-Table 3, Entry 1; Table 4, Entry 1; Table 5, Entry 1
Measurement Parameter
MBC
Unit
mg/L
Quantitative value
512
Measurement pX
2.68
Concomitants: Compound RN
1718733; 506008
Concomitants: Compound name
Ethanol; DMSO
Concomitants: Compound role
COM; COM
Desbois, Andrew P.; Lawlor, Keelan C.; Marine Drugs; vol. 11; nb. 11; (2013); p. 4544 - 4557, View in Reaxys 282 of 289 Substance Effect Bioassay Category
Antibiotic In Vitro (Efficacy)
Biological Species/NCBI Propionibacterium acnes ATCC 6919 ID Substance RN
984320View in Reaxys
Substance Name
dibenzoyl peroxide
Measurement Parameter
MIC
Unit
μM
Quantitative value
62.5
Measurement pX
4.2
Patent; BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS; Song, Peter I.; Armstrong, Cheryl; Ryu, Sunhyo; Park, Yoonkyung; US2014/274879; (2014); (A1) English, View in Reaxys 283 of 289 Substance Effect Bioassay Category
Antibiotic In Vitro (Efficacy)
Biological Species/NCBI Propionibacterium acnes ATCC 11828 ID Substance RN
984320View in Reaxys
Substance Name
dibenzoyl peroxide
Measurement Parameter
MIC
Unit
μM
Quantitative value
62.5
Measurement pX
4.2
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
160/162
2018-02-22 00:03:45
Patent; BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS; Song, Peter I.; Armstrong, Cheryl; Ryu, Sunhyo; Park, Yoonkyung; US2014/274879; (2014); (A1) English, View in Reaxys 284 of 289 Bioassay Category
Pharmacokinetic
Biological Species/NCBI Sprague Dawley rat ID Substance RN
984320View in Reaxys
Substance Name
benzoyl peroxide
Substance Dose
50 mg
Substance Route of Adm.
topical administration
Substance Dosing Regi- Single men Measurement Parameter
Concentration
Unit
μg/g
Quantitative value
146
Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys 285 of 289 Bioassay Category
Pharmacokinetic
Biological Species/NCBI Sprague Dawley rat ID Substance RN
984320View in Reaxys
Substance Name
benzoyl peroxide
Substance Dose
50 mg
Substance Route of Adm.
topical administration
Substance Dosing Regi- Single men Measurement Parameter
Concentration
Unit
μg/g
Quantitative value
367
Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys 286 of 289 Substance Effect Bioassay Category
Antibiotic In Vitro (Efficacy)
Biological Species/NCBI Propionibacterium acnes 11827 ID Substance RN
984320View in Reaxys
Substance Name
dibenzoyl peroxide
Measurement Parameter
ZI
Unit
mm
Quantitative value
0-6
Patent; Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; Yasman, Yuri; Privalova, Olga; Benaltabet, Lior; (39 pag.); US9682031; (2017); (B2) English, View in Reaxys 287 of 289 Substance Effect Bioassay Category
Antibiotic In Vitro (Efficacy)
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
161/162
2018-02-22 00:03:45
Biological Species/NCBI Propionibacterium acnes 11827 ID Substance RN
984320View in Reaxys
Substance Name
dibenzoyl peroxide
Measurement Parameter
ZI
Unit
mm
Quantitative value
12 - 17
Patent; Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; Yasman, Yuri; Privalova, Olga; Benaltabet, Lior; (39 pag.); US9682031; (2017); (B2) English, View in Reaxys 288 of 289 Substance Effect Bioassay Category
Antibiotic In Vitro (Efficacy)
Biological Species/NCBI Propionibacterium acnes 11827 ID Substance RN
984320View in Reaxys
Substance Name
dibenzoyl peroxide
Measurement Parameter
ZI
Unit
mm
Quantitative value
6 - 10
Patent; Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; Yasman, Yuri; Privalova, Olga; Benaltabet, Lior; (39 pag.); US9682031; (2017); (B2) English, View in Reaxys 289 of 289 Substance Effect Bioassay Category
Antibiotic In Vitro (Efficacy)
Biological Species/NCBI Propionibacterium acnes 11827 ID Substance RN
984320View in Reaxys
Substance Name
dibenzoyl peroxide
Measurement Parameter
ZI
Unit
mm
Quantitative value
6-8
Patent; Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; Yasman, Yuri; Privalova, Olga; Benaltabet, Lior; (39 pag.); US9682031; (2017); (B2) English, View in Reaxys
Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
162/162
2018-02-22 00:03:45